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Background: Mother-to-child transmission of HIV continues to be the leading cause of pediatric 
HIV infections. Prevention of mother-to-child transmission (PMTCT) care and treatment 
strategies have been shown to drastically reduce rates of vertical transmission but attrition along 
the PMTCT cascade is a persisting issue. One barrier for PMTCT is inconsistent medication 
adherence and program retention. Option B+ is the current strategy recommended by the World 
Health Organization (WHO) for PMTCT and includes the provision of combination antiretroviral 
therapy (ART) to all pregnant and postpartum HIV-infected women, regardless of CD4 cell count 
or clinical stage, to be continued for life from the time of treatment initiation.  
 
Study goal and specific aims: The overall goal of this dissertation was to further the current 
understanding of medication adherence and program retention of HIV-infected pregnant and 
postpartum women receiving Option B+ for PMTCT and how medication adherence and program 
retention may change over time. A mixed methods approach was used to address this goal. 
Manuscript one aims to summarize the existing Option B+ adherence and program retention 
literature. Manuscript two aims to measure rates of medication adherence and clinic visit 
attendance in pregnancy and the postpartum period as well as the effects of various factors on 
these outcomes for a cohort of HIV-infected pregnant women presenting for care and initiating 
treatment at Mulago National Referral Hospital. Manuscript three aims to explore the changing 
experiences of HIV-infected pregnant women and mothers with the Option B+ program at 
Mulago National Referral Hospital from pregnancy through six weeks postpartum as well as the 
changes in potential barriers and facilitators to adherence and program retention that may occur 




Methods: First, a systematic review of the current Option B+ adherence and program retention 
literature was performed by searching the PubMed, Embase, Global Health and Scopus databases 
for relevant peer-reviewed studies. Second, routinely collected PMTCT program data were used 
for a longitudinal analysis of adherence and clinic visit attendance from pregnancy through six 
months postpartum for a cohort of first-time initiators of Option B+ at Mulgo National Referral 
Hospital in 2014. Third, a series of longitudinal in-depth interviews during pregnancy and at six 
weeks postpartum were conducted with a subgroup of HIV-infected pregnant women 
participating in the “Friends for Life Circles” randomized controlled trial and assigned to receive 
the standard of care at Mulago National Referral Hospital.  
 
Results: The systematic review found that loss to follow-up (LTFU), patient self-report and pill 
counts were the most commonly used measures of program retention and medication adherence 
and that these outcomes varied greatly across studies and program implementation settings. The 
longitudinal data analysis found that a relatively low proportion of HIV-infected women were 
adherent in pregnancy and that the proportion of adherent women decreased at six months 
postpartum. A number of factors were found to predict adherence in pregnancy and six months 
postpartum, but only status disclosure was associated with sustained adherence at both time 
points. This study also found that postpartum clinic visit attendance remained consistent and that 
previous PMTCT experience, previous HIV diagnosis, time spent on ART during pregnancy and 
male partner counseling and testing in antenatal care were predictors of sustained clinic visit 
attendance at six weeks and six months postpartum. The in-depth interviews found medication 
adherence and clinic visit attendance to be consistently high among participants, but also 
identified a number of themes surrounding experiences with ART adherence and the Option B+ 
program in pregnancy and at six weeks postpartum. Effective messaging and counseling at the 
time of HIV testing and treatment initiation, support from health workers between clinic visits, 
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HIV status disclosure during pregnancy and a desire for a healthy baby and a healthy life were the 
biggest motivators for good medication adherence and clinic visit attendance, while concerns 
with unwanted HIV status exposure, modifying daily routines to prioritize ART adherence and 
health, concerns with the Option B+ approach and health facility limitations came through as 
potential barriers to good adherence and clinic visit attendance.  
 
Conclusions:  The results of this dissertation may be useful as PMTCT clinical care and research 
teams continue to strive toward the goal of eliminating vertical HIV transmission. First, this work 
confirms the limitations that exist with pill count adherence measures and should encourage 
continued efforts to improve and standardize adherence measurements in the future. Second, this 
work underscores the need for continued monitoring and evaluation of maternal medication 
adherence and program retention as well as interventions aimed at improving these outcomes. 
Focusing on strategies for improving ART adherence during pregnancy might be effective for 
improving and sustaining good adherence and program retention over time. More specifically, 
increasing effective status disclosure, supporting health workers to provide appropriate guidance 
during HIV testing and ART initiation as well as throughout pregnancy and addressing the 
specific needs of HIV-infected pregnant women who work outside the home or desire to work 
outside the home may be appropriate for improving adherence and program retention in 
pregnancy and the postpartum period.   
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Burden of HIV for women and children 
Over the last 15 years, the number of people living with HIV (PLWH) has increased from 
30.0 million1 to 36.9 million.2 Sub-Saharan Africa bears approximately 70% of the global HIV 
burden, and of the 25.8 million PWLH in this region, nearly 60% are estimated to be women.3 
Data show that HIV/AIDS has had an increasingly disproportionate impact on the women of sub-
Saharan Africa. In 1985 the number of men and women living with HIV/AIDS in this region was 
approximately equal, but today women ages 15-24 are more than three times as likely to become 
infected with HIV as men of the same age group.4 
Though most of the HIV epidemics across sub-Saharan African countries are generalized, 
national adult HIV prevalence varies substantially from 0.5% in Senegal to 27.7% in Swaziland.5 
Thus, in addition to looking at regional trends among women, it is important to note the country-
specific variations in female HIV prevalence. Table 1 is adapted from a 2013 United States 
Agency for International Development (USAID) report estimating HIV prevalence patterns by 
age and sex, and demonstrates the difference in HIV prevalence between women and men ages 
15-49, by country.6 These data show the heterogeneous nature of the HIV epidemic in sub-
Saharan Africa while supporting the notion that the HIV epidemic is largely driven by the 


















Table 1: HIV prevalence among women and men ages 15-49, by country6 
Age group 
  15-19 20-24 25-29 30-34 35-39 40-44 45-49 
  F* M* F M F M F M F M F M F M 
Southern Africa 
Lesotho 2009 4.1 2.9 24.1 5.9 35.4 18.4 40.7 40.2 42.3 35.4 36.1 39.3 29.5 32.1 
Zambia 2007 5.7 3.6 11.8 5.2 19.9 11.4 26.0 17.1 24.9 22.4 18.3 24.1 12.2 18.6 
Zimbabwe 2011 4.2 3.4 10.6 3.9 20.1 10.3 29.0 17.4 29.1 25.1 25.7 26.2 22.6 29.9 
East Africa 
Ethiopia 2011 0.2 0.0 0.9 0.2 3.0 0.9 3.7 1.0 3.0 3.0 1.9 2.1 1.8 1.4 
Kenya 2009 2.7 0.7 6.4 1.5 10.4 6.5 11.0 6.8 8.8 10.4 14.3 5.7 6.4 4.3 
Malawi 2010 4.2 1.3 6.4 2.8 13.5 6.9 20.8 10.7 23.8 18.2 20.4 20.8 16.1 15.0 
West Africa 
Burkina Faso 2010 0.2 0.4 0.4 0.5 1.2 0.5 2.4 1.1 1.7 1.2 2.0 1.4 1.7 1.1 
Guinea 2005 0.9 0.5 1.6 0.7 1.8 1.2 3.0 0.7 2.1 0.9 1.4 2.8 3.3 0.6 
Mali 2006 0.6 0.7 1.3 0.8 2.0 0.6 2.2 2.2 2.2 0.6 2.0 1.9 1.2 0.8 
*F=female; M=Male 
According to the Joint United Nations Program on HIV/AIDS (UNAIDS), there are 
approximately 1.5 million HIV-infected pregnant women around the world, 92% of whom reside 
in sub-Saharan Africa.7 HIV is a leading cause of death during pregnancy and the postpartum 
period in countries with high HIV prevalence and it contributes to maternal mortality and 
morbidity, especially in sub-Saharan Africa where 91% of all maternal deaths due to HIV take 
place.8 The World Health Organization (WHO) reports that approximately 1.8 million children 
under the age of 15 are currently living with HIV and 240,000 children were newly infected in 
2015.9  Without treatment, one in every three children living with HIV will die before his or her 
first year of life and one half of children living with HIV will die before reaching two years of 
age.10 Unfortunately, the provision of HIV treatment to children has consistently lagged behind 







Mother-to-child transmission of HIV 
 
Mother-to-child transmission (MTCT) has been responsible for the majority of pediatric 
HIV-1 infections.12  MTCT can happen in-utero, at delivery or during the breastfeeding period, 
with risks of transmission ranging from 5-10%, 10-20% and 5-20%, respectively, resulting in an 
overall transmission rate of between 15-45% without intervention.13  Studies have shown that 
maternal HIV infection, factors associated with delivery, other maternal infections, breastfeeding 
practices, genetics and characteristics of the maternal virus may be associated with rates of 
MTCT, but the key maternal factors affecting rates of vertical HIV transmission are maternal 
viral load and use of antiretroviral therapy (ART).14  Successful prevention of mother-to-child 
transmission (PMTCT) can reduce rates of transmission to less than 5%,15 but implementation of 
PMTCT strategies continues to be difficult, especially in resource-limited settings such as sub-
Saharan Africa. Experts in the field of HIV and PMTCT often refer to the “PMTCT cascade” as a 
way of addressing key areas along the HIV care and treatment continuum where challenges to 
PMTCT are most likely to occur. Figure 1 depicts a version of the PMTCT cascade similar to one 
put forth by the WHO. Attrition along the cascade is most commonly seen in resource-limited 
settings such that only a small proportion of all HIV-infected mothers present for care and 
successfully receive and adhere to the antiretroviral (ARV) prophylaxis regimens necessary for 
PMTCT. While developed countries are close to achieving elimination of vertical HIV 
transmission, it was estimated as recently as 2011 that only 15-30% of eligible women in 
resource-limited settings successfully completed the PMTCT cascade.16  In an effort to improve 
PMTCT outcomes and consequently improve maternal and child health, experts from various 
research communities in collaboration with the WHO and community and government partners 
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from countries with high HIV burden have continued to evaluate ways to improve the uptake of 
and adherence to PMTCT care and treatment services. 
 
 





PMTCT literature review 
 
Over two decades of research have shown that the use of ARVs can reduce the risk of 
MTCT by decreasing replication of the HIV virus and acting as HIV prophylaxis for the fetus and 
infant during and after virus exposure. The first clinical trial to show that an ARV regimen given 
to mothers and their infants could greatly reduce rates of MTCT of HIV was the ACTG 076 trial 
published in 1994.18  ACTG 076 was a randomized, double-blind clinical trial that enrolled HIV-
infected pregnant women and assessed the efficacy of zidovudine (AZT) for reducing the risk of 
vertical HIV transmission. Women with CD4+ cell counts greater than 200 cells/mm³ received 
















All women presenting for delivery 




either AZT or placebo at 14 weeks gestation and through labor and delivery. HIV-exposed infants 
also received the same regimen for the first six weeks of life. The initial results demonstrated that 
AZT reduced MTCT by approximately two thirds with only minimal short-term toxic effects.  
During follow-up of the mother-infant pairs, the study found that only 7.6% of infants in the 
treatment group were infected with HIV at 18 months, compared to 22.6% of infants in the 
placebo group. Following the results of this trial, the United States Public Health Service 
(USPHS) published guidelines recommending the use of AZT for perinatal PMTCT along with 
HIV counseling and voluntary testing for pregnant women. 
After the ACTG 076 trial, clinical trials between 1997 and 2002 continued to demonstrate 
reduced rates of MTCT in the United States and Europe, with vertical transmission rates 
decreasing to as low as 1.5%.19  PMTCT regimens were also tested for their efficacy 
internationally by varying the regimens, timing of treatment initiation and infant feeding 
practices. Specifically, the Centers for Disease Control and Prevention (CDC) trials in Thailand 
and CÔte d’Ivoire as well as the HIVNET 012 trial were instrumental in establishing feasible 






















Figure 2: Efficacy of international PMTCT regimens 
 
 
The CDC trial in Thailand was a randomized, placebo-controlled trial conducted with 
non-breastfeeding HIV-infected women evaluating a regimen of maternal AZT initiated at 36 
weeks gestation and continuing through labor and delivery.20  The study showed that short-course 
AZT was 50% efficacious, as well as safe and well-tolerated by the study population. It was 
concluded from this study that short-course AZT should be considered as an option for PMTCT 
in resource-limited settings unable to implement the 076 treatment regimen. A similar CDC study 
in the CÔte d’Ivoire among HIV-infected breastfeeding mothers was stopped early when results 
from Thailand became available, but results from infants reaching 3 months of age in CÔte 
d’Ivoire showed efficacy levels of 37%.21  Similarly, the Ditrame Study Group evaluated the 
same maternal antepartum and intrapartum regimen with the addition of AZT for seven days 
postpartum among breastfeeding women in Burkina Faso and the CÔte d’Ivoire and found a 
relative efficacy of 38% at 6 months.22 
The HIVNET 012 study in Uganda was originally designed as a randomized, double-







































(NVP) and AZT for PMTCT in resource-limited settings, but once the efficacy of short-course 
AZT was demonstrated the placebo arm was dropped and mother-infant pairs were randomized to 
receive either single-dose nevirapine (sdNVP) for the mother and infant or AZT for the mother 
during the intrapartum period with 7 days of infant prophylaxis.23 The study found a statistically 
significant difference in the estimated risk of HIV transmission at 14-16 weeks of 13.1% in the 
NVP group versus 25.1% in the AZT group. A subsequent intent-to-treat analysis found similar 
results that remained statistically significant.  
While these early studies demonstrated the efficacy of ARV regimens for decreasing in-
utero and intrapartum transmission, much of that efficacy was lost in the postpartum period due to 
transmission through breastfeeding. For instance, the Ditrame-Plus Study Group found that 
cumulative risks of vertical transmission for breastfeeding women receiving either zidovudine 
(ZDF) and sdNVP or ZDF and lamivudine (3TC) with sdNVP with early cessation within the first 
four months were higher than those receiving the same regimens but opting to formula feed.24  
Though replacement feeding was shown to remove the risk of HIV transmission through 
breastfeeding, a number of studies showed that replacement feeding was likely to increase the 
risk of infant malnutrition and death due to other infections. These studies also indicated that 
compared to mixed feeding practices, exclusive breastfeeding was associated with lower rates of 
transmission, and that early weaning and replacement feeding decreased HIV exposure but did 
not necessarily result in improved infant survival. One of the first studies to indicate that 
exclusive breastfeeding was protective against MTCT was conducted by the South African 
Vitamin A Study Group and followed a cohort of mother-infant pairs and showed that exclusive 
breastfeeding carried a significantly lower risk of HIV transmission than mixed feeding and a 
similar risk as no breastfeeding.25 The Mashi Trial also looked at differences in HIV infection 
rates between infants randomized to receive formula with one month of AZT and infants 
randomized to be breastfed with six months of AZT and found no significant difference in HIV-
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free survival between the two study arms.26 Similarly, a cohort study in Uganda examined infant 
survival by feeding practice and found excess mortality rates in the formula fed group when 
compared to the exclusively breastfed group.27 These results led to a number of subsequent 
studies exploring ways to decrease the risk of MTCT during the breastfeeding period through 
extended antiretroviral (ARV) regimens for infants and/or their mothers.   
Early studies examining infant prophylaxis for PMTCT included: a) the Six-Week 
Extended Nevirapine Studies (SWEN), evaluating six weeks of NVP infant prophylaxis28; b) the 
Post Exposure Prophylaxis for Infants Study (PEPI), evaluating 14 weeks of infant prophylaxis 
with NVP or NVP+AZT29 and c) the Breastfeeding Antiretrovirals and Nutrition Study (BAN), 
which included an infant prophylaxis study arm of six months of NVP.30 These studies 
demonstrated that infant prophylaxis with NVP greatly reduces vertical HIV transmission. These 
results along with the HPTN 046 study designed to evaluate the incremental benefit of a six-
month regimen versus a six-week regimen and showing lower transmission rates at six months as 
compared to six weeks,31 suggested that a longer duration of infant prophylaxis is more 
efficacious than a short-course regimen for PMTCT. 
Some key studies examining the safety and efficacy of maternal prophylaxis during the 
breastfeeding period for the purposes of PMTCT included: a) the Kesho Bora study, comparing 
the safety and efficacy of triple ARVs to AZT+sdNVP prophylaxis in pregnant women with 
WHO stage 1,2 or 3 infection or CD4 cell counts between 200 and 500 cells/mm³ and showing 
that vertical transmission during breastfeeding was significantly lower in the triple ARV group;32 
b) the Mma Bana study, comparing the administration of prophylaxis through a combination of 
nucleoside reverse transcriptase inhibitors (NRTIs) to the administration of protease inhibitor (PI) 
lopinavir/ritonavir (LPV/R) with AZT+3TC among HIV-infected women with CD4 cell counts 
greater than 200 cells/mm³ and resulting in an overall vertical transmission rate of 1.1% (though 
not powered to compare the two regimens)33 and c) the BAN study, comparing the efficacy of 
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maternal triple ARV prophylaxis for women with CD4 cell counts less than or equal to 250 
cells/mm³ to extended infant prophylaxis with NVP as a way to reduce postnatal vertical 
transmission of HIV and showing that when compared to the control group, both infant and 
maternal prophylaxis during the breastfeeding period resulted in a significantly lower risk of 
vertical transmission.30  These maternal ARV studies showed that prophylaxis for HIV-infected 
mothers can significantly reduce MTCT during breastfeeding and have informed WHO 
guidelines for PMTCT, leading to what is now referred to as Option B.  
 
WHO PMTCT recommendations and Option B+ 
Since 2000 when the WHO first put forth guidelines for PMTCT and infant feeding 
strategies for HIV-infected mothers, the international health community has continued to 
regularly update recommendations for PMTCT and infant feeding to reflect the most recent 
findings from the biomedical, public health and social science fields. The WHO guidelines 
influence the direction of international and bilateral funding agencies and are aimed at managers 
and healthcare providers in resource-limited countries responsible for establishing national 
policies, implementing PMTCT services and ensuring that high quality services are provided to 
those in need.   
The first version of the WHO PMTCT recommendations in 2000 supported the use of 
sdNVP for the mother at least  two hours before delivery, oral sdNVP for the infant within the 
first 72 hours of life and avoidance of all breastfeeding when replacement feeding was 
acceptable, feasible, affordable, sustainable and safe, with the option of exclusive breastfeeding 
for the first months of life in settings where replacement feeding was not appropriate.34  Since 
then recommendations have changed with the presentation of new evidence for best PMTCT 
practices. For instance, over time additional ARVs were recommended for the postpartum period 
when research found that administering sdNVP to the mother and infant, while efficacious and 
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affordable, resulted in a high incidence of viral resistance in women and children.35 Tables 1 and 
2a, b and c in Appendix A summarize the PMTCT and infant feeding recommendations revised 
by the WHO between 2004 and 2006. It is important to note that these recommendations did not 
address means of decreasing MTCT in the postpartum period except through modified 
breastfeeding practices.  
In 2010 the WHO differentiated between women requiring lifelong ART for their own 
health and those not qualifying for treatment. Tables 3a, b and c in Appendix A are from the 2010 
WHO document and outline the 2010 recommendations in detail.  In summary, pregnant women 
qualified for treatment based on their CD4 cell counts and WHO disease stages and women who 
did not qualify for treatment for their own health could receive either Option A or Option B as 
PMTCT prophylaxis. Option A included a shorter prophylaxis regimen for the mother comprised 
of AZT as early as 14 weeks gestation and sdNVP at labor with daily AZT and 3TC from labor 
until seven days postpartum and a longer prophylaxis regimen for the infant comprised of daily 
NVP from birth through one week beyond complete cessation of breastfeeding (or through four-
to six weeks of age if the mother was not breastfeeding). On the other hand, Option B included a 
longer prophylaxis regimen for the mother comprised of triple ARVs starting as early as 14 
weeks gestation and continued through the intrapartum period and childbirth if not breastfeeding 
or until one week after cessation of all breastfeeding, and a shorter prophylaxis regimen for the 
infant comprised of daily NVP or AZT from birth through four to six weeks of age regardless of 
infant feeding method. Option A and Option B were thought to be programmatically different but 
equally efficacious for reducing the risk of vertical HIV transmission for mothers ineligible for 
treatment, and countries were encouraged to evaluate each option and determine the best strategy 
for a national program.36  
Since 2010 the WHO has moved toward promotion of a third PMTCT option known as 
Option B+. This approach has been described as a single, universal strategy for both the treatment 
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of HIV-infected pregnant women and for PMTCT prophylaxis.37 Option B+ includes the 
provision of triple ART for HIV-infected pregnant women at the antenatal clinic regardless of 
clinical stage or CD4 cell count, to be continued for life. Table 2 is adapted from the April 2012 
WHO programmatic update and summarizes the differences between Option A, Option B and 
Option B+. 
With the deadline set by the Global Plan for 2015 for achieving elimination of MTCT on 
the horizon38 and growing concern that the global health community was not on track to meet this 
goal, the WHO asserted that switching to Option B+ could likely help overcome the operational 
and programmatic complexities that countries had been experiencing with the implementation of 
Option A, without increasing cost.39 
Between 2010 and 2012 key findings serving as rationale for the 2012 update included: 
1) new evidence from the HPTN052 study supporting ARV treatment as prevention for 
individuals with higher CD4 cell counts40; 2) reassuring data on the safety of efavirenz (EFV) as a 
first-line drug during pregnancy and approval of the tenofovir (TDF)/3TC/EFV fixed dose 
combination41; 3) improved prevention of sexual transmission of HIV to serodiscordant 
partners42; 4) increased risks to maternal health associated with stopping and starting triple ART 
in settings of high fertility and improved maternal health outcomes associated with earlier 










Table 2: WHO recommended options for PMTCT37 
 Mother Infant  
Treatment (CD4 count 
<350 cells/mm³ 
Prophylaxis (CD4 count 
≥350 cells/mm³) 
Option A Triple ARVs starting as 
soon as diagnosed, 
continued for life 
Antepartum: AZT 
starting as early as 14 
weeks gestation 
Intrapartum: at onset of 
labor, sdNVP and first 
dose of AZT/3TC 
Postpartum: daily 
AZT/3TC through 7 days 
postpartum 
Daily NVP from birth 
through 1 week beyond 
complete cessation of 
breastfeeding; or if not 
breastfeeding or if mother 
is no treatment, through 
age 4-6 weeks 
Option B Triple ARVs starting as 
soon as diagnosed, 
continued for life 
Triple ARVs starting as 
early as 14 weeks 
gestation and continued 
intrpartum and through 
childbirth if not 
breastfeeding or until 1 
week after cessation of 
all breastfeeding 
Daily NVP or AZT from 
birth through age 4-6 
weeks regardless of 
infant feeding method 
Option B+ Regardless of CD4 count, triple ARVs starting as 
soon as diagnosed, continued for life (Same for 
treatment and prophylaxis) 
Daily NVP or AZT from 
birth through age 4-6 
weeks regardless of 
infant feeding method. 
 
Malawi and Option B+ 
In 2011 the Malawian Ministry of Health (MoH) decided to implement Option B+ as the 
national PMTCT approach. This decision was based on the high incidence of infant HIV 
infections occurring in Malawi at that time and the notion that a major barrier for PMTCT in 
Malawi was the limited capacity of laboratories to perform CD4 cell counts necessary to 
implement either Option A or Option B.44  The implementation of Option B+ required the 
integration and decentralization of ART to all antenatal care (ANC) settings, re-training 
healthcare workers to familiarize them with the new strategy, changing the adult first-line ART 
regimen to include EFV and policy changes relating to task-shifting that allowed for clinical 
officers, medical assistants and nurses to start women on ART. 
Evaluations of Option B+ implementation in Malawi showed the program to be 
successful in some respects, but there were challenges that must also be addressed. The Malawi 
MoH reported an increase from 303 ART sites in June 2011 to 641 integrated PMTCT/ART sites 
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in September 201245 and a 2014 report from the WHO summarizing the Malawi experience with 
Option B+ stated that 80% of mothers testing positive were initiating ART.45 Currently it appears 
that Option B+ has led to increased availability, accessibility and utilization of PMTCT services 
in Malawi, but a 2015 study found that women who initiated Option B+ in Malawi exhibited 
greater withdrawal from services, greater loss to follow-up and decreased ART retention at 6 
months postpartum when compared to women enrolled in the PMTCT program before Option 
B+.46 
While promoting Option B+ as the way forward for PMTCT, the WHO also cautioned 
that limitations to the program might include: 1) insufficient health infrastructure for 
accommodating the increased clientele, 2) inadequate linking of maternal and pediatric care and a 
lack of mechanism for tracking losses to follow-up, leading to confusion about the follow-up 
schedule, suboptimal coverage of testing, diagnosing and treating HIV-exposed infants and a high 
potential for poor long-term program adherence, 3) limited data management capacity at the 
lower levels of the healthcare system, 4) stock-outs of HIV test kits and poor estimations of 
necessary medicine quantities, 5) negative reception from healthcare providers and clients to the 
same-day testing, counselling and ART initiation practices, 6) problematic quality of HIV testing 
(in 2012, 20% of HIV-infected pregnant women were falsely identified as HIV-negative and 4% 
of HIV-negative pregnant women were falsely identified as HIV-positive),  7) a feeling that the 
Option B+ program does not actively promote male partner involvement, 8) a loss of HIV-
infected pregnant women and mothers to neighboring countries where Option B+ is not being 
implemented and 9) a lack of human resources and a shortage of health workers needed to 
successfully implement Option B+.47  
To date, evaluation of the Option B+ program in Malawi has yielded mixed results. A 
CDC-funded national evaluation of Malawi’s PMTCT program evaluating vertical HIV 
transmission across 54 randomly selected health facilities in 10 districts found that among the 
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1,851 HIV-infected mothers with infants between four and 12 weeks of age, the overall MTCT 
rate was 3.9% while the transmission rate among women who had initiated ART during 
pregnancy was 2.8%.47 The same evaluation also noted that MTCT varied by timing of ART 
initiation, from 1.4% among women who initiated ART prior to the current pregnancy to 21.3% 
among women who had never initiated ART. However, a different evaluation of the Malawi 
Option B+ program found that close to one fifth of women initiating Option B+ in Malawi had 
become lost to follow-up by six months on treatment and that compared to women initiating ART 
due to low CD4 cell count or advanced clinical disease staging, women who initiated ART during 
pregnancy were five times more likely to never return for a follow-up visit after ART initiation.48  
The introduction of Option B+ in Malawi removed the need for a CD4 cell count and 
decentralized ART to all ANC sites, allowing for improved access and initiation of treatment for 
PMTCT. It is also possible that the Option B+ program could lower vertical rates of HIV 
transmission. However, ongoing monitoring and evaluation is necessary to further examine the 
challenges facing long-term Option B+ adherence and program retention after initial infant HIV 
test results are received. In addition, data from other countries currently implementing Option B+ 
must continue to be gathered and analyzed to see if the initial success experienced in Malawi is 
being replicated in other resource-limited settings and whether or not these countries are 
experiencing or will experience similar challenges with long-term implementation of Option B+.  
 
PMTCT and Option B+ in Uganda 
Uganda is one of the countries in sub-Saharan Africa that has transitioned from Option A 
to Option B+. The WHO has classified Uganda as one of the top ten high burden countries for 
PMTCT49 and thus, addressing PMTCT in Uganda is essential to achieving the goal of 
eliminating vertical HIV transmission. This categorization is due in combination to the number of 
HIV-infected pregnant women reaching approximately 120,000,50 the high maternal mortality 
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ratio of 343 per 100,000 live births51 and an infant mortality rate of approximately 62 per 1000 
live births.52  
The diversity of the Ugandan population, specifically of its women, is reflected in the 
variations in total fertility rates (TFRs) and percentages of women delivering at a facility by 
region and residence. The overall TFR in Uganda is 6.2 and 57.4% of all pregnant women deliver 
in a health facility, 53 but the differences in the regional TFRs and percentages of women 
delivering at facilities are presented in table 3 below.  
Table 3: Regional and residence-specific TFRs and health facility delivery coverage in 
Uganda54 
Region  Total fertility rate  Percent of women delivering at 
a facility (%) 
Kampala 3.3 92.9 
Central 1 5.6 61.7 
Central 2 6.3 69.1 
East Central 6.9 67.1 
Eastern 7.5 51.2 
Karamoja 6.4 27.1 
North 6.3 51.9 
West Nile 6.8 58.7 
Western 6.4 55.9 
Southwest 6.2 40.3 
Urban 3.8 89.5 
Rural  6.8 52.0 
Total 6.2 57.4 
 
According to the Uganda HIV and AIDS Country Progress Report put forth in 2014, the 
AIDS Indicator Survey showed an estimated HIV prevalence of 7.4% in the general population.54 
The report states that while adult HIV prevalence is 2% higher in women as compared to men 
ages 15-49 (8.2% vs. 6.1%), young women ages 15-29 are at least twice as likely to be infected 
with HIV as men of the same age. The report also showed variations in HIV prevalence by 
region, with the highest HIV prevalence observed in the Central 1 region including Kampala 
(10.1%) and the lowest HIV prevalence observed in the Mid-eastern region (4.1%). Figures 3 and 
4 below, adapted from the Country Progress Report, display HIV prevalence in Uganda according 
to age, sex and region and support the notion that the epidemic is generalized yet heterogeneous. 
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The same report demonstrates attrition along the PMTCT cascade. In 2014, 
approximately 93% of pregnant women in Uganda presented for at least one ANC visit. Of these 
women, approximately 94% received and HIV test and results, meaning in actuality only 87% of 
all pregnant women in Uganda received an HIV test and results. Of the 8% found to be HIV-
infected, 84% received ARTs, including women on ART prior to their current pregnancy and 
those initiating Option B+ for PMTCT. However, only 51% of HIV-exposed infants received an 
HIV test in the first two months of life, only 25% of HIV-exposed infants received ARVs for 
PMTCT and the proportion of women exhibiting good adherence throughout pregnancy, delivery 
and the postpartum period was not stated in this report. The gaps in the Uganda PMTCT cascade 
have resulted in a MTCT rate of somewhere between 5 and 8% across the country.55  



















































Figure 4: HIV prevalence in Uganda by region (2011)56 
 
 
In 2011, the MoH reported that a modes of transmission analysis in Uganda found 
vertical HIV transmission accounted for 18% of all new HIV infections and was the leading cause 
of HIV infection in children under 5.57 This data, coupled with the launch of the Global Plan, an 
ambitious initiative by the President’s Emergency Plan for AIDS Relief (PEPFAR) aimed toward 
elimination of childhood HIV infections by 2015, 58 led to the development of a country-specific 
vision for an HIV/AIDS-free generation by 2015. This MoH plan included the goal of virtual  
elimination of vertical HIV transmission and the reduction of mortality and morbidity among 
women living with HIV and among HIV-exposed and infected infants through four objectives 
aimed at providing: 1) reproductive health, HIV and sexually transmitted infection (STI) 
prevention and treatment services to 80% of women of reproductive age; 2) family planning 
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services to 80% of all women living with HIV; 3) the recommended package for PMTCT to 80% 
of HIV-infected women and their infants and 4) family-centered HIV care and treatment to 80% 
of HIV-infected pregnant and lactating women and their children, if infected with HIV.59  
Initially, the MoH instructed that these objectives would be achieved through implementation of 
the WHO-recommended Option A until further communication to transfer to Option B.  
However, following the rapid scale-up of Option B+ in Malawi, the government of 
Uganda decided to launch a similar program in September, 2012. The policy shift was welcomed 
with the understanding that under Option B+, pregnant women would receive the most effective 
care and treatment, HIV-exposed infants would receive the most effective prophylaxis regimen 
throughout pregnancy, birth and delivery, discordant male partners would be protected from 
infection and the implementation of this program would be easier on clinical staff and the Uganda 
health system.60  It was decided that due to financial challenges, health infrastructure limitations 
and an on-going shortage of public health human resources, Option B+ would be rolled out in a 
phased approach beginning with districts reporting the highest HIV prevalence.61  
Option B+ roll-out was completed in Uganda in 2013. According to the PEPFAR 2015 
Uganda Country Operational Plan, implementation focused on the introduction of facility-level 
mother-baby care points, decentralization of services and strengthening of monitoring and 
evaluation techniques to improve adherence and retention in care along the PMTCT cascade.61 
The same report pointed to successful outcomes such as an increase in the number of health 
facilities offering PMTCT services from 1,596 in 2012 to 3,248 in 2015 and maternal ART 
coverage increasing from 65% in 2012 to 87% in 2014. Despite these significant improvements, 
the effect of Option B+ on PMTCT program adherence and retention in Uganda remain largely 
unknown and the influence of Option B+ on the documented barriers to PMTCT program 




Measures of Adherence and Retention in Care 
Adherence is commonly thought of as the extent to which a patient takes medication or 
utilizes health services in the way intended by the healthcare provider.62 Accurate and reliable 
measures of adherence are difficult to obtain, especially in resource-limited settings and 
specifically for PMTCT treatment and care services. Though the WHO recommends adherence 
assessments for every patient initiating ART63 there is no gold standard for this measurement.64  
A number of studies have established that adherence is highly correlated with virologic 
suppression and therefore biological markers such as plasma concentrations of ART and HIV 
plasma viral load are considered the most objective measures of adherence.65 However, in 
resource-limited settings these indicators are generally not routinely collected and other strategies 
must be used to evaluate HIV medication adherence and program retention.  Common strategies 
for measuring adherence are described in this section below.  
 
Patient self-report 
In resource-limited settings where regular blood tests are not feasible due to limitations 
associated with costs and infrastructure, patient self-report is often used as an indicator of 
medication adherence.  Self-report does not require sophisticated lab techniques or highly trained 
personnel but may lead to an overestimation of adherence.66 Techniques for measuring self-report 
have not been standardized, making it difficult to compare estimates across studies. Nevertheless, 
patient self-report remains a popular tool for measuring adherence, especially as studies such as 
one conducted in Tanzania validate this method by showing a high correlation between results 
obtained from blood samples and patient self-report.67 A variety of self-report measures have 
been used to measure adherence, with recall periods varying from one to 30 days and studies 
differing in conclusions about which method and timeframe is most accurate.68  Some common 
strategies of self-report include: 1) visual analog scales (VAS) in which participants are asked to 
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indicate their degree of adherence along a straight horizontal line ranging from 0% to 100% 
adherence; 2) qualitative single item measures in which participants are asked to grade their 
ability to take all of their medications over a specific timeframe; 3) Adult AIDS Clinical Trial 
Group four-day recall (AACTG) in which participants are asked to report their number of missed 
doses over the past four days and 4) a seven-day qualitative measure in which participants are 
asked how many days they correctly took all doses of their medication in the past week. 69 
 
Pharmacy-based measures 
Compared to patient self-report, these measures of adherence are more routinely 
available, objective and less affected by recall or social desirability bias.70 According to a review 
of the ART adherence literature, pharmacy-based adherence measures (PAMs) do not include pill 
counts performed independently from routine clinic visits or monitoring with electronic devices.71  
The same review identified three categories of PAMs: 1) medication or drug possession ratio; 2) 
pill count and 3) pill pickup.  Table 4 below is adapted from this literature review and 
summarizes these measures. The review found that PAMs consistently predicted patient outcomes 
but concluded that additional research was necessary to determine the most predictive measures 
of adherence. Table 5 below is adapted from a recent USAID report on adult adherence to 
treatment and retention in care and highlights the advantages and disadvantages of the adherence 









Table 4: Pharmacy-based adherence measures (PAM)71 
PAM category Definition  Formula(e) 
Medication or drug possession 
ratio 
Amount of time an individual is 
in possession of ≥1 ARV or 
prescriptions for ARVs as a 
proportion of the time between 2 
ARV pick-ups or prescriptions. 
# of days ARV prescribed or 
dispensed/# of days in the interval 
Pill count Quantity of ARV pills an 
individual has used between 2 
ARV pickups as a proportion of 
the number of pills dispensed or 
as a proportion of time between 
pick-ups. 
(# of ARV pills dispensed-# of ARV 
pills returned)/#of ARV pills 
dispensed  
(#of days ARV pills dispensed-#of 
days ARV pills returned)/# of days 
in the interval 
Pill pickup Whether an individual picks up 
all or a majority of their 
prescribed ARVs and expresses 
the adherence estimate in 
dichotomous fashion. 
“Adherent”=(ARV refills picked 
up/ARV refills prescribed)> 
predefined cutoff value 
 
“Adherent” = (ARV refills picked 
up prior to previous refill 
finishing/ARV refills prescribed)>  
predefined cutoff value 
 
 
Table 5: Advantages, disadvantages and potential bias of adherence measurements72 




Patient self-report Simple, cheap Subjective; accuracy 








Pill counts Simple, objective Accuracy affected by 
inability to confirm 
who took pills, 
timing of doses and 
possibility of 
throwing away pills 









more predictive of 
viral load than self-
report 
Pharmacy data Simple, cheap, 
objective 
Requires patients to 
bring back pill bottles 
which may not be 
standard of care; 
inability to confirm 
who took pills and 
timing of doses 
Overestimates 
adherence 
Moderate to strong 
associations with 
viral load, CD4 
counts and AIDS-
related mortality 









May vary based on 
viral resistance, 
prior treatment 
failure or poor 




Medication event monitoring system (MEMS) 
The medication event monitoring system (MEMS) for measuring adherence is performed 
by electronically recording the opening and closing dates of bottles and is thought to be less 
susceptible to overestimation in comparison to patient self-report or pill counts.73 The rate of 
adherence is calculated as the number of times the drug bottle is opened divided by the number of 
prescribed doses and multiplied by 100%. While MEMS may be considered a more objective 
measure of adherence, it is also subject to limitations, namely that opening a bottle does not 
necessarily mean medication has been consumed.  MEMS is also a more difficult measure of 
adherence to execute in resource-limited settings and limited data exists regarding the feasibility 
of this method in these environments.74  
 
Service utilization indicators and measures of program retention 
In addition to measuring ART adherence, other measures of service utilization can be 
collected to monitor and assess PMTCT adherence and program retention.  Some indicators 
commonly found in the literature evaluating PMTCT programs include: 1) number of ANC 
and/or PMTCT visits attended; 2) whether or not a pregnant woman receives HIV counseling and 
testing services; 3) whether or not a pregnant woman receives her HIV test results; 4) whether or 
not an HIV-infected pregnant woman receives ART at the time of labor and delivery; 5) whether 
or not the HIV-exposed infant receives an HIV test and 6) whether or not an HIV-infected 
pregnant woman receives counseling on appropriate infant feeding practices. 
 
Adherence and Option B+ 
Adherence research prior to 2005 concluded that for successful long-term virologic 
suppression to be achieved 95% of the prescribed combination ART (cART) doses must be 
consumed.75 Since then, studies of ritonavir (RTV)-enhanced PIs or regimens based on 
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nonnucleoside reverse transcriptase inhibitors (NNRTIs) such as EFV have shown that successful 
virological suppression may be achieved at lower adherence levels of between 70-80%76 due to 
the higher potency and longer half-lives of these newer ART regimens.77  Regardless of ART 
regimen, a linear dose response relationship exists between higher adherence and improved 
virologic outcomes.78 To date, there are limited data on ART adherence during pregnancy and in 
the postpartum period under Option B+. A meta-analysis of existing adherence data from low-, 
middle- and high-income countries in the pre-Option B+ era found that ART adherence dropped 
from 73.5% during pregnancy to 53% in the postpartum period.79  More recently, an evaluation of 
virologic and immunologic failure in the first 24 months postpartum among HIV-infected women 
who initiated ART for life as part of the Mitra plus Study in Tanzania found that the proportion of 
women with viral loads greater than or equal to 400 copies/mL decreased significantly from 97% 
at enrollment to 16% at three months postpartum, but increased to 86% at 24 months 
postpartum.80  This trend is worrisome for the long-term effectiveness of Option B+ which by 
definition requires equally high levels of triple ART adherence during pregnancy and the 
postpartum period and does not necessarily address barriers to long-term adherence or program 
retention.  
The preliminary data from Malawi indicated that transitioning to Option B+ may increase 
the number of pregnant women who attend ANC, receive an HIV test, become aware of their 
positive status and subsequently begin ART for PMTCT, but it remains to be seen if long-term 
adherence can be achieved under this PMTCT approach or if these results can be replicated in 
other settings.  A recent implementation science study of the lessons learned from the early 
application of Option B+ put forth by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) 
reported varying levels of success for improving the percent of HIV-infected pregnant women 
accessing ART under Option B+, with results ranging from as high as 97% in Lesotho to as low 
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as 35% in the Democratic Republic of Congo and only four of the 11 countries reporting data for 
Option B+ program retention. 81 
Despite support for Option B+ from the WHO and many other international agencies and 
organizations, there are a number of issues that must be considered and studied relating to the 
long-term effectiveness of Option B+. As a recent Lancet editorial suggests, it is critically 
important to assess the feasibility of maintaining lifelong maternal ART adherence in resource-
limited settings constrained by unstable health infrastructure and challenging social norms.82  
Inconsistent adherence is a serious barrier for the elimination of HIV/AIDS and specifically for 
PMTCT and maternal and child health since it is associated with an increased risk for 
opportunistic infections,83 HIV disease progression84 and viral resistance to ART.85 Thus, it must 
be decided if the PMTCT benefits that could be achieved under Option B+ outweigh the potential 
negative effects on maternal and child health that could occur if appropriate levels of adherence 
cannot be maintained.  
As countries such as Uganda continue to carry out Option B+, country-specific 
implementation and program evaluation research is necessary to understand if adequate levels of 
adherence to this PMTCT program are being achieved. In addition to studying levels of 
adherence, it is equally important to describe the factors affecting adherence for HIV-infected 
pregnant women and so that appropriate interventions can be proposed for reducing the risk of 
suboptimal adherence and program retention that can negatively affect maternal health, child 
health and PMTCT.  
 
Factors affecting PMTCT adherence  
While research focusing on PMTCT-specific barriers to adherence in the Option B+ era 
is on-going, studies looking at barriers to adherence, both in the context of PMTCT and adult 
HIV treatment and prevention, do exist. It is believed that these factors can affect more than one 
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stage of the care and treatment cascade and may interact or reinforce each other at different times, 
leading to decreased levels of program retention and adherence.86 The most commonly identified 




Studies show that poor physical or mental health can negatively affect care-seeking 
practices. For example, depression has been linked to lower ARV adherence.87 A recent case-
control study of HIV-infected adults in Uganda showed that HIV-positive adults with lifetime 
depressive disorders had an increased risk of non-adherence when compared to those without 
lifetime depressive disorders and that the association was stronger for females versus males.88 
Additionally, individual state of health is a commonly cited risk factor associated with missing 
scheduled appointments.89 
 
Previous HIV diagnosis 
Whether a pregnant woman is finding out her HIV status for the first time during the 
current pregnancy or was diagnosed prior to the current pregnancy may also affect adherence. A 
systematic review of factors affecting the uptake of ART for PMTCT in sub-Saharan Africa 
found that psychological issues following HIV diagnosis were a key barrier to ART uptake.90  It 
can be hypothesized that a woman who is aware of her HIV status prior to her current pregnancy 
may have already had the opportunity to confront some of the psychological issues following 
initial HIV diagnosis, such as denial, shock and fear, and is therefore more likely to adhere to the 
PMTCT program during her current pregnancy than a pregnant woman who has been newly 
diagnosed with HIV. Similarly, a study looking at the timing of maternal HIV testing and uptake 
of PMTCT interventions in South African found that women diagnosed with HIV before their 
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current pregnancy were more likely to attend ANC before 20 weeks gestation and were more 
likely to receive maternal and infant prophylaxis as compared to women diagnosed with HIV 
during or after the current pregnancy.91  
 
Maternal CD4 cell count at ART initiation 
There is some evidence that maternal CD4 cell count at the time of ART initiation may 
affect PMTCT program retention. For instance, the same cohort study conducted in Kenya that is 
described above found that a higher CD4 count at the time of ART initiation was associated with 
an increased odds of disengagement from PMTCT treatment.93  A systematic review of barriers 
and facilitators to uptake of ARTs for PMTCT in sub-Saharan Africa claimed that maternal CD4 
cell count was not significantly associated with NVP adherence90 but this could be largely due to 
the fact that many of the included studies looked at women initiating ART under older WHO 
recommendations excluding those with higher CD4 counts from initiating treatment.  
 
Previous PMTCT experience 
Although this is difficult to measure and the strength of association varies by study, some 
research indicates that previous PMTCT experience could be associated with adherence. For 
example, a cohort study of adherence and virologic suppression during the first 24 weeks of ART 
among women in South Africa showed that women who were previously enrolled in a PMTCT 
program and had received sdNVP in a prior pregnancy were less likely to demonstrate incomplete 
adherence, defined as returning greater than 5% of medications as estimated by pill counts at 
scheduled visits, than women who had not received sdNVP for PMTCT.92  Currently, there is a 
lack of data comparing the rates of adherence to PMTCT programs between HIV-infected 
pregnant mothers who have had previous PMTCT program experience and those that are 




Gestational age appears to be associated with PMTCT program retention. A recent cohort 
study conducted in South Africa looking at the disengagement of HIV-infected pregnant and 
postpartum women from ART services found that later gestational age at ART initiation was a 
significant predictor of disengagement from care, defined as no clinic attendance within 56 days 
of a scheduled visit.93  On the other hand, a different cohort study of HIV-infected, ART-naïve, 
pregnant women initiating ART for PMTCT in Kenya showed that the odds of disengagement 
from care, defined as an interval of greater than 30 days between visits or before delivery, 
decreased with increased gestational age.94  
 
The postpartum period 
Research indicates that HIV-infected pregnant women and mothers are less likely to have 
good adherence in the postpartum period as compared to the antepartum period. For example, a 
meta-analysis of ART adherence in low-, middle- and high-income countries during and after 
pregnancy reported pooled estimates of adherence that were significantly higher in the 
antepartum period than in the postpartum period.80 Similarly, the same cohort study from South 
Africa cited above showed disengagement from care among pregnant women initiating ART was 
twice as likely in the postpartum period as compared to the antenatal period.92  
 
Perceived risk 
Today knowledge about HIV transmission and treatment is much improved, but just as a 
woman in a monogamous marriage may not consider herself at high risk for acquiring HIV and 
therefore resist an HIV test,95 an HIV-infected woman believing that she is healthy may feel that 
she has a low risk of vertically transmitting HIV and may therefore exhibit sub-optimal PMTCT 
adherence or program retention. Similarly, an HIV-infected mother receiving negative HIV test 
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results for her infant at 6 weeks postpartum may believe her child is no longer at risk of acquiring 
HIV and become less vigilant about adhering to medication or clinic visits for PMTCT in the 
breastfeeding period.  
 
Self-efficacy 
Self-efficacy can be defined as the belief one has in one’s own ability to complete a task 
or reach a goal.96 Although many pregnant women are concerned about their HIV status and 
preventing transmission to their infants, they may lack the self-efficacy to adhere to the PMTCT 
regimen. A recent cross-sectional analysis in Vietnam found that increased perceived self-
efficacy, defined in the study as participant confidence that he or she can comply with ART 
regimens, was associated with optimal adherence.97 Likewise, it was found that improved 
adherence-related self-efficacy was significantly associated with decreased viral load among 
minority women in the United States.98  For HIV-infected pregnant women in resource-limited 
settings, lacking the confidence that they can overcome barriers to PMTCT care and treatment 
may negatively affect their feelings of self-efficacy and result in suboptimal program adherence. 
 
Dynamics in the home 
Family relationships are another factor associated with adherence to PMTCT services. A 
study in Malawi showed that inequality in the house restricts women from accessing necessary 
resources for care and are therefore reliant upon others to decide if and when to initiate and 
continue PMTCT services.99  The relationship of women with certain family members such as 






Male partner involvement 
Many studies have shown that male partner involvement plays a significant role in the 
uptake and adherence to PMTCT services. For instance, some women refused HIV counseling or 
testing because they feared the reaction from their partners.101   Studies have also shown that 
HIV-infected women are at an increased risk for intimate partner violence.102 Alternatively, 
women are often more likely to start ARV prophylaxis, 103 deliver in a facility104 and adhere to 
follow-up care105 when male partners are involved in the care of their partners.  Studies have also 
shown that HIV-infected mothers with higher male partner involvement exhibited improved 
adherence to maternal and infant prophylaxis.106  
 
HIV-associated stigma 
Stigma has been an on-going obstacle for all HIV-infected individuals and especially for 
ART adherence. For example, a cross-country analysis of HIV-infected individuals in five 
African countries found that perceived stigma had a highly significant association with neglecting 
to take all prescribed medications.107  In 2012, a policy paper sponsored by the USAID, PEPFAR 
and the Healthy Policy Project reviewed existing academic and programmatic evidence of the 
effects of stigma and discrimination on PMTCT and found that HIV-related stigma and 
discrimination negatively impacted service uptake and adherence for women and infants along 
each step of the PMTCT cascade.108  The same report also presented a mathematical model 
hypothesizing that an estimated 44% of all vertical HIV transmission could be avoided with a 
significant reduction in stigma and discrimination. 
 
Disclosure of HIV status 
It has been found that status disclosure by HIV-infected pregnant women to their partners 
is associated with an increased utilization of PMTCT services and that HIV-infected pregnant 
30 
 
women who have disclosed their status to their partners find it easier to store and take their ART 
than those women who have not disclosed their HIV status to their partners.109  A cross-sectional 
study in Ethiopia found that disclosure was more likely at later disease stages and when partners 
lived the same house, discussions about HIV testing had already taken place and the partner’s 
HIV status was known. 110 
 
Social networks and support 
Research has shown that social support is important for HIV program retention and has 
been linked to improved drug adherence.111 Qualitative studies looking at adherence in 
Botswana112 and Tanzania113 found that patients who reported not having strong social networks 
within the community lost motivation for treatment adherence. On the other hand, motivational 
groups for HIV-infected women in Nigeria have been associated with significantly higher levels 
of ART adherence when compared to a control group.114  Similarly, a pilot study in South 
Africa115 found that HIV-infected pregnant women receiving support from the mothers2mothers 
peer mentoring program showed an improved ability to establish social support and reduce 
depression scores as compared to HIV-infected pregnant women in the control group receiving 
standard services. The same study showed that compared to women in the control group, women 
participating in the intervention had improved attendance at follow-up medical visits, a common 
measure of PMTCT program adherence. Recently, a cross-sectional study in Rwanda116 found 
that HIV-infected individuals participating in an association for PLWHA and/or receiving care at 
sites which regularly conducted home visits exhibited lower odds of ART non-adherence when 






Place of delivery  
Studies show that place of delivery may affect the adherence and program retention of 
HIV-infected pregnant women and mothers. For instance, a cohort study in Zambia looking at 
predictors of non-adherence to sdNVP found an increased odds of both maternal non-adherence 
and infant non-adherence, defined as no maternal NVP consumption and no infant NVP 
consumption respectively, for women delivering at home as compared to women delivering in 
clinics.81  Similarly, a recent literature review looking at medication adherence for PMTCT in 
sub-Saharan Africa found that giving birth at home was associated with low adherence to ARV 
prophylaxis.117  
 
Transportation and economic concerns 
The time and distance it takes to travel to facilities as well as the cost of transportation 
have been shown to affect behaviors associated with HIV testing, receipt of results and service 
utilization.118  A qualitative study of HIV-infected women attending ANC in Malawi found that 
economic concerns such as transport costs represented the greatest barrier to accessing 
treatment.119  Along the same lines, a case-control study of determinants of non-adherence to 
sdNVP for PMTCT in Rwanda found that women attending  two or less ANC visits were more 
likely to be non-adherent than those attending more than two visits.120  Regular ANC attendance 
is directly associated with utilization of ANC services and the underlying cause of irregular ANC 
attendance may be the cost of travel to and from the clinic.  
 
Political and health system environment and functionality 
Studies have shown that social welfare and insurance policies can affect HIV service use 
and health outcomes.121 Health system functionality also affects PMTCT adherence behaviors. 
For instance, a qualitative study from Uganda found that health service factors such as long 
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waiting times at the clinic and negative interactions with staff were barriers for adherence to 
highly active antiretroviral therapy (HAART) for HIV-infected mothers.122  Similarly, a cross-
sectional analysis of mostly African American males from the Johns Hopkins HIV Cohort 
Study123  as well as a cross-sectional pilot study of HIV-infected pregnant women in South 
Africa124 found that a close patient-provider relationship (i.e. the patient perceiving that he or she 
is “known as a person”) was significantly associated with receiving and adhering to HAART. In 
resource-limited settings, ensuring an adequate supply of ART drugs is also a significant barrier 
to adherence.125  
 
Conceptual framework 
Evolution of the Social Ecological Model 
The factors described above can be thought of as determinants of PMTCT medication 
adherence and program retention. Some of these factors are individual characteristics while others 
are structural and environmental factors that influence and are influenced by the characteristics of 
the individual HIV-infected pregnant woman. This notion of reciprocal causation between the 
individual and the environment, as well as the theory that health behaviors simultaneously shape 
and are shaped by multiple levels of social influence, are features of the Social Ecological Model 
(SEM) for health promotion put forth by McLeroy et al. in 1988. The underlying assumption of 
the model is that changes to a specific social environment may produce the desired changes in 
health behavior of the individual, and that support of the individual within the population is key 
to realizing this environmental change.126  McLeroy et al. adapted the ecological model 
formalized by Bronfenbrenner in the 1970s and 1980s127 to describe five levels at which the 
health outcome of interest (i.e. health behavior) is determined: 1) intrapersonal factors 
(characteristics of the individual); 2) interpersonal processes and primary groups (formal and 
informal social networks and social support systems); 3) institutional factors (social institutions 
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with organizational characteristics and rules and regulations for operation); 4) community factors 
(relationships among organizations, institutions and informal networks within defined 
boundaries) and 5) public policies (local, state and national laws and policies).103  
The McLeroy SEM addressed the importance of moving away from an individual 
behavior change model and toward interventions directed at changing structural and 
environmental factors that negatively affect health behaviors. However, this SEM did not account 
for the role that contextual factors such as culture, social class, racism, gender or economics may 
play in individual health behaviors.128  These factors are especially important for explaining and 
intervening on HIV/AIDS-related behaviors such as adherence and program retention, especially 
since HIV is now more commonly recognized as a social disease driven largely by discrepancies 
in resources and power, such that disadvantaged individuals are less likely to adhere to HIV 
medication and stay in care. To examine structural and environmental interventions for reducing 
the risk of HIV in developing countries, Sweat and Denison developed an ecological theory of 
levels of causation of HIV incidence that comprised four levels of causation, including a 
superstructural level absent from the SEM made up of macrosocial and political arrangements, 
resources and power differences resulting in unequal advantages such as economic 
underdevelopment, poverty and sexism.129  The three levels nested within the superstructural 
level were the structural level (laws, policies and standard operating procedures similar to the 
SEM level of public policy), the environmental level (individual living conditions, resources and 
opportunities as well as recognition of individual, structural and superstructural factors) and the 
individual level (the way the environment is experienced and acted upon by the individual).106  
 
Conceptual framework for PMTCT adherence and program retention  
The theoretical approach of Sweat and Denison and the SEM proposed by McLeroy et al. 
informed the conceptual framework developed for this dissertation. The factors affecting PMTCT 
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medication adherence and program retention described above have been grouped together by the 
level of social influence at which they act. These levels include: 1) the individual HIV-infected 
pregnant woman; 2) relationships with family and peers; 3) institutional and organizational 
factors; 4) community characteristics; 5) public policy and 6) macro-social and macro-political 
factors. The double sided arrows represent the potential for bi-directional influence at each level. 
For example, the Option B+ policy has the potential to affect the PMTCT adherence behaviors 
and program retention of the individual HIV-infected pregnant woman both directly and 
indirectly through the nested levels of social influence, but changes to the Option B+ policy may 
also occur as a result of factors associated with the individual HIV-infected pregnant woman and 
the additional nested levels of social influence. Similarly, macro-social and macro-political 
factors such as HIV-associated stigma, gender inequality, economic underdevelopment and 
poverty undoubtedly affect the implementation of Option B+ as well as other factors associated 
with PMTCT adherence and program retention at the different levels of social influence, but at 
the same time, altering these macro-level influences may be dependent on changes happening at 
the lower levels of social influence. The conceptual framework depicted in figure 5 below was 













Figure 5: Conceptual framework for determinants of PMTCT medication adherence and 
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The overall goal of this project was to improve the current understanding of changes to 
medication adherence and program retention over time for HIV-infected pregnant women and 
mothers enrolled in the Option B+ program for PMTCT of HIV and how various factors may 
affect these outcomes in pregnancy and the postpartum period. A mixed methods approach was 
used to accomplish this study goal. 
 
Specific aims 
Specific aim 1:  
To summarize the most current medication adherence and program retention findings in 
the antenatal and postnatal periods for HIV-infected pregnant women and mothers receiving 
Option B+ for PMTCT in different implementation settings through a systematic review of the 
current Option B+ adherence and program retention literature.  
 
Specific aim 2:  
To measure changes to Option B+ adherence and program retention from pregnancy to 
six months postpartum for a representative sample of HIV-infected pregnant women and mothers 
at Mulago National Referral Hospital who are newly initiating Option B+ for their current 
pregnancies and to assess the impact of the following factors on Option B+ adherence and 
program retention over time: 1) Previous HIV diagnosis; 2) Previous PMTCT program 
experience; 3) Status disclosure; 4) Baseline CD4 cell count; 5) Time since ART initiation during 





Specific aim 3:  
To qualitatively explore the experiences of HIV-infected pregnant women with adherence 
and the Option B+ program under the standard of care at Mulago National Referral Hospital and 
to understand how these experiences, as well as factors affecting these experiences, may change 
from pregnancy to the early postpartum period.  
 
METHODS 
Specific aim 1: Systematic review of the Option B+ adherence and program retention literature 
 The systematic review of Option B+ adherence and program retention literature included 
all peer-reviewed articles assessing Option B+ maternal medication adherence and program 
retention in countries that had adopted or were beginning to adopt this approach as the national 
strategy. Studies measuring the medication adherence and program retention of HIV-infected 
pregnant women and mothers seeking care and treatment during pregnancy and in the postpartum 
period in the countries implementing Option B+ as the national strategy for PMTCT were 
included in the systematic review.  
The following databases were searched for this review: PubMed (last searched on 
December 29, 2016), Embase (last searched on December 30, 2016), Global Health (last searched 
on December 30, 2016) and Scopus (last searched on December 30, 2016). The databases were 
searched using key words and medical subject headings (MESH) for HIV, Option B+ countries, 
pregnancy, the postpartum period, and vertical transmission. To account for the start of Option 
B+ implementation, the search strategy was limited to studies published since January 1, 2010 
and taking place in countries known to be piloting, rolling out or fully implementing the Option 
B+ guidelines. Titles and abstracts were imported into EndNote X7.7 and duplicates were 
identified and removed. Reference lists of included articles were also searched for additional 
relevant publications.  
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Titles and abstracts were independently screened by one researcher using criteria 
established prior to the study selection process and then full-text versions of potentially relevant 
articles were assessed for eligibility. Given the outcomes of interest for this review, all 
quantitative and mixed-methods study designs were eligible, but qualitative studies were 
excluded. Further inclusion criteria included: 1) Option B+ as the PMTCT approach, 2) pregnant 
or postpartum women living with HIV as the study population, 3) reporting of medication 
adherence or program retention and 4) presentation of primary data and the eligibility criteria 
were applied to each study in that order. To ensure quality of data through the peer review 
publication process, conference and presentation abstracts were excluded. Commentaries, 
editorials and reviews were also excluded from the study, but references were searched for 
potential sources of primary data.  
Data extraction was performed independently and the paper authors, journal, year of 
publication, study period, country, year of national Option B+ implementation, study setting, 
study population, study design, sample size, ART regimen, adherence or program retention 
indicator(s) and study findings were obtained from each study. Results of statistical tests for 
measures of association were included when relevant to the study. Additional information 
provided in the study about the PMTCT program, such as recommended number of clinic visits 
before delivery or counseling and testing procedures, was also noted for context.  
Study quality was independently assessed with guidance from the Effective Public Health 
Practice Project criteria (EPHPP). Studies were rated as strong, moderate or weak in terms of 







Specific aim 2: Measuring changes in Option B+ adherence and clinic visit attendance over time  
 Changes in Option B+ ART adherence and clinic visit attendance over time were 
measured through the utilization of routine PMTCT program data collected and entered into an 
electronic database by Makerere University-Johns Hopkins University (MU-JHU) Research 
Collaboration staff at Mulago National Referral Hospital for the purposes of routine program 
evaluation. Longitudinal data from HIV-infected pregnant women attending Mulago Hospital and 
enrolling in the PMTCT program during pregnancy in 2014 were analyzed in this study. Mulago 
Hospital was chosen as the study site due to the high volume of HIV-infected pregnant women 
presenting for care and the richness of the existing PMTCT databases as well as the partnership 
that exists between Johns Hopkins University and Makerere University though the MU-JHU 
research collaboration.  
Mulago National Referral Hospital is located in the northern part of Kampala City and is 
one of two national referral hospitals in the country. It is the largest hospital in Uganda and the 
teaching hospital for the Makerere University College of Health Sciences. The PMTCT program 
at Mulago National Referral Hospital began in April, 2000 with funding from EGPAF and 
included voluntary counseling and testing for pregnant women and sd-NVP at onset of labor with 
sd-NVP for the infant at birth. In 2005 the PMTCT guidelines were updated to include routine 
counseling and HIV testing and AZT or AZT/3TC from 28 weeks gestation and sd-NVP at the 
onset of labor for HIV-infected pregnant women with a CD4 count of less than or equal to 200 
cells/mm.3 The routine counseling and testing approach resulted in a large increase in the number 
of identified HIV-infected pregnant women attending Mulago for ANC and as a result, the 
follow-up clinic was created in February, 2006. The purpose of the follow-up clinic was to retain 
HIV-infected pregnant women and mothers in care for the first 18 months postpartum before they 
were referred to the Makerere University Joint AIDS Program Immune Suppression Syndrome 
(MJAP ISS) clinic or a different clinic of choice for ongoing HIV care and treatment. The follow-
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up clinic dispensed ART, provided treatment for opportunistic infections and offered sexual and 
reproductive health services such as family planning and cervical cancer screening. In 2010, 
Mulago adopted the WHO-recommended Option A approach PMTCT. Option A included a 
prophylaxis regimen of AZT from 14 weeks gestation and NVP syrup for infants for the first six 
weeks of life. In 2012, Mulago transitioned from Option A to Option B+ to reflect the most 
current WHO guidelines for PMTCT.  
Today, the Option B+ program includes provider initiated HIV counseling and testing in 
ANC and same-day ART initiation with a TFV/3TC/EFV triple combination regimen as the first-
line therapy, irrespective of CD4 cell count. All HIV-infected pregnant women are also expected 
to receive Co-trimoxazole prophylaxis. The timing and frequency of ANC clinic visits varies by a 
number of factors including gestational age at presentation to ANC, psychosocial (PSS) 
evaluation and disease severity, but HIV-infected pregnant women enrolled in care are generally 
scheduled to return to clinic two weeks after ART initiation and then monthly until delivery. 
HIV-infected women delivering at Mulago are expected to initiate exclusive breastfeeding within 
an hour of delivery and HIV-exposed infants are expected to receive NVP syrup at birth. Follow-
up of HIV-exposed infants and mothers takes place at the postnatal clinic and includes DNA 
polymerase chain reaction (PCR) testing of HIV-exposed infants, distribution of infant 
prophylaxis, immunization and growth monitoring. The first infant HIV test is expected to be 
done by six weeks postpartum and results are expected to be received one week later or at the 
next clinic visit. As previously stated, maternal health services and ART are provided at the 
follow-up clinic. 
This longitudinal cohort study included HIV-infected pregnant women presenting for 
ANC at Mulago National Referral Hospital from January 1, 2014 to December 31, 2014. All 
HIV-infected pregnant adult women of reproductive age (18-49 years old) who presented to 
Mulago National Referral Hospital in 2014, had attended at least two ANC visits and were new 
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initiators of Option B+ for their current pregnancies were included in this study. HIV-infected 
pregnant women included in the study were either ART-naïve or had initiated a previous form of 
ART prophylaxis for past pregnancies under old PMTCT guidelines but were new initiators of 
Option B+.  Women were excluded from the study if they were younger than 18 years old at the 
time of Option B+ initiation, had initiated a PMTCT regimen other than the one indicated by 
Option B+, were not new initiators of Option B+ for PMTCT or initiated Option B+ after the 
ANC period. Women were also excluded if the pregnancy did not result in a live birth. A 
longitudinal cohort study design was used to account for changes in Option B+ ART adherence 
and program retention over time from ANC through six months postpartum.  
Data abstracted for this study took place from May 4, 2016 to August 1, 2016. Routinely 
collected indicators regularly entered into the Mulago PMTCT program electronic database were 
extracted for this study. In addition, data abstraction was performed from patient medical charts 
and the PMTCT clinic log books to obtain ART adherence and program retention information for 
the first ANC visit post-ART initiation and again at six weeks postpartum and six months 
postpartum. As described above, data was collected for all HIV-infected pregnant women who 
enrolled in the Option B+ PMTCT program beginning on January 1, 2014. A local research 
assistant was trained to assist the first author of this study with data abstraction and her work was 
validated by the first author of this study.  Data from the PMTCT database and medical chart/log 
book abstraction were merged to create the longitudinal dataset necessary for this analysis to take 
place.  
 The primary outcomes for this study were maternal ART adherence and clinic visit 
attendance at the first ANC visit after enrollment into the PMTCT program and again at six 
weeks and six months postpartum. At Mulago, medication adherence is measured and recorded 
by PMTCT clinic counselors trained to perform ART pill counts. Patients are instructed to return 
to each clinic appointment with the ART pill box and counselors count the number of pills 
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remaining at the current clinic visit. The number of pills remaining are subtracted from the 
number of pills dispensed at the last clinic visit to determine the number of pills swallowed 
between visits. The number of pills wasted, as self-reported by the patient, are also subtracted 
from the number of pills last dispensed and ART adherence is then calculated by dividing the 
number of pills actually swallowed by the number of pills expected to have been swallowed 
based on the date ART was last dispensed and the number of pills left over at the last visit. 
Patients were categorized as adherent or non-adherent based on a 95% and an 80% pill count 
adherence cutoff. The 95% cutoff was utilized to remain consistent with the definitions of optimal 
and suboptimal adherence used by the PMTCT clinic at Mulago. The 80% cutoff was included to 
reflect the minimum level of adherence necessary for successful viral suppression described in 
the literature.76 If adherence at any time point could not be ascertained, it was recorded as 
“unknown.” An unknown adherence outcome was the result of either patients failing to return 
with the pill box or not being able to determine the number of pills last dispensed at the previous 
visit due to incomplete information in the medical charts or clinic log books. In addition to the 
medication adherence definition described above, a broader definition of non-adherence was also 
utilized in a separate analysis to capture patients who were either non-adherent to ART or had 
either failed to return with the pill box or did not return for the scheduled clinic visit.  
 The six-week and six-month postpartum visits were identified for each patient by 
estimating the scheduled clinic visit dates using the infant date of birth found in the PMTCT 
database for each patient. Due to variations in scheduling of clinic visit appointments, visits 
occurring between five and eight weeks postpartum and five and seven months postpartum were 
considered valid time points for data collection for the six-week and six-month postpartum visits, 
respectively. If visits occurred both before and after the estimated visit date but within the 
indicated window, the visit determined to be closest to the estimated visit date was used for the 
purposes of this study.  
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Information routinely entered into the PMTCT database and the clinic log books were 
used to obtain demographic and clinic characteristics and to measure the effects of the following 
factors on changes in ART adherence and clinic visit attendance: 1) Previous HIV diagnosis was 
determined using the PMTCT screening form and recorded as “Yes” if the patient had been 
diagnosed before the current pregnancy or “No” if the patient had been newly diagnosed with 
HIV during the current pregnancy; 2) Previous PMTCT experience was determined using the 
PMTCT enrollment form and recorded as “Yes” if the patient had initiated ART for PMTCT 
during a previous pregnancy or “No” if the patient had never initiated ART for PMTCT prior to 
the current pregnancy; 3) Status disclosure by the first visit post-ART initiation was obtained 
from the PMTCT psychosocial form and recorded as “Yes” if HIV status had been disclosed or 
“No” if the patient had not disclosed her status at that time. The relationship of the disclosed to 
the participant (e.g. husband, mother, friend, etc.) was also recorded when available; 4) Baseline 
CD4 count at program enrollment was collected from the PMTCT registration and lab forms and 
categorized as greater than 350 cells/mm3 or less than or equal to 350 cells/mm3 in accordance 
with the previous WHO CD4 cutoff for treatment vs. prophylaxis for HIV-infected pregnant and 
postpartum women; 5) Time since ART initiation during pregnancy was calculated using the date 
of ART initiation and the date of delivery and categorized as more than 30 days on ART before 
delivery or less than or equal to 30 days on ART before delivery; 6) Partner counseling and 
testing by the first ANC visit post-ART initiation was determined using the PMTCT screening 
form and recorded as “Yes” if the partner had been tested for and counseled about HIV or “No” if 
the partner had not been tested for or counseled about HIV at this time; 7) Psychosocial support 
group meeting attendance was determined using the clinic log books and recorded as “Yes” if the 
patient had attended at least one psychosocial support group meeting or “No” if the patient had 
not attended any psychosocial support group meetings  during pregnancy or by six weeks and six 
months postpartum.  
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 Statistical analyses were performed using Stata software version 12 (StataCorp, College 
Station, TX). Baseline characteristics and demographics were summarized categorically and with 
means and standard deviations (SDs) when relevant.   
The proportions of adherent patients and patients attending scheduled clinic visits were 
calculated for each visit and McNemar’s Chi Squared statistic for paired data was used to detect 
differences in the proportion of adherent patients and patients attending scheduled clinic visits 
between each time point of interest. Unadjusted and adjusted odds ratios with 95% confidence 
intervals (CIs) were obtained using univariate and multivariate logistic regression to estimate the 
associations between medication adherence or clinic visit attendance and each factor of interest. 
Multivariate logistic regression included all factors tested in the univariate analyses and then 
backward selection was used to select the final models predicting medication adherence and 
clinic visit attendance at each time point. P-values less than or equal to 0.05 were considered 
statistically significant in the univariate and multivariate analyses. A “p-to-remove” value of 
p=0.20 was used in the model selection process such that predictors were removed one at a time 
beginning with the predictor with the highest p-value until the p-values of all predictors left in the 
model were less than or equal to 0.20.  
 
Specific aim 3: Understanding experiences with adherence and the Option B+ program 
 The experiences of HIV-infected pregnant women and mothers with ART adherence and 
the Option B+ program were also explored at Mulago National Referral Hospital. A subset of 
HIV-infected pregnant women who had been randomized to the control arm of a randomized 
controlled trial (RCT) entitled, “Using Enhanced Peer Group Strategies to Support Option B+ in 
Uganda.” This RCT aims to measure the effectiveness of a community-based peer support group 
intervention at improving long-term ART adherence under Option B+. The RCT, commonly 
referred to as the “Friends for Life Circles” study, began enrollment in May, 2015 and participant 
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enrollment is ongoing. The study aims to randomize a combined total of 540 HIV-infected 
pregnant women at Mulago Hospital in Kampala and Mityana Hospital the Mityhana District, 
approximately 74 kilometers (48 miles) northwest of Kampala. A 1:1 randomization is taking 
place such that 270 participants will receive the community-based peer support group 
intervention and 270 participants will receive the MoH standard of care under the Option B+ 
Program.  
To be eligible for inclusion into the RCT, women must be 1)18 years or older; 2)  
pregnant, as confirmed through a clinical assessment or pregnancy test; 3) HIV-positive, as 
confirmed through a HIV-positive sero-status at the time of screening; 4) accepting of Option B+ 
for PMTCT; 5) able and willing to provide written informed consent to participant in the 
randomized trial; 6) agreeing to attend the study clinic for scheduled appointments and 7) 
accepting of home visits as needed, to ensure follow up throughout the study period.  When 
enrolling participants, distance from the study clinic and intentions to move out of the catchment 
area within the next two years is also being taken into account. To be included in the subset of 
control arm participants enrolled in this study, HIV-infected pregnant women were required to 
meet the study eligibility criteria described above. In addition, only HIV-infected pregnant 
women presenting for care in the last trimester of pregnancy at Mulago Hospital were included in 
this study.  
Longitudinal in-depth interviews with HIV-infected pregnant women were conducted 
prospectively to gain a better understanding of the experiences of HIV-infected pregnant women 
and mothers with adherence and the Option B+ program over time. In this study, a subset of the 
first 16 participants in the last trimester of pregnancy who were enrolled in the “Friends for Life 
Circles” study and randomized to receive standard of care at Mulago Hospital were purposively 
selected to be interviewed once during pregnancy at the one month post-ART initiation study visit 
and again at six weeks postpartum. The “Friends for Life Circles” RCT began enrollment on May 
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16, 2016 and the final in-depth interview participant was enrolled into the study on January 27, 
2017.   
All interviews were conducted by a local co-investigator or one of two local study 
counselors with the aid of semi-structured field guides. The co-investigator conducting interviews 
had a master’s degree in nursing, extensive experience in HIV counseling and some prior 
experience with qualitative research. This was the first qualitative research experience for the two 
study counselors conducting the interviews. One counselor had a bachelor’s degree in nursing and 
the other had a bachelor’s degree in social work. Both counselors had HIV counseling experience 
prior to study initiation. The interview team received multiple trainings on proper interview 
techniques, use of the semi-structured field guides and the goals of each interview prior to study 
initiation.  
The semi-structured field guides were created prior to study initiation and included 
suggested interview questions and probes relevant to the activities and experiences surrounding 
each study visit. The ANC interview aimed to focus on the experiences of the HIV-infected 
pregnant women with HIV testing, treatment initiation, status disclosure, male partner 
involvement, stigma and social networks and how these experiences may have influenced the 
ART adherence and clinic attendance. The six-week postpartum interview aimed to focus on the 
experiences of the HIV-infected mothers with infant HIV testing, infant HIV prophylaxis, 
maternal ART adherence, clinic visit attendance and changes in status disclosure, male partner 
involvement, stigma and/or social networks. Interviews lasted between 30 minutes to one hour 
and took place upon completion of all other “Friends for Life Circles” study activities. The in-
depth interview team consisting of the study coordinator, the co-investigator and two study 
counselors met weekly with the first author prior to and during the initial data collection period 
and then monthly as data collection progressed, to practice interviewing techniques, discuss 
arising themes and refine the interview guides for a more iterative research process.  
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All interviews were conducted in Luganda and digitally recorded after obtaining verbal 
approval from each participant. Interviews were then directly transcribed and translated into 
English for analysis by a trained qualitative analysis consulting team with experience in previous 
National Institutes of Health (NIH) or PEPFAR-supported qualitative research studies. No 
identifying information was linked to any audio files or transcripts. To protect privacy and 
maintain confidentiality, interviews were held in a private location within the health facility. 
Participants were offered light refreshments and reimbursed for transportation to and from the 
clinic.  
Transcripts were reviewed and read over multiple times as they were received, and 
analytic memos were written to reflect on developing patterns, categories, themes and concepts in 
the data.  The analytic memos were then coded and categorized according to their content. The 
coding and categorization process was based both on emergent themes from the data and a priori 
themes based on the interview guides. All transcripts were coded using the scheme developed 
from the analytic memos, with additional codes added as they appeared, if considered relevant to 
addressing the study goal. Transcripts from interviews at pregnancy and six-weeks postpartum 
were coded and analyzed separately, and another series of analytic memos and codes were 
developed to reflect the changes in experiences of participants over time from pregnancy to six-
weeks postpartum. Coding was performed manually and tracked through the use of multiple 
Excel spreadsheets.  
Ethical approval to conduct this research was obtained from the institutional review 
boards of the Johns Hopkins University School of Medicine, the University of California San 
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PART ONE:  
Maternal ART adherence and program retention in pregnancy and the postpartum period 
for HIV-infected women receiving Option B+ for prevention of mother-to-child 





 Mother-to-child transmission of HIV is responsible for the majority of pediatric HIV 
infections. Implementation strategies to prevent vertical HIV transmission have continued to 
evolve over time. Option B+ is the current World Health Organization recommendation for 
preventing mother-to-child transmission of HIV and consists of a single, universal strategy for 
both treatment of HIV-infected pregnant women and for infant prophylaxis. Option B+ includes 
the provision of triple ART for all HIV-infected pregnant women at the antenatal clinic regardless 
of clinical stage or CD4 cell count to be continued for life. Inconsistent adherence is a serious 
barrier for the elimination of HIV/AIDS and specifically for preventing vertical HIV transmission 
and maternal and child health. Previous research, including systematic reviews and meta-
analyses, have shown that medication adherence and program retention of HIV-infected pregnant 
women and mothers decreases over time, but this research was mostly published before countries 
adopted the current WHO recommendation for PMTCT. 
 The goal of this systematic review was to summarize the maternal medication adherence 
and program retention literature since implementation of the Option B+ program began in Malawi 
in 2010. The PubMed, Embase, Global Health and Scopus databases were searched for relevant 
data and study quality was rated based on bias, study design, confounders, methods for data 
collection and appropriateness of the data analysis.  
 Out of the 4,712 records screened, 19 studies were included in this review. All of the 
studies were from sub-Saharan Africa. The most common measures of program retention and 
medication adherence were loss to follow-up, self-report and pill count adherence. Program 
retention and adherence varied greatly across studies. Overall, more evidence is necessary to 
improve the current understanding of Option B+ maternal medication adherence and program 
retention over time and the factors that may affect these outcomes in pregnancy and the 







 Mother-to-child transmission (MTCT) is responsible for the majority of pediatric HIV-1 
infections.1  MTCT can happen in-utero, at delivery or during the breastfeeding period, with risks 
of transmission ranging from 5-10%, 10-20% and 5-20%, respectively, resulting in an overall 
vertical transmission rate of between 15-45% without intervention.2  Successful prevention of 
mother-to-child transmission of HIV (PMTCT) can reduce rates of transmission to less than 5%,3 
but implementation of PMTCT strategies continues to be difficult, especially in resource-limited 
settings such as sub-Saharan Africa. Experts in the field of HIV and PMTCT often refer to the 
“PMTCT cascade” as a way of addressing key areas along the HIV care and treatment continuum 
where challenges to PMTCT are most likely to occur. Attrition along the cascade is most 
commonly seen in resource-limited settings such that only a small proportion of all HIV-infected 
mothers present for care and successfully receive and adhere to the antiretroviral (ARV) 
prophylaxis regimens necessary for PMTCT4. While developed countries are close to achieving 
elimination of vertical HIV transmission, it has been estimated that only 15-30% of eligible 
women in resource-limited settings successfully completed the PMTCT cascade.4  In an effort to 
improve PMTCT outcomes and consequently improve maternal and child health, experts from 
various research communities in collaboration with the World Health Organization (WHO) and 
community and government partners from countries with high HIV burden have continued to 
evaluate ways to improve the uptake and adherence to PMTCT care and treatment services. 
 Inconsistent adherence is a serious barrier for the elimination of HIV/AIDS and 
specifically for PMTCT and maternal and child health since it is associated with an increased risk 
for opportunistic infections,5 HIV disease progression6 and viral resistance to ART.7 Previous 
research, including a meta-analysis of adherence to antiretroviral therapy during pregnancy and 
after pregnancy in low-, middle- and high-income countries, has shown that medication 
adherence tends to decrease between the antenatal and postnatal periods.8  Similarly, a review 
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looking at linkage and retention of HIV-positive pregnant women in care and treatment services 
found high attrition between HIV testing and accessing long-term services.9 However, these 
reviews were based mostly on research evaluating programs implementing past WHO 
recommendations, before Option B+ became the recommended PMTCT strategy for resource-
limited countries.  
 Option B+ is the current WHO recommendation for PMTCT. This approach has been 
described as a single, universal strategy for both the treatment of HIV-infected pregnant women 
and for PMTCT prophylaxis.10 Option B+ includes the provision of triple ART for HIV-infected 
pregnant women at the antenatal clinic regardless of clinical stage or CD4 cell count, to be 
continued for life as soon as HIV status is ascertained. Option B+ implementation began in 
Malawi in 2010 as a response to the high incidence of infant HIV infection and limited capacity 
of laboratories to perform CD4 cell counts necessary to implement the previous WHO 
recommendations.11 As implementation of Option B+ programs continues in different settings, 
more information is being uncovered about maternal ART adherence and program retention. The 
scope of this systematic review focuses specifically on maternal ART adherence and retention in 
care after ART initiation in order to gain a more current and comprehensive understanding of the 
feasibility of consistent long-term maternal ART adherence and program retention under the 




A review of the Option B+ adherence and program retention literature was conducted by 
searching for data published in the following databases: PubMed (last searched on December 29, 
2016), Embase (last searched on December 30, 2016), Global Health (last searched on December 
30, 2016) and Scopus (last searched on December 30, 2016). The databases were searched using 
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key words and medical subject headings (MESH) for HIV, Option B+ countries, pregnancy, the 
postpartum period, and vertical transmission. As a reference, the detailed electronic search 
strategy for the PubMed search can be found in Appendix B. To account for the start of Option 
B+ implementation, the search strategy was limited to studies published since January 1, 2010 
and taking place in countries known to be piloting, rolling out or fully implementing the Option 
B+ guidelines. Titles and abstracts were imported into EndNote X7.7 and duplicates were 
identified and removed. Reference lists of included articles were also searched for additional 
relevant publications.  
 
Study selection  
Titles and abstracts were independently screened by one researcher using criteria 
established prior to the study selection process and then full-text versions of potentially relevant 
articles were assessed for eligibility. Given the outcomes of interest for this review, all 
quantitative and mixed-methods study designs were eligible, but qualitative studies were 
excluded. Further inclusion criteria included: 1) Option B+ as the PMTCT approach, 2) pregnant 
or postpartum women living with HIV as the study population, 3) reporting of medication 
adherence or program retention and 4) presentation of primary data and the eligibility criteria 
were applied to each study in that order. To ensure that published data had gone through a 
comprehensive peer review process, conference and presentation abstracts were excluded. 
Commentaries, editorials and reviews were also excluded from the study, but references were 
searched for potential sources of primary data.  
 
Data extraction and analysis  
 Data extraction was performed independently and the paper authors, journal, year of 
publication, study period, country, year of national Option B+ implementation, study setting, 
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study population, study design, sample size, ART regimen, adherence or program retention 
indicator(s) and study findings were obtained from each study. Results of statistical tests for 
measures of association were included when relevant to the study. Additional information 
provided in the study about the PMTCT program, such as recommended number of clinic visits 
before delivery or counseling and testing procedures, was also noted for context.  
 
Assessment of bias and study quality 
Study quality was independently assessed with guidance from the Effective Public Health 
Practice Project criteria.12 Studies were rated as strong, moderate or weak in terms of selection 
bias, study design, confounders and methods for data collection.   
 
FINDINGS 
Characteristics of included studies 
 The database searches yielded 4,708 records with an additional 4 records found through 
searching the reference lists of included articles and relevant reviews. After removing duplicates, 
screening abstracts and full-text reviews, 19 studies were identified that met the inclusion criteria 
for this review (Figure 1). Overall, the studies were conducted in seven different countries. The 
majority of studies were conducted in Malawi (n=7), three studies were conducted in Ethiopia, 
two studies each were conducted in Mozambique, South Africa, Uganda and Zimbabwe and one 
study was conducted in Rwanda. Six studies were conducted in urban settings, five in rural 
settings and five in both urban and rural settings. For three studies the study setting was not 
explicitly stated and therefore unclear. The majority of studies were conducted at a variety of 
health facilities (n=9). Four studies each were conducted exclusively in either hospitals or health 
centers and two studies did not specify the type of health facility. The studies included in this 
review were either prospective cohort studies (n=8), retrospective cohort studies (n=7) or cross-
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sectional studies (n=3), and one study was described as a pre-post quasi-experimental study. Nine 
of the studies reported on retention in care, four studies reported on medication adherence and six 
studies provided information for both outcomes. For all studies, the Option B+ maternal ART 
regimen was a once-daily combination regimen comprised of tenofovir (TFV), lamivudine (3TC) 
and efavirenz (EFV). 
Figure 1: Prisma flow diagram summarizing literature search
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Program retention  
 The most frequently used indicator of Option B+ program retention was loss to follow-up 
(LTFU) from the time of ART initiation. However, the period of time used to define LTFU 
ranged from three weeks to six months. Some studies also differentiated between study 
participants being LTFU and having no follow up since the first ART initiation visit. Seven of the 
studies looked at program retention for pregnant women and six looked at program retention for 
pregnant and postpartum women. Two studies looked only at program retention in the postpartum 
period. The basic characteristics of studies evaluating retention in care are summarized in Table 1 
of Appendix C.  
Table 2 of Appendix C summarizes the program retention findings of each study. The 
median LTFU rate among all studies reporting this outcome was 17% (range: 11.2%, 48.5%). 
Studies that were able to compare program retention under Option B+ to program retention under 
the previous Option A recommendation consistently reported an increased risk of LTFU 
associated with the Option B+ program.29,31 For example, one study comparing Option B+ LTFU 
to Option A LTFU in a historical cohort in Mozambique found that women in the Option B+ 
program were nearly twice as likely to be lost to follow-up at one year since ART initiation and 
over three times more likely to stop care after the ART initiation visit.29 Similarly, all studies 
looking at day of ART initiation found that initiating ART on the same day as HIV diagnosis was 
associated with an increased risk of LTFU when compared to initiating treatment at least one day 
after HIV diagnosis.26,34  Risk of LTFU was also found to be significantly greater for younger 
women as compared to older women across most studies.27,28, 34, 38, 39  While some studies found 
pregnant women significantly more likely to be LTFU than postpartum women,33, 39others found 
this association to be nonsignificant.28 Type of health facility and CD4 cell count and/or WHO 
clinical stage at ART initiation were sometimes found to be significantly associated with LTFU, 
however the direction of association was inconsistent across studies.  
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Maternal ART adherence  
 Of the 10 studies reporting maternal ART adherence under the Option B+ program, six 
utilized self-report, two utilized pill counts, one utilized prescription pick-up and one utilized 
treatment discontinuation as the adherence indicator. In studies using self-report, participants 
were asked to assess the number of missed doses in either the last three days or the last month. 
The number of missed doses were reported and zero missed doses was commonly used as the 
definition of good adherence. In studies using pill counts as the measure of adherence, 95% 
adherence was the cutoff for adequate or good adherence. The study population consisted of 
pregnant women, pregnant and postpartum women or only postpartum women for seven, two and 
one study, respectively. The basic characteristics of studies evaluating Option B+ medication 
adherence are summarized in Table 3 of Appendix C.  
 Table 4 of Appendix C reports the medication adherence findings of each study. The time 
at which adherence was evaluated varied, with some studies measuring adherence at three, six or 
12 months after ART initiation while others assessing it specifically at the time of the study visit. 
Only one study measured adherence during pregnancy and in the postpartum period, but reported 
only an overall measure of adherence over time.42 The median percent of adherent participants 
across studies was 87.9% (range: 51.3%, 97.8%). The one study comparing ART adherence in the 
post-Option B+ and the pre- Option B+ eras in one year since ART initiation found adherence to 
be slightly higher in the pre-Option B+ era, but the difference was not statistically significant.30 
Only one studied assessed differences in adherence between pregnant and postpartum women, but 
no significant difference was found.33 One study in Ethiopia looking at ART adherence during 
pregnancy found that receiving counseling on side effects and HIV status disclosure were 
significantly associated with improved medication adherence,40  while a different study in 
Ethiopia looking at adherence in pregnancy and the postpartum period found that women were 
less likely to be adherent if they received care at a hospital vs. a health facility, resided in a rural 
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residence vs. urban residence or faced challenges with initiating ART on the same day as HIV 
testing.43  One study in South Africa looking specifically at the effects of ART side effects on 
adherence found that frequency and severity of side effects were both associated with an 
increased risk of missed doses.42 
 
Quality assessment 
 The results of the Effective Public Health Practice Project (EPHPP) quality assessment 
are summarized in Appendix D.  In this review, the “intervention” being evaluated was the 
implementation of the Option B+ program. Since the majority of the studies included in this 
review were evaluations of existing Option B+ programs using programmatic data, there were no 
randomized controlled trials and risk of bias was largely due to lack of blinding and/or study 
design. Similarly, it was difficult to assess intervention integrity since the consistency with which 
the Option B+ program was being implemented was not explicitly reported in most studies.  
 
DISCUSSION  
 This study aimed to systematically review measures of program retention and medication 
adherence for HIV-infected pregnant women and mothers receiving Option B+ for PMTCT. In a 
WHO meeting to address retention in HIV programs, program retention was defined as, 
“continuous engagement from diagnosis in a package of prevention, treatment, support and care 
services.”13  The same meeting also identified important challenges and inconsistencies with 
regards to defining interruptions in program retention along the HIV care and treatment 
continuum as well as distinguishing between “loss to follow-up,” defined as patients with 
unknown outcomes and reflecting gaps in knowledge and information systems versus 
“disengagement from care,” which implies known reasons for ceasing to access care and reflects 
the need for a service delivery response.13  Nevertheless, this review found that LTFU was the 
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most commonly used indicator of Option B+ program retention. The length of time since ART 
initiation at which LTFU was assessed varied between studies and rates of LTFU also varied 
across studies and ranged from 11.2% to 48.5%, indicating that differences in specific program 
settings as well as the length of time for which LTFU is evaluated may have significant effects on 
the program retention outcome. In the studies that were able to compare program retention 
between the Option B+ and the Option A approaches, LTFU was significantly higher under with 
the Option B+ program. With Option A, only women with CD4 cell counts of less than or equal 
to 350 cells/mm3 were started on triple ART, while women with higher CD4 counts received 
short-course AZT prophylaxis through seven days postpartum.10  It is therefore possible that the 
difference observed in program retention between the two approaches could be due to the fact 
that women with lower CD4 cell counts who are in need of HIV treatment for their own health 
are more likely than women with higher CD4 cell counts who feel otherwise healthy to be 
retained in care. In addition, initiating ART on the same day as HIV testing was found to be 
significantly associated with an increased risk of LTFU across studies. This finding was 
consistent with qualitative research findings that reported same-day initiation of treatment as a 
health facility challenge to the provision of Option B+.14   Both of these findings suggest that 
challenges with transitioning to Option B+ from Option A may have existed during study 
implementation and underscore the importance of providing adequate support and counseling on 
the day of HIV testing and treatment initiation to ensure program retention. Alternatively, re-
considering the test-and-treat approach as part of the Option B+ recommendation may be 
appropriate and evaluating an intervention focused on delaying treatment initiation could be 
useful. It may also be the case that as Option B+ becomes more familiar to clinic staff and 
patients, the barriers associated with the test-and-treat approach may subside. For instance, one 
study included in this review found that program retention improved in later years of program 
implementation.39 It is also important to note that clinic visit attendance was not a primary 
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outcome in any of the studies included in this review. While it is important to measure rates of 
LTFU it is equally important to assess whether or not HIV-infected pregnant women and mothers 
are adhering to their scheduled visits since it has been shown that HIV-infected patients who 
missed clinic visits in the first six months of treatment but were retained in care were at an 
increased risk of death and LTFU and may have poorer immunological and virologic outcomes.15 
Furthermore, additional research is needed to specifically track HIV-infected pregnant women 
and mothers who have been reported as LTFU by facilities to understand firstly if these women 
have been truly lost, and secondly to understand the reasons for LTFU or changes in location of 
care. For example, one study in western Kenya looking at outcomes of HIV patients defined as 
LTFU who were enrolled in the Academic Model Providing Access to Healthcare (AMPATH) 
program found that 12.8% of those originally classified as lost were not truly LTFU and that of 
these, 14% were receiving care at a different clinic from the one where treatment was initiated 
and 51.5% had transferred to a different program.16 Understanding what happens to HIV-infected 
pregnant women and mothers defined as LTFU under Option B+ is crucial for not only improving 
PMTCT care and treatment services, but for improving the methods used to trace and follow 
women who choose to continue care somewhere different from where care was initiated.   
 Patient self-report and pill count adherence were the indicators most commonly utilized 
by studies included in this review to measure maternal medication adherence and the proportion 
of adherent participants in each study varied greatly from 51.3% to 97.8%, signifying the 
potential effects of different implementation settings as well as the limitations associated with 
these measures of medication adherence. While pill counting is a low-cost approach, it requires 
additional time from already overburdened health workers as well as effective training, 
monitoring and evaluation of the pill count calculation and recording process.17 Patient self-report 
is also a simple and inexpensive method for measuring adherence but may be affected by social 
desirability bias, recall bias or confusion surrounding the way self-report questions are interpreted 
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by patients.18 Viral load testing is considered the most objective indicator of medication 
adherence, but is still considered too expensive to implement regularly for the purposes of 
adherence monitoring in most resource-limited settings.19 As a result, more work needs to be 
done to evaluate adherence screening tools that are cheap and easy to implement across various 
settings but have high sensitivity and good reliability. In one example, a recent study evaluating a 
self-report adherence measure using a simple three-item scale to screen for elevated viral load 
among pregnant and postpartum women on ART in South Africa concluded that having an 
increased viral load was consistently associated with lower median adherence scores.20 The study 
investigators concluded that using this tool may be a good first-stage screening procedure for 
adherence but that the routine use of this specific adherence scale in different settings must be 
further evaluated and that more attention should be given to maternal ART adherence monitoring 
in low resource settings.20  
Among the studies included in this review, good adherence was commonly defined as 
either missing zero doses by self-report or achieving 95% adherence by pill count. These 
adherence definitions are consistent with earlier ART effectiveness research that found 95% pill 
consumption was necessary for successful long-term virologic suppression.21 However, more 
recent studies evaluating nonnucleoside reverse transcriptase inhibitors (NNRTIs) such as EFV 
have shown that successful virus suppression may be achieved at levels of adherence between 
70% and 80%22 due to the higher potency and longer half-lives of these ART regimens.23  It could 
be useful to conduct additional maternal ART adherence studies to evaluate if viral load 
suppression can be obtained or if rates of vertical HIV transmission and maternal and child health 
outcomes are negatively affected at these lower rates of medication adherence under the Option 
B+ approach.  
Maternal ART adherence was not significantly affected by the switch to Option B+ in the 
one study comparing adherence in the pre- and post- Option B+ era, but selection bias may have 
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affected this outcome since the review showed LTFU was greater in the post-Option B+ era but 
adherence measures were not available for study participants who had been LTFU.  Only one 
study looked at the difference in Option B+ medication adherence between pregnant and 
postpartum women and the association was not significant. The PMTCT adherence literature 
prior to Option B+ implementation consistently found adherence to be greater in pregnancy as 
compared to the postpartum period,8 so more studies aimed at assessing differences in adherence 
between the antenatal and postnatal periods under the current WHO recommendation for PMTCT 
are needed. One study included in this review found that frequency, type and severity of side 
effects were associated with maternal medication adherence while a different study found that 
being counseled on potential side effects was associated with a significantly increased odds of 
adherence in pregnancy. These findings are consistent with qualitative research conducted in 
Malawi that reported side effects to be one of the most commonly cited reasons for stopping ART 
among women enrolled in the Option B+ program in Lilongwe.24 As a result, interventions 
targeting health workers and PMTCT counselors that are aimed specifically at effective 
techniques for counseling about potential ART side effects may prove useful for improving 
medication adherence among HIV-infected pregnant women and mothers across a variety of 
PMTCT care and treatment settings. Similarly, strategies to reduce the severity and frequency of 
side effects could also improve maternal ART adherence.  
The narrow scope of this review may be considered one limitation of the study. This 
review only assessed ART adherence and program retention after ART had been initiated and did 
not look more broadly at gaps along the PMTCT cascade. As some of the studies included in this 
review suggest, the same-day test-and-treat approach to Option B+ implementation may 
negatively affect ART adherence and program retention and it would therefore be useful to study 
gaps between HIV testing and ART initiation in more detail. Similarly, this review does not 
assess infant prophylaxis adherence or program retention, which are key outcomes necessary for a 
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comprehensive understanding of the Option B+ program effect on PMTCT. Another limitation of 
the study is that this database search did not include viral load as a key search term for assessing 
adherence. Though viral suppression is considered the most objective indicator of ART 
adherence, it was not being regularly and routinely performed in many of the low-income settings 
implementing Option B+ at the time of concept search formulation for this review. There is also a 
distinction to be made between viral suppression and the act of medication adherence, which was 
the outcome of interest for this study.  An additional limitation of this review is that the strength 
of evidence provided by each study is restricted by study design. There were no randomized 
controlled trials evaluating adherence or program retention at the time of the database search and 
only observational studies were included in the review. Although randomized controlled trials are 
considered the strongest study design with respect to limiting bias and determining a true 
association, it was most likely difficult to assign Option B+ as an intervention in a randomized 
controlled trial after it had already become the WHO recommendation for PMTCT. In the future, 
randomized controlled trials evaluating interventions aimed at improving Option B+ program 
retention and adherence may be utilized to acquire more information about these outcomes under 
various standards of care. A final limitation of this study is that differences in the stages of Option 
B+ program rollout and implementation as well as specific program implementation strategies 
across different settings are not reflected in this review. Some of the studies included do evaluate 
the associations between year of program implementation or health care delivery model on 
adherence and program retention, but this information was not systematically captured across 
studies.  
 This is the first study, to the knowledge of the author, to conduct a systematic review of 
maternal medication adherence and program retention for PMTCT in the context of Option B+. 
This review found a wide range of program retention and adherence outcomes across studies and 
did not identify any studies measuring changes in medication adherence and program retention 
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over time for the same cohort of women. Furthermore, the effects of different factors on program 
retention and medication adherence varied across studies and the limited number of studies 
evaluating these effects made it difficult to confidently draw conclusions about these associations. 
As a result, these findings support the need for long-term, longitudinal monitoring and evaluation 
of Option B+ program retention and medication adherence in different health care delivery 







1.  Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, Treluyer JM,  Leroy V, 
Rouzioux C, Blanche S, Dabis F. Universal antiretroviral therapy for pregnant and breastfeeding 
HV-1 infected women: towards elimination of mother-to-child transmission of HIV-1 in 
resource-limited settings. Clin Infect Dis, 2009; 49(12):1936-45. 
 
2. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick DJ, Rogers M, 
Shaffer N. Prevention of mother-to-child transmission in resource-poor countries; translating 
research into policy and practice. JAMA, 2000; 283 (9): 1175-82. 
3. President’s Emergency Plan for AIDS Relief. Prevention of Mother-to-Child Transmission of 
HIV: Expert Panel Report and Recommendations to the U.S. Congress and U.S. Global AIDS 
Coordinator. 2010; http://www.pepfar.gov/documents/organization/135465.pdf 
 
4. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, et al. HIV prevention 
transformed: The new prevention research agenda. Lancet, 2011; 378 (9787):269-78. 
 
5. San-Andrés FJ, Rubio R, Castilla J, Pulido F, Palao G, de Pedro I, Costa JR, del Palacio A. 
Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the 
effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 
1989-1997. Clin Infect Dis, 2003; 36(9):1177-95. 
6. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS. The combined 
effect of modern highly active antiretroviral therapy regimens and adherence on mortality over 
time. J Acquir Immune Defic Syndr, 2009; 50(5):529-36. 
 
7. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, Hogg RS, Harrigan PR.The 
relationship between resistance and adherence in drug-naïve individuals initiating HAART is 
specific to individual drug classes. J Acquir Immune Defic Syndr, 2008; 49(3):266-71. 
8. Nachega JB, UthmanOA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, 
Stringer JSA, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after 
pregnancy in low-income, middle-income and high-income countries: a systematic review and 
meta-analysis. AIDS, 2012; 26:000-000. 
 
9. Ferguson L, Grant AD, Watson-Jones D, Kahawita T, Ong’ech JO, Ross DA. Linking women 
who test HIV-positive in pregnancy-related services to long-term HIV care and treatment 
services: a systematic review. Trop Med Int Health, 2012; 17(5): 564-80. 
 
10. World Health Organization, Programmatic update: Use of Antiretroviral drugs for treating 





11. Impact of an Innovative Approach to Prevent Mother-to-Child Transmission of HIV-Malawi, 
July 2011-September 2012. Morbidity and Mortality Weekly Report. Centers for Disease Control 
and Prevention, 2013; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6208a3.htm 
 
12. Effective Public Health Practice Project (EPHPP), Quality Assessment tool for Quantitative 
studies. http://www.ephpp.ca/tools.html 
 
13. Retention in HIV Programmes: Defining the challenges and identifying solutions. Meeting 
report. World Health Organization, Geneva, Switzerland, 2011. 
http://whqlibdoc.who.int/publications/2012/9789241503686_eng.pdf 
 
14. Helova A, Akama E, Bukusi EA, Musoke P, Nalwa WZ, Odeny TA,  Onono M, Spangler SA, 
Turan JT, Wanga I, Abuogi LL. Health facility challenges to the provision of Option B+ in 
western Kenya: a qualitative study. Health Policy Plan, 2016; 32(2): 283-291. 
 
15. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first 
six months on antiretroviral treatment: a retrospective analysis in a large public sector HIV clinic 
in South Africa. J Int AIDS Soc, 2010; 13:49. 
 
16. Rachlis B, Ochieng D, Geng E, Rotich E, Ochieng V, Maritim B, Ndege S, Naanyu V, Martin 
J, Keter A, Ayuo P, Diero L, Nyambura M, Braitstein P. Evaluating outcomes of patients lost to 
follow-up in a large comprehensive care treatment program in western Kenya. J Acquir Immune 
Defic Syndr, 2015; 68(4): e46-e55.  
 
17. Albrecht S, Semrau K, Kasonde P, Sinkala M, Kankasa C, Vwalika C. Predictors of 
nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV 
transmission. J Acquir Immune Defic Syndr 2006; 41(1):114-8. 
 
18. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report 
measures of antiretroviral therapy adherence: A review with recommendations for HIV research 
and clinical management. AIDS Behav, 2006;10 (3):227-45. 
 
19. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, 
Perrin L, Rodriguez W. HIV viral load monitoring in resource-limited regions: optional or 
necessary? BMC Med Res Methodol. 2011;11:149. 
 
20. Phillips T, Brittain K, Mellins CA, Zerbe A, Remien  RH, Abrams EJ, Myer L, Wilson IB. A 
self-reported adherence measure to screen for elevated HIV viral load in pregnant and postpartum 
women on antiretroviral therapy. AIDS Behav, 2017; 21(2): 450-461.  
 
21. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern 




22. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer 
antiretroviral medications. Ann Pharmacother 2011; 45:372-79.  
 
23. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to 
nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann 
Intern Med 2007; 146:564-73.  
 
24. Kim MH, Zhou A, Mazenga A, Ahmed S, Markham C, Zomba G, Simon K, Kazembe PN, 
Abrams EJ. Why did I stop? Barriers and facilitators to uptake and adherence to ART in Option 
B+ HIV care in Lilongwe, Malawi. PLoS One, 2016; 11(2): e0149527. 
 
25. Auld AF, Shiraishi RW, Couto A, Mbofana F, Colborn K, Alfredo C, Ellerbrock TV, Xavier 
C, Jobarteh K. A Decade of Antiretroviral Therapy Scale-up in Mozambique: Evaluation of 
Outcome Trends and New Models of Service Delivery Among more than 300,000 Patients 
Enrolled During 2004-2013. J Acquir Immune Defic Syndr, 2016; 73(2). 
 
26. Chan AK, Kanike E, Bedell R, Mayuni I, Manyera R, Mlotha A, Harries AD, van Oosterhout 
J, van Lettow M. Same day HIV diagnosis and antiretroviral therapy initiation affects retention in 
Option B+ prevention of mother-to-child transmission services at antenatal care in Zomba 
District, Malawi. JIAS, 2016; 19:20672. 
 
27. Dzangare J, Takarinda KC, Harries AD, Tayler-Smith K, Mhangara M, Apollo TM, Mushavi 
A, Chimwaza A, Sithole N, Magure T, Mpofu A, Dube F, Mugurungi O. HIV testing uptake and 
retention in care of HIV-infected pregnant and breastfeeding women initiated on ‘Option B+’ in 
rural Zimbabwe. Trop Med and Int Health, 2016; 21(2): 202-209. 
 
28. Ford D, Muzambi M, Nkhata MJ, Abongomera G, Joseph S, Ndlovu M, Mabugu T, Grundy 
C, Chan AK, Cataldo F, Kityo C, Seeley J, Katabira E, Gilks CF, Reid A, Hakim J, Gibb DM and 
the Lablite Team. Implementation of antiretroviral therapy for life in pregnant/breastfeeding 
HIV+ women (Option B+) alongside rollout and challenging guidelines for ART initiation in 
rural Zimbabwe: the Lablite Project experience. J Acquir Immune Defic Syndr,2016.  
 
29. Llenas-Garcia J, Jorgensen-Wikman P, Hobbin M, Mussa MA, Ehmer J, Keiser O, Mbofana 
F, Wandeler G for SolidarMed and IeDEA-Southern Africa. Retention in care of HIV-infected 
pregnant and lactating women starting ART under Option B+ in rural Mozambique. Trop Med Int 
health, 2016; 21(8): 1003-1012.  
 
30. Kamuyango AA, Hirschhorn LR, Wang W, Jansen P, Hoffman RM. One-year outcomes of 
women started on antiretroviral therapy during pregnancy before and after implementation of 
Option B+ in Malawi: a retrospective chart review. World J AIDS, 2015; 4(3): 332-337. 
 
31. Kim MH, Ahmed S, Hosseinipour MC, Giordano TP, Chiao EY, Yu X, Nguyen C, 
Chimbwandira F, Kazembe PN, Abrams EJ. The Impact of Option B+ on the Antenatal PMTCT 




32. Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, Cohan D, Okiring J, 
Charlebois ED, Kamya MR, Havlir DV. Viral Suppression and Retention in Care up to 5 Years 
After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda. J Acquir 
Immune Defic Syndr, 2016; 74(3): 279-284. 
 
33. Landes M, Sodhi S, Matengeni A, Meaney C, van Lettow M, Chan AK, van Oosterhout JJ. 
Characteristics and outcomes of women initiating ART during pregnancy versus breastfeeding in 
Option B+ in Malawi. BMC Public Health, 2016; 16: 713. 
 
34. Mitiku I, Arefayne M, Mesfin Y, Gizaw M. Factors associated with loss to follow-up among 
women in Option B+ PMTCT Programme in northeast Ethiopia: a retrospective cohort study. 
JIAS, 2016; 19:20662. 
 
35. Price AJ, Kayange M, Zaba B, Chimbwandira FM, Jahn A, Chirwa Z, Dasgupta AZN, 
Katundu C, Saul JL, Glynn JR, Koole O, Crampin AC. Uptake of prevention of mother-to-child 
transmission using Option B+ in northern rural Malawi: a retrospective cohort study. Sex Transm 
Infect, 2014; 90:309-314. 
 
36. Schnack A, Rempis E, Decker S, Braun V, Rubaihayo J, Busingye P, Tumwesigye NM, 
Harms G, Theuring S. Prevention of Mother-to-Child Transmission of HIV in Option B+ Era: 
Uptake and Adherence During Pregnancy in Western Uganda. AIDS Patient Care and STDS, 
2016; 30(3): 110-118. 
 
37. Schwartz SR, Clouse K, Yende N, Van Rie A, Bassett J, Ratshefola M, Pettifor A. 
Acceptability and Feasibility of a Mobile Phone-Based Case Management Intervention to Retain 
Mothers and Infants from an Option B+ Program in Postpartum HIV Care. Matern Child Health 
J, 2015; 19:2029-2037. 
 
38. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, Chirwa Z, 
Ng'ambi W, Bakali A, Phiri S, Myer L, Valeri F, Zwahlen M, Wandeler G, Keiser O for Ministry 
of Health in Malawi and IeDEA Southern Africa. Retention in care under universal Antiretroviral 
Therapy for HIV Infected Pregnant and Breastfeeding Women (“Option B+” in Malawi. AIDS, 
2014; 28(4): 589-598. 
 
39. Tweya H, Gugsa S, Hosseinipour M, Speight C, Ng'ambi W, Mphatso B, Chikonda J, 
Chauma A, Khomani P, Phoso M, Mtande T, Phiri S. Understanding factors, outcomes and 
reasons for loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, 
Malawi. Trop Med and Int Health, 2014; 19 (11): 1360-1366. 
 
40. Ebuy H, Yebyo H, Alemayehu M. Level of adherence and predictors of adherence to the 
Option B+ PMTCT programme in Tigray, northern Ethiopia. International Journal of Infectious 
Diseases, 2015; 33:123-129. 
 
41. Gill MM, Hoffman HJ, Bobrow EA, Mugwaneza P, Ndatimana D, Ndayisaba GF, Baribwira 
C, Guay L, Asiimwe A. Detectable Viral Load in Late Pregnancy among Women in the Rwanda 




42. Phillips T, Cois A, Remien RH, Mellins CA, McIntyre JA, Abrams EJ, Myer L. Self-
Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant 
Women Under Option B+: A Prospective Study. PLoS One, 2016; DOI: 10.1371. 
 
43. Tsegaye D, Deribe L, Wodajo S. Levels of adherence and factors associated with adherence 
to option B+ prevention of mother-to-child transmission among pregnant and lactating mothers in 
selected government health facilities of South Wollo Zone, Amhara Region, northeast Ethiopia, 





PART TWO:  
Changes in adherence and clinic visit attendance for HIV-infected pregnant women and 
mothers receiving Option B+ for prevention of mother-to-child transmission of HIV: An 




 Option B+ is the current WHO-recommended approach for preventing vertical HIV 
transmission and includes the provision of combination antiretroviral therapy to all pregnant and 
postpartum HIV-infected women, regardless of CD4 cell count or clinical stage, to be continued 
for life form the time of treatment initiation. Program retention and long-term medication 
adherence continue to be of concern under this approach and little is currently known about 
changes to adherence or clinic visit attendance over time for HIV-infected pregnant women and 
mothers. This study aims to improve the understanding of changes to Option B+ adherence and 
clinic visit attendance over time from pregnancy through six months postpartum.  
 A program evaluation of adherence and clinic visit attendance from pregnancy to six 
months postpartum was performed in a cohort of first-time initiators of Option B+ at Mulago 
National Referral Hospital in 2014. Data from the PMTCT program database as well as medical 
charts and clinic log books were used to measure pill count adherence and clinic visit attendance 
as well as a variety of factors potentially associated with these outcomes. Univariate and 
multivariate logistic regression was used to estimate the associations between the outcomes and 
each factor of interest. Backward model selection was used to select the final models predicting 
medication adherence and clinic visit attendance at each time point.  
 480 HIV-infected women were included in the study. Of these, 52.1% and 44.8% were 
adherent during pregnancy and at six months postpartum, respectively, using a 95% adherence 
cutoff and 64.4% and 56.9% were adherent during pregnancy and at six months postpartum, 
respectively, using an 80% adherence cutoff. 71.9% and 73.8% attended clinic at six weeks and 
six months postpartum, respectively. A number of factors were found to predict adherence in 
pregnancy and at six months postpartum, but disclosure was the only factor associated with 
sustained adherence at both time points. Previous PMTCT experience, previous HIV diagnosis, 
time since ART initiation during pregnancy and male partner counseling and testing in antenatal 
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care were all predictors of sustained clinic visit attendance at six weeks and six months 
postpartum. 
 This study underscores the importance of continued monitoring and evaluation of 
adherence and clinic visit attendance from pregnancy throughout the postpartum period and the 





 The most recently issued World Health Organization (WHO) recommendation for 
preventing mother-to-child transmission of HIV (PMTCT) is called Option B+ and includes the 
provision of combination antiretroviral therapy (ART) to all pregnant and postpartum HIV-
infected women, regardless of CD4 cell count or WHO clinical stage, to be continued for life 
from the time of treatment initiation.1  It is believed that in addition to improving PMTCT in 
pregnancy and the breastfeeding period, successful implementation of the Option B+ approach 
may reduce the risk of sexual transmission and ensure improved maternal health outcomes due to 
uninterrupted HIV treatment.2 However, improved PMTCT and maternal and child health 
outcomes can only be achieved with consistently high medication adherence since a linear dose 
response relationship exists between adherence and improved virologic outcomes.3 PMTCT 
program retention also needs to be considered in the context of Option B+ since retention in care 
has been shown to directly affect adherence outcomes and viral suppression.4 
 Since its initial implementation in Malawi in 2011, the number of HIV-infected women 
initiating treatment during pregnancy has consistently and significantly improved in settings that 
have adopted the Option B+ approach.5 Nevertheless, inconsistent retention in care and long-term 
medication adherence continue to be of concern. For example, only two thirds of women 
initiating ART during pregnancy in Malawi were retained in care after three years6 and an 
evaluation of  viral load (an outcome shown to be highly correlated with medication adherence7) 
in the first 24 months postpartum among HIV-infected women who initiated ART for life as part 
of the Mitra plus Study in Tanzania found that the proportion of women with viral loads greater 
than or equal to 400 copies/mL decreased significantly from 97% at enrollment to 16% at three 
months postpartum, but increased to 86% at 24 months postpartum.8 
Uganda adopted Option B+ for PMTCT in 2012.9 In 2016, Ministry of Health (MoH) 
facilities reported that over 95% of pregnant women had been tested for HIV and that the large 
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majority of the pregnant women testing positive were initiated on ART.10 However, a recent 
study in Western Uganda found that only 51% of HIV-infected women who initiated Option B+ 
exhibited greater than or equal to 95% adherence during pregnancy and over 20% exhibited poor 
adherence, defined as a pill count adherence of less than 80%.11 In addition, little is currently 
known about Option B+ adherence or program retention in the postpartum period in Uganda or 
other settings implementing Option B+ and a recent paper aimed at identifying gaps in the 
research literature with respect to uptake and barriers to postpartum HIV care found that few 
studies have focused on continued engagement of HIV-infected mothers beyond six weeks 
postpartum.12 This study aims to improve the current understanding of changes to Option B+ 
medication adherence and program retention over time from pregnancy through six months 
postpartum for a cohort of HIV-infected women at Mulago National Referral Hospital who were 
first-time initiators of Option B+ for PMTCT.  
  
METHODS 
Mulago National Referral Hospital and the PMTCT program 
Mulago National Referral Hospital is located in the northern part of Kampala City and is 
one of two national referral hospitals in the country. It is the largest hospital in Uganda and the 
teaching hospital for the Makerere University College of Health Sciences. The PMTCT program 
at Mulago National Referral Hospital began in April, 2000 with funding from the Elizabeth 
Glaser Pediatric AIDS Foundation (EGPAF) and included voluntary counseling and testing for 
pregnant women and single-dose Nevirapine (sd-NVP) at onset of labor with sd-NVP for the 
infant at birth. In 2005 the PMTCT guidelines were updated to include routine counseling and 
HIV testing and Zidovudine (AZT) or Zidovudine/Lamivudine (AZT/3TC) from 28 weeks 
gestation and sd-NVP at the onset of labor for HIV-infected pregnant women with a CD4 count 
of less than or equal to 200 cells/mm.3  The routine counseling and testing approach resulted in a 
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large increase in the number of identified HIV-infected pregnant women attending Mulago for 
antenatal care (ANC) and as a result, the follow-up clinic was created in February, 2006. The 
purpose of the follow-up clinic was to retain HIV-infected pregnant women and mothers in care 
for the first 18 months postpartum before they were referred to the Makerere University Joint 
AIDS Program Immune Suppression Syndrome (MJAP ISS) clinic or a different clinic of choice 
for ongoing HIV care and treatment. The follow-up clinic dispensed ART, provided treatment for 
opportunistic infections and offered sexual and reproductive health services such as family 
planning and cervical cancer screening. In 2010, Mulago adopted the WHO-recommended 
Option A approach PMTCT and then transitioned to Option B+ to reflect the most current WHO 
guidelines for PMTCT.  
Today, the Option B+ program includes provider initiated HIV counseling and testing in 
ANC and same-day ART initiation with the Tenofovir/Lamivudine/Efavirenz (TFV/3TC/EFV) 
triple combination regimen as the first-line therapy, irrespective of CD4 cell count. All HIV-
infected pregnant women are also expected to receive Co-trimoxazole prophylaxis. Though the 
timing and frequency of ANC clinic visits vary by a number of factors including gestational age 
at presentation to ANC, psychosocial (PSS) evaluation and disease severity, HIV-infected 
pregnant women enrolled in care are generally scheduled to return to clinic two weeks after ART 
initiation and then monthly until delivery. HIV-infected women delivering at Mulago are 
expected to initiate exclusive breastfeeding within an hour of delivery and HIV-exposed infants 
are expected to receive Nevirapine (NVP) syrup at birth. Follow-up of HIV-exposed infants and 
mothers takes place at the postnatal clinic and includes DNA polymerase chain reaction (PCR) 
testing of HIV-exposed infants, distribution of infant prophylaxis, immunization and growth 
monitoring. The first infant HIV test is expected to be done by six weeks postpartum and results 
are expected to be received one week later or at the next clinic visit. As previously stated, 
maternal health services and ART are provided at the follow-up clinic. 
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Study design and population 
Changes in Option B+ ART adherence and clinic visit attendance over time were 
measured through the utilization of routine PMTCT program data collected and entered into an 
electronic database by Makerere University-Johns Hopkins University (MU-JHU) Research 
Collaboration staff at Mulago Hospital for the purposes of routine program evaluation. 
Longitudinal data from HIV-infected pregnant women attending Mulago Hospital and enrolling 
in the PMTCT program during pregnancy from January 1, 2014 to December 31, 2014 were 
included in this study. All HIV-infected pregnant adult women of reproductive age (18-49 years 
old) who presented to Mulago National Referral Hospital in 2014, had attended at least two ANC 
visits and were new initiators of Option B+ for their current pregnancies were included in this 
study. HIV-infected pregnant women included in the study were either ART-naïve or had 
initiated a previous form of ART prophylaxis for past pregnancies under old PMTCT guidelines 
but were new initiators of Option B+.  Women were excluded from the study if they were 
younger than 18 years old at the time of Option B+ initiation, had initiated a PMTCT regimen 
other than the one indicated by Option B+, were not new initiators of Option B+ for PMTCT or 
initiated Option B+ after the ANC period. Women were also excluded if the pregnancy did not 
result in a live birth. A longitudinal cohort study design was used to account for changes in 




 Data collection for this study took place from May 4, 2016 to August 1, 2016. Routinely 
collected indicators regularly entered into the Mulago PMTCT program electronic database were 
extracted for this study. In addition, data abstraction was performed from patient medical charts 
and the PMTCT clinic log books to obtain ART adherence and program retention information for 
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the first ANC visit post-ART initiation and again at six weeks postpartum and six months 
postpartum. As described above, data was collected for all HIV-infected pregnant women who 
enrolled in the Option B+ PMTCT program beginning on January 1, 2014. A local research 
assistant was trained to assist the first author of this study with data abstraction and her work was 
validated by the first author of this study.  Data from the PMTCT database and medical chart/log 
book abstraction were merged to create the longitudinal dataset necessary for this analysis to take 
place.  
 
Study outcomes, exposures and definitions 
 The primary outcomes for this study were maternal ART adherence and clinic visit 
attendance at the first ANC visit after enrollment into the PMTCT program and again at six 
weeks and six months postpartum. At Mulago, medication adherence was measured and recorded 
by PMTCT clinic counselors trained to perform ART pill counts. Patients were instructed to 
return to each clinic appointment with the ART pill box and counselors counted the number of 
pills remaining at the current clinic visit. The number of pills remaining were subtracted from the 
number of pills dispensed at the last clinic visit to determine the number of pills swallowed 
between visits. The number of pills wasted, as self-reported by the patient, were also subtracted 
from the number of pills last dispensed and ART adherence was then calculated by dividing the 
number of pills actually swallowed by the number of pills expected to have been swallowed 
based on the date ART was last dispensed and the number of pills left over at the last visit. 
Patients were categorized as adherent or non-adherent based on a 95% and an 80% pill count 
adherence cutoff. The 95% cutoff was utilized to remain consistent with the definitions of optimal 
and suboptimal adherence used by the PMTCT clinic at Mulago. The 80% cutoff was included to 
reflect the minimum level of adherence necessary for successful viral suppression described in 
the literature.13 If adherence at any time point could not be ascertained, it was recorded as 
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“unknown.” An unknown adherence outcome was the result of either patients failing to return 
with the pill box or not being able to determine the number of pills last dispensed at the previous 
visit due to incomplete information in the medical charts or clinic log books. In addition to the 
medication adherence definition described above, a broader definition of non-adherence was also 
utilized in a separate analysis to capture patients who were either non-adherent to ART or had 
either failed to return with the pill box or did not return for the scheduled clinic visit.  
 The six-week and six-month postpartum visits were identified for each patient by 
estimating the scheduled clinic visit dates using the infant date of birth found in the PMTCT 
database for each patient. Due to variations in scheduling of clinic visit appointments, visits 
occurring between five and eight weeks postpartum and five and seven months postpartum were 
considered valid time points for data collection for the six-week and six-month postpartum visits, 
respectively. If visits occurred both before and after the estimated visit date but within the 
indicated window, the visit determined to be closest to the estimated visit date was used for the 
purposes of this study.  
Information routinely entered into the PMTCT database and the clinic log books were 
used to obtain demographic and clinic characteristics and to measure the effects of the following 
factors on changes in ART adherence and clinic visit attendance: 1) Previous HIV diagnosis was 
determined using the PMTCT screening form and recorded as “Yes” if the patient had been 
diagnosed before the current pregnancy or “No” if the patient had been newly diagnosed with 
HIV during the current pregnancy; 2) Previous PMTCT experience was determined using the 
PMTCT enrollment form and recorded as “Yes” if the patient had initiated ART for PMTCT 
during a previous pregnancy or “No” if the patient had never initiated ART for PMTCT prior to 
the current pregnancy; 3) Disclosure status by the first visit post-ART initiation was obtained 
from the PMTCT psychosocial form and recorded as “Yes” if HIV status had been disclosed or 
“No” if the patient had not disclosed her status at that time. The relationship of the disclosed to 
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the participant (e.g. husband, mother, friend, etc.) was also recorded when available; 4) Baseline 
CD4 count at program enrollment was collected from the PMTCT registration and lab forms and 
categorized as greater than 350 cells/mm3 or less than or equal to 350 cells/mm3 in accordance 
with the previous WHO CD4 cutoff for treatment vs. prophylaxis for HIV-infected pregnant and 
postpartum women; 5) Time since ART initiation during pregnancy was calculated using the date 
of ART initiation and the date of delivery and categorized as more than 30 days on ART before 
delivery or less than or equal to 30 days on ART before delivery; 6) Partner counseling and 
testing by the first ANC visit post-ART initiation was determined using the PMTCT screening 
form and recorded as “Yes” if the partner had been tested for and counseled about HIV or “No” if 
the partner had not been tested for or counseled about HIV at this time; 7) Psychosocial support 
group meeting attendance was determined using the clinic log books and recorded as “Yes” if the 
patient had attended at least one psychosocial support group meeting or “No” if the patient had 
not attended any psychosocial support group meetings  during pregnancy or by six weeks and six 
months postpartum.  
 
Sample size considerations 
 The estimated sample size necessary to correctly reject the null hypothesis with 95% 
confidence and 80% power that there would be no difference in the proportion of adherent 
patients between pregnancy and six months postpartum was first calculated based on a recent 
longitudinal ART adherence study for PMTCT in Zambia since it was one of the only studies 
reporting medication adherence in a resource-limited setting for the same cohort of HIV-infected 
women in pregnancy and six months postpartum.14 This study found a 12% drop in ART 
adherence between pregnancy (82.5%) and six months postpartum (70.5%). Utilizing the sample 
size calculation for paired data, it was estimated that a sample size of approximately 98 HIV-
infected women would be necessary to detect a 12% change in the proportion of adherent women 
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between pregnancy and six months postpartum. Since longitudinal measures of adherence in the 
Option B+ era are largely unknown, a more conservative sample size estimate predicting a 5% 
change in the proportion of adherent patients from pregnancy to at six months postpartum was 
also calculated. Utilizing these parameters, it was estimated that a sample size of approximately 
218 HIV-infected women would be needed to detect this change in adherence with 95% 
confidence and 80% power.   
 
Data analysis 
Statistical analyses were performed using Stata software version 12 (StataCorp, College 
Station, TX). Baseline characteristics and demographics were summarized categorically and with 
means and standard deviations (SDs) when relevant.   
The proportions of adherent patients and patients attending scheduled clinic visits were 
calculated for each visit and McNemar’s Chi Squared statistic for paired data was used to detect 
differences in the proportion of adherent patients and patients attending scheduled clinic visits 
between each time point of interest. Unadjusted and adjusted odds ratios with 95% confidence 
intervals (CIs) were obtained using univariate and multivariate logistic regression to estimate the 
associations between medication adherence or clinic visit attendance and each factor of interest. 
Multivariate logistic regression included all factors tested in the univariate analyses and then 
backward selection was used to select the final models predicting medication adherence and 
clinic visit attendance at each time point. P-values less than or equal to 0.05 were considered 
statistically significant in the univariate and multivariate analyses. A “p-to-remove” value of 
p=0.20 was used in the model selection process such that predictors were removed one at a time 
beginning with the predictor with the highest p-value until the p-values of all predictors left in the 





Study population characteristics  
In 2014, 1,106 HIV-infected pregnant women presented to Mulago National Referral 
Hospital for ANC and required ART initiation. Of these women, 880 were newly enrolled into 
the Option B+ program and 599 attended at least two ANC visits. 102 patients were excluded 
from the analysis due to missing charts (72 active patients and 30 inactive patients at the time of 
data collection) and 17 were excluded due to a non-live birth pregnancy outcome (i.e. still birth, 
miscarriage or death soon after birth), resulting in a sample size of 480 for the study.  
The socio-demographic and clinical characteristics of the patients included in this 
analysis are summarized in Table 1. The mean age of the study population was 25.9 (SD=4.8 
years). 42.9% were between 18 and 24, 49.2% were between 25 and 34 and 6.0% were at least 35 
years of age. 56.3% had at least a secondary level of education and 34.2% reported a primary 
education level or no education. Approximately 45% of the pregnant women included in the 
study reported being employed and 86.9% reported being married at the time of enrollment into 
the PMTCT program. 65.4% of pregnant women reported having given birth at least once before 
the current pregnancy while 31.3% were nulliparous. 64.6% of pregnancy women included in the 
study had a baseline CD4 cell count of greater than 350 cells/mm3 and 34.4% had a baseline CD4 
cell count of less than or equal to 350 cells/mm3. Only 16.9% of pregnant women had previous 
experience with PMTCT and only 25.4% had been diagnosed with HIV prior to the current 
pregnancy. 35.4% of pregnant women had not disclosed their HIV status at the time of PMTCT 
program enrollment. Of the 58.3% who had disclosed, the majority had disclosed to a spouse 






Table 1: Socio-demographics and clinical characteristics at PMTCT program enrollment 
(N=480) 

















































































Trends in medication adherence 
 Table 2a summarizes the ART adherence profile of the study population at each visit. 
The proportion of adherent patients decreased over time between pregnancy and six months 
postpartum from 52.1% to 44.8% using the 95% adherence cutoff and 64.4% to 56.9% using the 
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80% adherence cutoff. 17.1% of pregnant women had an unknown adherence status at the first 
ANC visit post-ART initiation. At six months postpartum, 14.8% had an unknown adherence 
status and 18.3% did not return for the six months postpartum visit. At six weeks postpartum, 
more than half of the women (51.7%) had an unknown adherence status because the number of 
pills dispensed at the time of labor and delivery (i.e. the number of pills dispensed at the last 
clinic visit before six weeks postpartum) was not being routinely recorded in the patient medical 
charts or clinic log books at this time. Adherence information at six weeks postpartum was only 
available for women who had presented for an unscheduled or early clinic visit in the postpartum 
period before six weeks postpartum. Due to these findings, the six-week postpartum time point 
was excluded from the subsequent medication adherence analyses.  
Table 2b summarizes the data utilized for McNemar’s Chi Squared test for paired data to 
test the hypothesis that the proportion of adherent patients remained constant over time between 
the first ANC visit post-ART initiation and six months postpartum. Using the 95% cutoff and 
both definitions of non-adherence (less than 95% medication adherence only or less than 95% 
medication adherence, returned without the pill box or did not return for clinic visit), the 
differences in the proportions of women who were adherent at the first ANC visit post-ART 
initiation and adherent at the six-month postpartum visit were only marginally significantly 
different (p=0.074 and p=0.055, respectively). However, when the 80% adherence cutoff was 
applied to both definitions of non-adherence (less than 80% medication adherence only or less 
than 80% medication adherence, returned without pill box or did not return for clinic visit), the 
differences in the proportions of women who were adherent at ANC were significantly different 







Table 2a: Adherence at ANC, six weeks and six months postpartum, N=480 
Adherence cutoff  Proportion adherent at 
ANC (%) 
Proportion adherent at 
six weeks postpartum 
(%) 
Proportion adherent at 
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*Patients who returned without pill boxes or the number of pills last dispensed could not be determined 
from the information in the medical charts.  
**Patients who did not return within the time window.  
 
Table 2b: Proportion of adherent women at ANC and six months postpartum  
95% adherence (nonadherence=<95%medication adherence) 







Adherent in ANC (%) 130 (70.7) 37 (57.8) 167 (67.3)  
Non-adherent in ANC (%) 54 (29.3) 27 (42.2) 81 (32.7) 
Total (%) 184 (100.0) 64 (100.0) 248 (100.0) 
95% adherence (nonadherence= <95% adherence or returned without pill box/did not return) 







Adherent in ANC (%) 130 (62.2)  105 (45.5) 235 (53.4) 
Non-adherent in ANC (%) 79 (37.8) 126 (54.5) 205 (46.6) 
Total (%) 209 (100.0) 231 (100.0) 440(100.0) 
80% adherence (nonadherence= <80% medication adherence) 







Adherent in ANC (%) 195 (84.8) 12 (66.7) 207 (83.5) 
Non-adherent in ANC (%) 35 (15.2) 6 (33.3) 41 (16.5) 
Total (%) 230 (100.0) 18 (100.0) 248 (100.0) 
80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 







Adherent in ANC (%) 195 (73.6) 98 (56.0) 293 (66.6) 
Non-adherent in ANC (%) 70 (26.4) 77 (44.0) 147 (33.4) 
Total (%) 265 (100.0) 175 (100.0) 440 (100.0) 
 
Adherence in antenatal care 
Tables 1a and 1b in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 95% adherence 
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in ANC. Using the nonadherence definition of medication adherence less than 95%, factors that 
affected medication adherence were education level, baseline CD4 cell count and whether or not 
a patient had received PMTCT treatment or prophylaxis for a previous pregnancy. In the 
univariate analyses, patients with at least a secondary education level were almost 50% more 
likely to be adherent than patients with no education or a primary education level (unadjusted 
OR=1.48, p=0.096) and women who had received PMTCT treatment or prophylaxis during a 
previous pregnancy were 39% less likely to be adherent at ANC than women who were first-time 
initiators of a PMTCT program (unadjusted OR=0.61, p=0.071). In the multivariate analysis, 
education and previous PMTCT program experience remained marginally significant with respect 
to medication adherence (adjusted OR=1.73, p=0.056 and adjusted OR=0.53, p=0.086, 
respectively) and additionally, HIV-infected pregnant women with higher CD4 cell counts were 
significantly more likely than women with lower CD4 cell counts at ART initiation to be non-
adherent in ANC (adjusted OR=0.55, p=0.036).  
In the analysis defining nonadherence as medication adherence less than 95% or not 
having returned to clinic with the ART pill box, the univariate analyses found similar trends for 
education level and baseline CD4 cell count as described above (unadjusted OR=1.69, p=0.010 
and unadjusted OR=0.60, p=0.009, respectively). In addition, having been diagnosed with HIV 
prior to the current pregnancy and disclosure before the first ANC visit post-ART initiation were 
significantly associated with achieving at least 95% adherence at this clinic visit (unadjusted 
OR=1.61, p=0.028 and unadjusted OR=1.72, p=0.006, respectively). In the multivariate analysis, 
education level, baseline CD4 cell count, previous HIV diagnosis and disclosure remained 
significantly associated with 95% adherence at the first ANC visit post-ART initiation (adjusted 
OR=2.00, p=0.005, adjusted OR=0.53, p=0.010, adjusted OR=1.52, p=0.112 and adjusted 
OR=1.84, p=0.011, respectively).  
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Tables 1c and 1d in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 80% adherence 
in ANC. Using the nonadherence definition of medication adherence less than 80%, HIV-infected 
pregnant women who reported being married were 2.34 times as likely to be adherent at the first 
ANC visit post-ART initiation (p=0.062), but this association become non-significant in the 
multivariate analysis (adjusted OR=2.48, p=0.107). HIV-infected pregnant women with higher 
baseline CD4 cell counts remained less likely to be adherent in ANC in both the univariate and 
multivariate logistic regressions and this association became marginally significant in the 
adjusted model (unadjusted OR=0.67, p=0.156 and adjusted OR=0.52, p=0.070).  
In the analysis defining nonadherence as medication adherence less than 80% or 
returning to clinic without the ART pill box, lower baseline CD4 cell count continued be 
associated with adherence in the univariate and multivariate analyses (unadjusted OR=0.54, 
p=0.005 and adjusted OR=0.55, p=0.022). In addition, HIV-infected pregnant women who had 
disclosed their status were approximately two times as likely to be adherent (unadjusted OR=183, 
p=0.004 and adjusted OR=2.07, p=0.003). 
 
Predictive models for adherence in antenatal care 
 Table 3 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. For all the predictive models, in model 1 a 
95% adherence cutoff was used and nonadherence was defined as a pill count adherence of less 
than 95%. In model 2, a 95% adherence cutoff was used and nonadherence was defined as a pill 
count adherence of less than 95%, having returned to ANC without the pill box, or not having 
returned to clinic.  In model 3, an 80% adherence cutoff was used and nonadherence was defined 
as a pill count adherence of less than 80%. In model 4, an 80% adherence cutoff was used and 
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nonadherence was defined as a pill count adherence of less than 80%, having returned to ANC 
without the pill box, or not having returned to clinic.  
CD4 cell count at baseline and disclosure by the first ANC visit post-ART initiation were 
included in all four models. In all four cases, HIV-infected pregnant women with CD4 cell counts 
greater than 350 cells/mm3 were approximately 50% less likely to be adherent at the first ANC 
visit post-ART initiation than women with CD4 cell counts less than or equal to 350 cells/mm3. 
HIV-infected pregnant women who had disclosed their HIV status by the time of the first ANC 
visit post-ART initiation were more likely to be adherent than women who had not disclosed, 
with the odds of good adherence ranging from 49% in model 1 to 96% in model 4. Higher 
education level and having been diagnosed with HIV prior to the current pregnancy were 
predictors of good adherence in all the models except model 3. Women with at least a secondary 
education level were between 50% (model 1) and 90% (model 2) more likely to be adherent than 
women with a primary education level or no education, and women who had been diagnosed with 
HIV prior to the current pregnancy were between 47% (model 4) and 66% (model 2) more likely 
to be adherent than women who were newly diagnosed with HIV during the current pregnancy. 
Previous experience with PMTCT was associated with an approximately 40% decreased odds of 
adherence in model 1 and model 2 and being employed was as associated with a 48% decreased 
odds of adherence in morel 3 and a 31% decreased odds of adherence in model 4. Parity was only 
predictive of adherence in model 2, with multiparous women expected to be 41% more likely 
than nulliparous women to be adherent in ANC. Marital status was only predictive of adherence 
in model 3, with married women expected to be more than two times as likely as unmarried 








Table 3: Predictive models for adherence in antenatal care* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Education 1.50 (0.92, 2.45) 0.107 
Baseline CD4 0.55 (0.33, 0.91) 0.021 
Previous PMTCT 0.60 (0.33, 1.09) 0.093 
Previous HIV diagnosis 1.62 (0.92, 2.85) 0.094 
Disclosure 1.49 (0.91, 2.43) 0.113 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Education 1.90 (1.22, 2.96)  0.004 
Parity 1.41 (0.89, 2.24) 0.143 
Baseline CD4 0.52 (0.33, 0.81) 0.004 
Previous PMTCT 0.64 (0.37, 1.09) 0.102 
Previous HIV diagnosis  1.66 (1.01, 2.72) 0.044 
Disclosure 1.80 (1.17, 2.76) 0.008 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Employment 0.52 (0.28, 0.98) 0.043 
Marital status 2.12 (0.74, 6.07) 0.160 
Baseline CD4 0.51 (0.26 (1.00) 0.051 
Disclosure 1.69 (0.91, 3.13) 0.094 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Education 1.51 (0.95, 2.40) 0.078 
Employment 0.69 (0.44, 1.08) 0.107 
Baseline CD4 0.52 (0.32, 0.83) 0.007 
Previous HIV diagnosis 1.47 (0.87, 2.48) 0.152 
Disclosure  1.96 (1.26, 3.04) 0.003 
*Reference groups: 1) Education: none/primary; 2) Baseline CD4: ≤350 cells/mm3; 3) Previous PMTCT: 
No; 4) Previous HIV diagnosis: No; 5) Disclosure: No; 6) Parity: 0; 7) Employment: housewife/not 
employed; 8) Marital status: Not married 
 
Adherence at six months postpartum 
 Tables 2a and 2b in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 95% adherence 
at six months postpartum. Using the nonadherence definition of medication adherence less than 
95%, education, parity, baseline CD4 cell count and adherence status in ANC were found to be 
associated with adherence at six months postpartum in the univariate analyses. HIV-infected 
mothers with at least a secondary level of education were nearly 80% more likely to be adherent 
than mothers with a primary level of education or no education (unadjusted OR=1.79, p=0.039). 
Mothers who had given birth at least once before the current pregnancy were 50% less likely to 
be adherent at six months postpartum than nulliparous mothers (unadjusted OR=0.50, p=0.022) 
and mothers with a CD4 cell count of greater than 350 cells/mm3 were also approximately 50% 
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less likely to be adherent at six months postpartum than mothers with baseline CD4 cell count of 
less than or equal to 350 cells/mm3 (unadjusted OR=0.52, p=0.020). Under this definition of 
adherence, having been adherent at the ANC visit was associated with a 76% increased odds of 
adherence at six months postpartum (unadjusted OR=1.76, p=0.061). In the multivariate analysis, 
only the association between parity and adherence remained significant (adjusted OR=0.39, 
p=0.043) 
 In the analysis defining nonadherence as medication adherence less than 95%, returning 
to clinic without the ART pill box or not returning to clinic for the six-month postpartum visit, 
baseline CD4 cell count and adherence status in ANC followed the same trends as described 
above (unadjusted OR=0.57, p=0.005 and unadjusted OR=1.97, p<0.001, respectively). In 
addition, length of time spent on ART during pregnancy as well as having attended at least one 
psychosocial support group meeting between ART initiation and six months postpartum and 
having attended the six-week postpartum clinic visit were significantly associated with an odds of 
adherence at six months postpartum. HIV-infected pregnant women who had initiated ART more 
than 30 days prior to delivery were 42% less likely to be adherent at six months postpartum 
compared to women who had initiated ART 30 days or less prior to delivery (unadjusted 
OR=0.58, p=0.004). On the other hand, having attended at least one psychosocial support group 
meeting between ART initiation and six months postpartum as well as having attended the six-
week postpartum clinic visit were associated with an approximately two (unadjusted OR=1.97, 
p=0.009) and three (unadjusted OR=3.12, p<0.001) times increased odds of adherence at six 
months postpartum, respectively. However, the multivariate analysis results showed that only 
adherence status at the first ANC visit post-ART initiation and clinic visit attendance at six weeks 
postpartum were associated with an increased odds of adherence at six months postpartum 
(adjusted OR=2.00, p=0.006 and adjusted OR=2.78, p=0.001, respectively).   
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Tables 2c and 2d in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 80% adherence 
at six months postpartum. Using the nonadherence definition of medication adherence less than 
80%, adherence status at ANC was the only factor found to be associated with adherence at six 
months postpartum in the univariate analyses and women who were adherent in ANC were nearly 
three times as likely to be adherent at six months postpartum (unadjusted OR=2.79, p=0.054). 
Having been diagnosed with HIV prior to the current pregnancy was also marginally associated 
with a decreased odds of adherence at six months postpartum (unadjusted OR=0.44, p=0.071). In 
the multivariate analysis, adherence at the first ANC visit post-ART initiation remained 
significantly associated with adherence at six months postpartum (adjusted OR=3.12, p=0.012) 
and the association between previous HIV diagnosis and adherence also became significant 
(adjusted OR=0.10, p=0.003).  
 In the analysis defining nonadherence as medication adherence less than 80%, returning 
to clinic without the ART pill box or not returning to clinic for the scheduled visit, older age, 
baseline CD4 cell count, psychosocial group meeting attendance, clinic attendance at six weeks 
postpartum and adherence at the first ANC visit post-ART initiation were associated with 
adherence at six months postpartum in the univariate analyses. HIV-infected women ages 35-60 
were over four times as likely to be adherent at six months postpartum than women ages 18-24 
(unadjusted OR=4.64, p=0.006). HIV-infected pregnant women with a baseline CD4 cell count of 
greater than 350 remained less likely to be adherent at six months postpartum than women with a 
baseline CD4 cell count of less than or equal to 350 cells/mm3 (unadjusted OR=0.70, p=0.077) 
and having attended at least one psychosocial support group meeting between ART initiation and 
six months postpartum as well as having attended the six week postpartum clinic visit were 
associated with an increased odds of adherence at six months postpartum (unadjusted OR=2.23, 
p=0.004 and unadjusted OR=3.73, p=<0.001, respectively). HIV-infected pregnant women who 
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were defined as adherent in ANC under this definition of adherence were more than two times as 
likely to be adherent as at six months postpartum as compared to women who were not adherent 
in ANC (unadjusted OR=2.19, p<0.001). In the multivariate analysis, the associations between 
maternal age, CD4 at baseline and psychosocial support group attendance with adherence at six 
months postpartum became non-significant (adjusted OR=2.61, p=0.166, adjusted OR=0.82, 
p=0.492 and adjusted OR=1.31, p=0.446, respectively) while the associations between adherence 
at the first-ANC visit post-ART initiation and clinic attendance at six weeks postpartum with 
adherence at six months postpartum remained strong (adjusted OR=2.00, p=0.014 and adjusted 
OR=2.81, p=0.001), respectively). In addition, women who had been previously diagnosed with 
HIV were 46% less likely than women who were newly diagnosed with HIV during the current 
pregnancy to be adherent at six months postpartum in the multivariate analysis (adjusted 
OR=0.54, p=0.043).  
 
Predictive models for adherence at six months postpartum 
Table 4 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. The only factor found to be predictive of 
adherence at six months postpartum in all four models was adherence at the first ANC visit post-
ART initiation. HIV-infected pregnant women found to be adherent in ANC were predicted to be 
between two (model 1) and 3.65 (model 3) times as likely as women who were not adherent in 
ANC to be adherent at six months postpartum. Parity was predictive of adherence at six months 
postpartum in model 1 and model 2, but contrary to adherence in ANC, women who were 
multiparous were between 35% (model 2) and 58% (model 1) less likely than nulliparous women 
to be adherent at six months postpartum. Baseline CD4 count was also predictive of adherence at 
six months postpartum in model 1 and model 2, and women with higher CD4 cell counts 
continued to be approximately 50% less likely to be adherent than women with lower CD4 cell 
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counts in these two prediction models. Previous HIV diagnosis was predictive of adherence at six 
months postpartum in model 3 and model 4, but having been previously diagnosed with HIV was 
associated with between a 30% (model 4) and 76% decreased odds of adherence at six months 
postpartum in comparison to being newly diagnosed with HIV during the current pregnancy. 
Having a partner who was counseled and tested for HIV in ANC as well as having attended at 
least one psychosocial support group meeting between ART initiation and six months postpartum 
were predictive of good adherence in model 2 and model 4. Women with partners who had been 
counseled and tested for HIV were approximately 60% more likely than women with partners 
who had not been counseled and tested for HIV to be adherent at six months postpartum and 
women who had attended at least one psychosocial support group meeting were more than twice 
as likely as women who had attended no psychosocial support group meetings to be adherent at 
six months postpartum. 
Table 4: Predictive models for adherence at six months postpartum* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Parity 0.42 (0.21, 0.85) 0.015 
Baseline CD4 0.54 (0.29, 1.01) 0.054 
Previous PMTCT 0.61 (0.31, 1.20) 0.151 
Adherence in ANC 2.00 (1.07, 3.74) 0.000 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Parity  0.65 (0.43, 0.99) 0.047 
Baseline CD4 0.58 (0.38, 0.87) 0.009 
Partner counseled/tested for HIV 1.63 (0.99, 2.68) 0.055 
PSS group attendance 2.17 (1.28, 3.66) 0.004 
Adherent in ANC 1.99 (1.34, 2.97) 0.001 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Previous HIV diagnosis 0.24 (0.09, 0.67) 0.006 
Adherent in ANC 3.65 (1.21, 11.01) 0.022 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Previous HIV diagnosis 0.70 (0.45, 1.11) 0.131 
Partner counseled/tested for HIV 1.67 (0.99, 2.81) 0.053 
PSS group attendance 2.29 (1.29. 4.06) 0.005 
Adherent in ANC 2.28 (1.50, 3.45) 0.000 
*Reference groups: 1) Parity: 0; 2) Baseline CD4: ≤350 cells/mm; 3) Previous PMTCT: No; 4) Adherence 






Adherence at ANC and six months postpartum 
 Tables 3a and 3b in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 95% adherence 
at both the ANC visit and the six-month postpartum visit. Using the nonadherence definition of 
medication adherence less than 95%, the univariate analyses found that a higher education level, 
status disclosure and having a partner who was counseled and tested for HIV in ANC were 
associated with a 71%, 67% and 77% increased odds of adherence at both time points, but that 
these results were only marginally significant (unadjusted OR=1.71, p=0.055, unadjusted 
OR=1.67, p=0.064 and unadjusted OR=1.77, p=0.075, respectively). In the multivariate analysis, 
only higher education remained associated with adherence at both time points (adjusted OR=2.01, 
p=0.051). Employment also became associated with adherence at both time points in the 
multivariate analysis, and HIV-infected women who reported being employed were 47% less 
likely to be adherent at both time points than women who reported being unemployed or 
housewives (adjusted OR=0.53, p=0.060).  
 In the analysis defining nonadherence as medication adherence less than 95%, returning 
to clinic without the ART pill box or not returning to clinic for the six-month postpartum visit, the 
univariate analyses once again showed that a higher education level, disclosure and having a 
partner who was counseled and tested for HIV in ANC were associated with adherence at both 
clinic visits (unadjusted OR=1.37, p=0.047, unadjusted OR=1.75, p=0.016 and unadjusted 
OR=1.66, p=0.047, respectively). In addition, HIV-infected pregnant women and mothers with a 
CD4 cell count of  greater than 350 cells/mm3 were found to be 39% less likely to be adherent at 
both time points as HIV-infected pregnant women and mothers with a CD4 cell count of less than 
or equal to 350 cells/mm3 (unadjusted OR=0.61, p=0.020). Having attended at least one 
psychosocial support group meeting between ART initiation and six months postpartum was also 
marginally associated with increased odds of adherence at both time points in the univariate 
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analysis (unadjusted OR=1.57, p=0.087). In the multivariate analysis, education and disclosure 
continued to remain associated with adherence at both time points (adjusted OR=1.79, p=0.043 
and adjusted OR=1.84, p=0.028, respectively). In addition, women who had spent more than 30 
days on ART during pregnancy were 41% less likely than women who had spent 30 days or less 
on ART during pregnancy to be adherent at both time points in the multivariate analysis (adjusted 
OR=0.59, p=0.039).  
Tables 3c and 3d in Appendix E summarize the results of the univariate and multivariate 
logistic regression models looking at the effects of different factors on achieving 80% adherence 
at both the ANC visit and the six-month postpartum visit. Using the nonadherence definition of 
medication adherence less than 80%, the univariate analyses found that HIV-infected pregnant 
women and mothers who were employed at the time of ART initiation were 44% less likely than 
HIV-infected pregnant women and mothers who were not employed at the time of ART initiation 
to be adherent at both time points, but the association was only marginally significant (unadjusted 
OR=0.56, p=0.083). The univariate analyses also found that married women were over five times 
as likely as unmarried women to be adherent at both time points and that women who had 
disclosed their HIV status were nearly two times as likely as women who had not disclosed their 
HIV status to be adherent at both time points (unadjusted OR=5.07, p=0.003 and unadjusted 
OR=1.97, p=0.036, respectively). In the multivariate analysis, education, marital status and 
disclosure continued to be associated with adherence at both time points (adjusted OR=0.46, 
p=0.061, adjusted OR=3.93, p=0.045 and adjusted OR=2.08, p=0.072, respectively).  
 In the analysis defining nonadherence as medication adherence less than 80%, returning 
to clinic without the ART pill box or not returning to clinic for the six-month postpartum visit, 
baseline CD4 cell count, disclosure and time spent on ART during pregnancy were significantly  
associated with adherence at both time points in the univariate analyses. Women who had 
baseline CD4 cell counts greater than 350 cells/mm3 were 37% less likely than women who had 
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baseline CD4 cell counts less than or equal to 350 cells/mm3 to be adherent at both time points 
(unadjusted OR=0.63, p=0.024). HIV status disclosure was associated with a 31% increased odds 
of adherence at both time points while having spent more than 30 days on ART during pregnancy 
was associated with a 42% decreased odds of adherence at both time points (unadjusted 
OR=1.69, p=0.011 and unadjusted OR=0.58, p=0.006, respectively). In the multivariate analysis, 
the association between baseline CD4 cell count and adherence at both time points became 
nonsignificant (adjusted OR=0.76, p=0.260) but the associations between disclosure and 
adherence and time spent on ART during pregnancy and adherence remained strong (adjusted 
OR=1.91, p=0.009 and adjusted OR=0.54, p=0.007, respectively).  
 
Predictive models for adherence in antenatal care and six months postpartum 
Table 5 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. The only factor found to be predictive of 
adherence at both time points was disclosure. Women who had disclosed their HIV status by the 
first ANC visit post-ART initiation were between 1.56 (model 4) and 2.03 (model 3) times more 
likely to be remain adherent at both time points than women who had not disclosed their HIV 
status by the first ANC visit post-ART initiation. Education was predictive of sustained adherence 
in model 1 and model 2, with women reporting at least a secondary level of education being 
between 14% (model 1) and 47% (model 2) more likely than women reporting a primary level of 
education or no education to maintain adherence at both time points. Employment was predictive 
of adherence in model 1 and model 3, with women who were employed being between 39% 
(model 1) and 51% (model 3) less likely than women who were not employed to maintain 
adherence at both time points. Marital status was predictive of adherence in model 3 and model 4, 
with women who were married being between approximately two (model 4) and three and a half 
110 
 
(model 3) times more likely than women who were not married to maintain adherence at both 
time points. 
Table 5: Predictive models for adherence at ANC and six months postpartum* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Education 1.86 (1.00, 3.46) 0.050 
Employment  0.61 (0.34, 1.11) 0.109 
Disclosure  1.65 (0.92, 2.97) 0.093 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Education 1.53 (0.95, 2.46) 0.084 
Baseline CD4 0.65 (0.41, 1.03) 0.064 
Disclosure 1.91 (1.18, 3.10) 0.008 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Employment 0.49 (0.23, 1.03) 0.059 
Marital status 3.50 (1.02, 12.06) 0.047 
Disclosure  2.03 (0.98, 4.31) 0.055 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Marital status  1.91 (0.75, 4.91) 0.178 
Disclosure  1.56 (1.00, 2.44) 0.051 
Time on ART in pregnancy 1.44 (0.83, 2.52) 0.196 
*Reference groups: 1) Education: none/primary; 2) Employment: housewife/not employed; 3) Disclosure: 
No; 4) Baseline CD4: ≤350 cells/mm3; 5) Marital status: not married; 6) Time on ART in pregnancy: ≤30 
days 
 
Clinic visit attendance in the postpartum period 
Tables 6a and 6b summarizes the clinic visit attendance profile of the study population at 
six weeks and six months postpartum. 21.9% of HIV-infected mothers did not return within the 
designated window for the six-week postpartum visit and 19.0% did not return within the 
designated window for the six-month postpartum visit. McNemar’s Chi Squared test for paired 
data found that the proportion of HIV-infected mothers who attended the clinic at six weeks 
postpartum was not significantly different from the proportion of HIV-infected mothers who 









Table 6a: Clinic visit attendance at six weeks and six months postpartum, N=480 
 Yes (%) No (%) Missing/Unknown (%) 
Attended at six weeks 
postpartum 
345 (71.9) 105 (21.9) 30 (6.25) 
Attended at six months 
postpartum 




Table 6b: Proportion of HIV-infected mothers attending clinic visits at six weeks and six 
months postpartum  
 Attended at six months postpartum  
Attended at six weeks 
postpartum 
Yes (%) No (%) Total (%) 
Yes (%) 298 (84.9)  40 (45.5) 338 (77.0) 
No (%) 53 (15.1) 48 (54.6) 101 (23.0) 
Total (%) 351 (100.0) 88 (100.0) 439 (100.0) 
 
 
Clinic visit attendance at six weeks postpartum 
 Table 4 in Appendix D summarizes the results of the univariate and multivariate logistic 
regression models looking at the effects of different factors on clinic attendance at six weeks 
postpartum. In the univariate analyses, previous PMTCT program experience was associated with 
47% decreased odds of attending the clinic at six weeks postpartum and having been diagnosed 
with HIV prior to the current pregnancy was associated with a 95% increased odds of attending 
the clinic at six weeks postpartum (unadjusted OR=0.53, p=0.020 and unadjusted OR=1.95, 
p=0.022, respectively). Being classified as adherent at the first ANC visit post-ART initiation was 
also associated with an increased odds of attending the clinic at six weeks postpartum in the 
univariate analyses under both the 95% and 80% adherence cutoffs (unadjusted OR=1.96, 
p=0.003 and unadjusted OR=1.81, p=0.010, respectively). In the multivariate analyses, the effect 
of adherence in ANC was no longer significant (adjusted OR=1.58, p=0.117 and adjusted 
OR=1.63, p=0.108 for 95% and 80% adherence cutoffs, respectively) and the effects of previous 
PMTCT program experience and previous HIV diagnosis became only marginally significant 
(adjusted OR=0.47, p=0.082 and adjusted OR=2.05, p=0.092, respectively). 
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Predictive models for clinic visit attendance at six weeks postpartum 
Table 7 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. Having been previously diagnosed with HIV 
before the current pregnancy and good adherence in ANC were predictive of clinic visit 
attendance at six weeks postpartum in all four models. Women who had learned their HIV status 
before the current pregnancy were between 58% (model 1) and 91% (model 4) more likely than 
women who were newly diagnosed with HIV to attend the clinic at six weeks postpartum and 
women who were classified as having good adherence in ANC were between 61 % (model 3) and 
71% (model 1) more likely than women who had poor adherence in ANC to attend the clinic at 
six weeks postpartum. Older age and previous PMTCT program experience were predictive of 
attendance at six weeks postpartum in all the models with the exception of model 1. Women 
between the ages of 25 and 60 were more likely to attend the clinic at six weeks postpartum than 
women between the ages of 18 and 24. On the other hand, Women who had been previously 
exposed to a PMTCT program were between 35% (model 3) and 49% (model 4) less likely than 
women who were new to the PMTCT program to attend the clinic at six weeks postpartum. 
Having a partner who was counseled and tested for HIV in ANC as well as having attended at 
least one psychosocial support group meeting between ART initiation and six weeks postpartum 
were predictive of good adherence in model 2 and model 4. Women with partners who had been 
counseled and tested for HIV were between 31% (model 4) and 38% (model 2) more likely than 
women with partners who had not been counseled and tested for HIV to attend the clinic at six 
weeks postpartum and women who had attended at least one psychosocial support group meeting 
were almost 70% more likely than women who had attended no psychosocial support group 





Table 7: Predictive models for clinic visit attendance at six weeks postpartum* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Previous HIV diagnosis 1.58 (0.85, 2.95) 0.150 
Adherent in ANC 1.71 (1.02, 2.85) 0.041 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Maternal age 1.43 (0.89, 2.30) 
3.25 (0.92, 11.53) 
0.136 
0.067 
Previous PMTCT 0.53 (0.30, 0.93) 0.028 
Previous HIV diagnosis  1.87 (1.04, 3.36) 0.038 
Partner counseled/tested for HIV 1.62 (0.88, 2.99) 0.124 
PSS group attendance  1.67 (0.82, 3.42) 0.159 
Adherent in ANC  1.70 (1.07, 2.71) 0.024 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Maternal age 1.43 (0.85, 2.40) 
2.38 (0.66, 8.55) 
0.183 
0.183 
Previous PMTCT 0.65 (0.35, 1.21) 0.174 
Previous HIV diagnosis 1.64 (0.88, 3.08) 0.120 
Adherent in ANC 1.61  (0.88, 2.95) 0.120 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Maternal age 1.48 (0.92, 2.37) 
3.29 (0.93, 11.59) 
0.106 
0.064 
Previous PMTCT 0.52 (0.29, 0.90) 0.022 
Previous HIV diagnosis  1.91 (1.06, 3.45) 0.031 
Partner counseled/tested for HIV  1.63 (0.88, 3.01) 0.118 
PSS group attendance  1.69 (0.83, 3.46) 0.151 
Adherent in ANC  1.67 (1.04, 2.68) 0.033 
*Reference groups: 1) Previous HIV diagnosis: No; 2) Adherent in ANC: No; 3) Maternal age: 18-24 
years; 4) Previous PMTCT: No; 5) Partner counseled/tested: No; 6) PSS group attendance: None 
 
 
Clinic visit attendance at six months postpartum  
Table 5 in Appendix E summarizes the results of the univariate and multivariate logistic 
regression models looking at the effects of different factors on clinic attendance at six months 
postpartum. In the univariate analyses, older women in the 25 to 34 and 35 to 60 age groups were 
more likely to attend at six months postpartum than younger women ages 18-24 (unadjusted 
OR=1.60, p=0.053 and unadjusted OR=9.67, p=0.028, respectively), but these association 
became nonsignificant in the multivariate analysis (adjusted OR=1.33, p=0.431 and adjusted 
OR=5.18, p=0.140, respectively). Similarly, HIV-infected pregnant women and mothers who had 
attended at least one psychosocial support group meeting between ART initiation and six months 
postpartum were more than three and a half times more likely than women who had attended no 
psychosocial support group meetings to attend the clinic at six months postpartum in the 
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univariate analysis (unadjusted OR=3.56, p=0.002), but this association was no longer significant 
in the multivariate analysis (adjusted OR=2.02, p=0.159). HIV-infected pregnant women who had 
spent more than 30 days on ART in pregnancy were almost three times more likely than those 
who had spent 30 days or less on ART in pregnancy to attend the clinic at six months postpartum 
(unadjusted OR=2.88, p<0.0001) in the univariate analysis and more than three and a half times 
more likely to attend clinic at six months postpartum in the multivariate analysis (adjusted 
OR=3.58, p<0.001). HIV-infected pregnant women who were adherent in ANC based on the 80% 
cutoff were more than two times as likely as women who were not adherent in ANC to attend the 
clinic at six months postpartum in the univariate analysis (unadjusted OR=2.11, p=0.002), but this 
association was not significant in the multivariate analysis (adjusted OR=1.51, p=0.233). The 
strongest predictor of clinic attendance at six months postpartum was clinic attendance at six 
weeks postpartum. HIV-infected mothers who attended the clinic at six weeks postpartum were 
more than six times as likely as HIV-infected mothers who did not attend the clinic at six weeks 
postpartum to attend the clinic at six months postpartum in the univariate analysis (unadjusted 
OR=6.75, p<0.001), and this association remained strong and significant in the multivariate 
analysis (adjusted OR=5.19, p<0.001).  
 
Predictive models for clinic visit attendance at six months postpartum 
 Table 8 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. Employment, marital status, psychosocial 
support group meeting attendance, time spent on ART in pregnancy and attendance at six weeks 
postpartum were all predictive of attendance at six months postpartum in all four models. Women 
who reported being employed were approximately 40% less likely than women who reported not 
being employed to attend the clinic at six months postpartum. Women who reported being 
married almost three times more likely than women who reported not being married to attend the 
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clinic at six months postpartum, women who attended at least one psychosocial support group 
meeting between ART initiation and six months postpartum were more than twice as likely as 
women who had not attended a psychosocial support group meeting to attend the clinic at six 
months postpartum, women who had initiated ART more than 30 days before delivery were over 
three times as likely as women who had initiated ART less than or equal to 30 days before 
delivery to attend the clinic at six months postpartum and women who had attended the clinic at 
six weeks postpartum were more than five times as likely as women who had not attended the 
clinic at six weeks postpartum to attend the clinic at six months postpartum.  
 
Table 8: Predictive models for clinic visit attendance at six months postpartum* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Employment 0.61 (0.33, 1.13) 0.113 
Marital status 2.92 (0.97, 8.77) 0.056 
PSS group attendance  2.23 (0.87, 5.73) 0.097 
Time on ART in pregnancy 3.30 (1.68, 6.49) 0.001 
Attendance at six weeks 
postpartum 
5.95 (3.14, 11.28) 0.000 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Employment  0.56 (0.30, 1.06) 0.073 
Marital status 2.65 (0.87, 8.08) 0.088 
PSS group attendance  2.19 (0.85, 5.62) 0.103 
Time on ART in pregnancy  3.20 (1.60, 6.36) 0.001 
Adherent in ANC 1.65 (0.88, 3.09) 0.115 
Attendance at six weeks 
postpartum 
5.14 (2.68, 9.85) 0.000 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Employment 0.61 (0.33, 1.13) 0.113 
Marital status 2.92 (0.97, 8.77) 0.056 
PSS group attendance  2.23 (0.87, 5.73) 0.097 
Time on ART in pregnancy  3.30 (1.68, 6.49) 0.001 
Attendance at six weeks 
postpartum  
5.95 (3.14, 11.28) 0.000 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Employment  0.58 (0.31, 1.09) 0.091 
Marital status 2.66 (0.87, 8.17) 0.087 
PSS group attendance  2.15 (0.84, 5.52) 0.113 
Time on ART in pregnancy  3.18 (1.59, 6.34) 0.001 
Adherent in ANC 1.63 (0.86, 3.06) 0.131 
Attendance at six weeks 
postpartum 
5.18 (2.70, 9.94) 0.000 
*Reference groups: 1) Employment: Housewife/not employed; 2) Marital status: Not married; 3) PSS 
group attendance: None; 4) Time on ART in pregnancy: ≤30 days; 5) Attendance at six weeks postpartum: 
No; 6) Adherence in ANC: No 
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Clinic visit attendance at six weeks and six months postpartum 
  
Table 6 in Appendix E summarizes the results of the univariate and multivariate logistic 
regression models looking at the effects of different factors on clinic attendance at both six weeks 
and six months postpartum. In the univariate analysis, women between 35 and 60 years old were 
approximately three and a half times more likely than women between 18 and 24 years old to 
attend the clinic at both time points (unadjusted OR=3.55, p=0.024), but this association was not 
as significant in the multivariate analysis (adjusted OR=3.44, p=0.071). In the univariate analysis, 
women who had previously received PMTCT treatment or prophylaxis were 39% less likely than 
women who had not previously received any PMTCT treatment or prophylaxis to attend the clinic 
at both time points (unadjusted OR=0.61, p=0.060), but this association was also not significant 
in the multivariate analysis (adjusted OR=0.63, p=0.207). Women who were previously 
diagnosed with HIV before the current pregnancy were twice as likely as women who were newly 
diagnosed with HIV to attend the clinic visit at both time points in the univariate and multivariate 
analyses (unadjusted OR=2.04, p=0.006 and adjusted OR=2.03, p=0.031). Similarly, women who 
had spent more than 30 days on ART during pregnancy were more than twice as likely as women 
who had spent 30 days or less on ART during pregnancy to attend the clinic at both time points, 
and the association was significant in the univariate and multivariate analyses (unadjusted 
OR=2.19, p=0.002 and adjusted OR=2.05, p=0.020). Having a partner who was counseled and 
test for HIV in ANC, having attended at least one psychosocial support group meeting between 
ART initiation and six months postpartum and 95% or 80% adherence at the first ANC visit post-
ART initiation were all associated with clinic visit attendance at both time points (unadjusted 
OR=1.66, p=0.065, unadjusted OR=1.75, p=0.043, unadjusted OR=1.91, p=0.002 and unadjusted 





Predictive models for clinic visit attendance at six weeks postpartum and months postpartum 
 Table 9 lists the factors included in the predictive models obtained from the backwards 
selection process for each definition of adherence. Previous PMTCT program experience, having 
been previously diagnosed with HIV, having a partner who was counseled and tested for HIV in 
ANC and time spent on ART in pregnancy were predictive of attendance at both time points in all 
four models. Previous PMTCT program experience was associated with between a 39% (model 
4) and 32% (model 2) decreased odds of attendance at both clinic visits while women who had 
been diagnosed with HIV prior to the current pregnancy were approximately twice as likely as 
women who were newly diagnosed with HIV to attend the clinic at both time points. Having a 
partner who was counseled and tested for HIV in ANC was associated with between a 71% 
(model 1) and 85% (model 2) increased odds of clinic attendance at both time points and women 
who had initiated ART more than 30 days before delivery were approximately twice as likely as 
women who had initiated ART later in pregnancy to attend the clinic at both time points. Higher 
education level was actually associated with a 32% decreased odds of attendance at both clinic 
visits in models 1, 2 and 3 while attending at least one psychosocial support group meeting 
between ART initiation and six months postpartum predicted attendance at both clinic visits in 
every model with the exception of model 1. Good adherence in ANC was associated with an 















Table 9: Predictive models for clinic visit attendance at six weeks and six months 
postpartum* 
Model 1: 95% adherence (nonadherence=<95%medication adherence) 
Factor Adjusted OR (95% CI) p-value 
Education 0.68 (0.43, 1.07) 0.095 
Previous PMTCT 0.65 (0.38, 1.13) 0.127 
Previous HIV diagnosis  1.94 (1.13, 3.44) 0.017 
Partner counseled/tested for HIV 1.71 (0.97, 3.03) 0.063 
Time on ART in pregnancy  2.10 (1.24, 3.57) 0.006 
Model 2: 95% adherence (nonadherence=<95% adherence or returned without pill box/did not return) 
Education 0.68 (0.43, 1.10) 0.114 
Previous PMTCT 0.68 (0.39, 1.20) 0.181 
Previous HIV diagnosis  1.81 (1.04, 3.15) 0.037 
Partner counseled/tested for HIV 1.85 (1.02, 3.35) 0.043 
PSS group attendance  1.73 (0.94, 3.20) 0.079 
Time on ART in pregnancy  2.01 (1.16, 3.46) 0.012 
Adherent in ANC  1.49 (0.95, 2.34) 0.084 
Model 3: 80% adherence (nonadherence= <80% medication adherence) 
Education 0.68 (0.43, 1.08) 0.102 
Previous PMTCT 0.62 (0.36, 1.08) 0.094 
Previous HIV diagnosis  1.98 (1.15, 3.43) 0.014 
Partner counseled/tested  1.74 (0.98, 3.08) 0.058 
PSS group attendance  1.63 (0.90, 2.98) 0.108 
Time on ART in pregnancy  1.99 (1.17, 3.40) 0.011 
Model 4: 80% adherence (nonadherence= <80% adherence or returned without pill box/did not return) 
Previous PMTCT 0.61 (0.36, 1.04) 0.069 
Previous HIV diagnosis 1.78 (1.06, 3.00) 0.030 
Partner counseled/tested for HIV 1.83 (1.03, 3.26) 0.039 
PSS group attendance  1.81 (1.02, 3.23) 0.044 
Time on ART in pregnancy  1.82 (1.07, 3.11) 0.027 
Adherent in ANC  1.51 (0.96, 2.36) 0.072 
*Reference groups: 1) Education: None/primary; 2) Previous PMTCT: No; 3) Previous HIV diagnosis: No; 
4) Partner counseled/tested: No; 5) Time on ART in pregnancy: ≤ 30 days; 6) PSS group attendance: None; 




This study found that of the 1,106 HIV-infected pregnant women who required ART 
initiation, 79% were enrolled in the Option B+ program and of these, only 68% attended more 
than one visit in ANC. These findings were consistent with the Malawi Option B+ program in 
2014 which resulted in approximately 80% of HIV-infected pregnant women being initiated on 
treatment.15 However, these results also highlight the gaps that continue to exist in the PMTCT 




Trends and predictors of adherence 
This study found that ART adherence decreased over time from 52.1% in ANC to 44.8% 
at six months postpartum using the 95% adherence cutoff and from 64.4% in ANC to 56.9% at 
six months postpartum using the 80% adherence cutoff. This decrease in ART adherence over 
time from pregnancy to the postpartum period is consistent with findings from the meta-analysis 
conducted by Nachega et al. looking at PMTCT adherence over time that reported a drop in 
medication adherence from 73.5% during pregnancy to 53% in the postpartum period.16 
Similarly, a study in western Uganda also looking at Option B+ adherence in 2014 found that 
only 51% HIV-infected women who initiated ART exhibited greater than or equal to 95% 
adherence during pregnancy.11   While it is possible that adherence to ART under Option B+ has 
improved in the three years since this cohort of women was enrolled into the program, the low 
proportion of adherent women at both time points as well as the significant decrease in adherence 
over time merit an in-depth exploration of the factors associated with poor adherence as well as 
interventions targeted at improving and sustaining adherence over time. This study also found 
that 17.1% of HIV-infected pregnant women and 14.8% of HIV-infected mothers had unknown 
adherence at ANC and six months postpartum, respectively. Pill count adherence could not be 
calculated for these women if they had not brought back their pill boxes or if the number of pills 
dispensed at the last clinic visit could not be determined by the PMTCT counselor at the current 
visit. Pill counts have been found in the literature to correlate more significantly with viral load 
and CD4 counts than patient self-report17 and are often used in resource limited settings where 
viral load and CD4 count measures are not routinely performed. This study indicates that 
additional counseling about the importance of returning to clinic with the pill box or interventions 
to improve the pill box return rate may be necessary if this measure of adherence is to be relied 
upon in the future. Furthermore, additional training of PMTCT counselors may be beneficial to 
improve the pill box return rate and to assist counselors with successfully measuring and 
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recording pill count adherence at each clinic visit.  Adherence at six months postpartum could 
also not be determined for 18.3% of women who did not return within the established five to 
seven month visit window. This finding was in line with results of other studies looking at 
retention in care under Option B+, where loss to follow-up ranged from 11.2% in Malawi18 to 
38% Mozambique19 by six months since ART initiation and 24% in South Africa20 by 12 months 
after delivery.  
This study found that adherence could not be calculated for the majority of HIV-infected 
mothers presenting for care at six weeks postpartum because the number of pills dispensed at 
labor and delivery (i.e. the last visit before six months postpartum) could not be ascertained for 
51.7% of women and 21.5% did not return to the clinic at six weeks postpartum. While the issue 
of unknown adherence at six weeks postpartum may be specific to Mulago National Referral 
hospital, it once again underlines the limitations of pill count procedures for determining 
medication adherence. Routine viral load testing for PMTCT is currently being rolled out at 
Mulago, but attention should be paid to the gap in pill count adherence at six weeks postpartum 
and data collection procedures at labor and delivery should be addressed and improved to address 
this gap.  
The models obtained from this study found that baseline CD4 cell count, previous 
PMTCT experience, disclosure, education, employment status and HIV diagnosis prior to the 
current pregnancy were predictive of good adherence in ANC. Women with CD4 cell counts 
greater than 350 cells/mm3 were 50% less likely than women with lower CD4 cell counts to be 
adherent in ANC and similarly, women with previous PMTCT program experience were 40% 
less likely than women who were completely ART-naïve to be adherent in ANC. These findings 
suggest that some challenges may have existed with respect to transitioning to Option B+ from 
the previous Option A approach where HIV-infected pregnant women with CD4 cell counts 
greater than 350 cells/mm3 were counseled about and initiated on PMTCT prophylaxis as opposed 
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to lifetime treatment for their own health. These findings signify the importance of effective 
counseling at the time of ART initiation to ensure that pregnant women who may feel otherwise 
healthy or who have had experience with previous PMTCT guidelines are fully aware of the 
Option B+ treatment regimen and the importance of maintaining good adherence at all times. In 
this study, HIV status disclosure was associated with a 49% to 96% increased odds of adherence 
at the first ANC visit post-ART initiation. This result was consistent with findings in the PMTCT 
adherence literature. For example, one study in Zimbabwe looking at factors affecting uptake of 
PMTCT services found that women who had disclosed their status were 30% more likely to 
obtain treatment or prophylaxis for PMTCT.21 In this study, women with at least a secondary 
level of education were between 50% and 90% more likely to be adherent in ANC than women 
with lower levels of education. This finding was consistent with the study from Western Uganda 
that found higher education level to be associated with increased odds of retention in care under 
the Option B+ program.11 This study found that having been diagnosed with HIV prior to the 
current pregnancy was associated with a 47% to 66% increased odds of adherence in ANC but 
that 74.2% of HIV-infected pregnant women presenting for ANC were obtaining their HIV status 
for the first time. These findings are relevant to the Option B+ test-and-treat approach where 
HIV-infected pregnant women are expected to initiate ART immediately after diagnosis and 
consistent with findings from qualitative studies that have shown same-day initiation of 
treatment, to be a challenge for successful Option B+ program implementation.22 In this study, 
women who reported being employed were between 31% and 48% less likely to be adherent in 
ANC than women who were not employed at the first ANC visit post-ART initiation. While this 
result may seem counterintuitive at first, qualitative studies have shown that fear of stigma or 
discrimination is associated with poor medication adherence.23 It is possible that women who 
work outside of the home are fearful of having their HIV status exposed at work and therefore do 
not take ART at work. Similarly, women enrolled in the Option B+ program are counseled by 
122 
 
PMTCT counselors to take ART at the same time every day. It is possible that being employed 
outside of the home is more disruptive to a daily routine that allows for consistent adherence.  
 The only factor found to predict adherence at six months postpartum in this study, 
regardless of the definition for adherence that was used in the prediction model, was adherence at 
the first ANC visit post-ART initiation. Women who were adherent at the first ANC visit post-
ART initiation were at least twice as likely to be adherent at six months postpartum than women 
who were not adherent in ANC. One systematic review looking at interventions to improve 
postpartum retention in PMTCT and ART care found that interventions using phone calls or text 
messages improved early postpartum retention in PMTCT care and treatment, different levels of 
integration of PMTCT and ART services had mixed effects on postpartum program retention and 
that several other trials aimed at improving postpartum retention in care were ongoing but had yet 
to publish results.24 However, the results of this study indicate that long-term postpartum ART 
adherence might be significantly improved if efforts are focused on continued improvement of 
adherence in the antenatal period, especially since only 52.1% and 64.4% of women were at least 
95% and 80% adherent, respectively, in this study.  
 The only factor in this study found to predict sustained adherence in ANC and at six 
months postpartum regardless of the definition of adherence specified in the prediction model, 
was disclosure in the antenatal period, by the first visit post-ART initiation. HIV-infected 
pregnant women who had disclosed their HIV status to at least one person by this clinic visit were 
up to two times more likely than women who had not disclosed their status to be adherent in ANC 
and sustain this good adherence at six months postpartum. Since only 58.3% of HIV-infected 
pregnant women had disclosed their HIV status by the first ANC visit post-ART initiation, 
interventions aimed at facilitating early disclosure may be beneficial for improving adherence in 




Trends in clinic visit attendance 
 Of the 480 women included in this study at the first ANC visit post-ART initiation, 
71.9% of women presented for care at six weeks postpartum and 73.8% presented for care at six 
months postpartum. Predictive models for clinic visit attendance at six weeks postpartum found 
that having been diagnosed with HIV prior to the current pregnancy and having good adherence 
in ANC were strong predictors of clinic visit attendance at six weeks postpartum. HIV diagnosis 
prior to the current pregnancy was associated with 58% to 91% increased odds of attendance at 
six weeks postpartum. This trends was consistent with the study from Western Uganda that found 
women who were previously diagnosed with HIV before the current pregnancy to be more than 
three times as likely as women who were newly diagnosed with HIV to be retained in care.11   
Good adherence in ANC was associated with a 61% to 70% increased odds of attendance at six 
weeks postpartum. Although little has been presented in the literature about the association 
between adherence in pregnancy and clinic visit attendance in the postpartum period, this study 
suggests that more research should be conducted to explore the validity and reliability of this 
association. In most of the prediction models resulting from this study, older age was also 
predictive of attendance at six weeks postpartum. This result was similar to what was found in a 
study in Zimbabwe looking at factors affecting program retention where older women were less 
likely to be lost to follow-up than younger women initiating Option B+ for PMTCT.25 This 
suggests that specifically targeting younger women for PMTCT counseling and support services 
may lead to improved program retention in the postpartum period. Most of the prediction models 
in this study also found that previous PMTCT program experience was associated with an 
approximately 50% decreased odds of attendance at six weeks postpartum. Some research has 
found that facility resource constraints and a lack of client-friendly services are barriers to 
successful PMTCT program implementation.26   It is possible that negative experiences with 
previous PMTCT programs may have affected program retention in the postpartum period in this 
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study, but a more in-depth understanding of the previous experiences of HIV-infected women 
with PMTCT programs may be necessary to better understand this association. 
 Predictive models for attendance at six months postpartum found a number of factors 
predicting attendance at this time point, including employment status, psychosocial support group 
meeting attendance, time since ART initiation in pregnancy and attendance at six weeks 
postpartum. Similarly to the association with adherence, employment outside of the home 
predicted an approximately 40% decreased odds of attendance at six months postpartum. It is 
possible that inflexible work schedules or financial need took precedence over clinic visit 
attendance at six months postpartum, but these results indicate that more should be done to 
support the HIV care and treatment of working pregnant women and mothers. Although only 
18% of women attended at least one psychosocial support group meeting between treatment 
initiation in pregnancy and six months postpartum, women who did attend are more than twice as 
likely as women who did not attend to present for a clinic visit at six months postpartum. While it 
is possible that receiving this psychosocial support has an effect on program retention, it is also 
possible that women who were more likely to attend psychosocial support group meetings were 
the same women who would likely attend regularly scheduled clinic visits. It would therefore be 
necessary to conduct additional research specifically isolating the effects of psychosocial support 
interventions on program retention in order to better understand this association. HIV-infected 
pregnant women who initiated ART more than 30 days before delivery were more than three 
times as likely as women who had initiated ART less than 30 days before delivery to attend the 
clinic at six months postpartum. It is possible that initiating ART earlier in pregnancy allows for 
women to become more accustomed with the Option B+ program or that initiating ART earlier in 
pregnancy facilitates stronger relationships between the HIV-infected women and the care 
providers, therefore leading to improved clinic visit attendance at six months postpartum. It was 
also found in this study that attendance at six weeks postpartum was a strong predictor of 
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attendance at six months postpartum, signifying that interventions aimed at improving early 
postpartum program retention could have long-lasting effects on program retention in the later 
postpartum period and that more should be done to improve attendance at six weeks postpartum.  
 This study also found previous PMTCT program experience, previous diagnosis with 
HIV, time since ART initiation in pregnancy and psychosocial support group meeting attendance 
to be strong predictors of sustained clinic visit attendance at both six weeks and six months 
postpartum. In addition, although only 20% of women had partners who had been counseled and 
tested for HIV in ANC, partner counseling and testing was associated with between 71% and 
85% increased odds of attending both clinic visits in the postpartum period. This finding is 
supported in the literature, where male partner involvement in ANC was found to be associated 
with improved uptake of PMTCT interventions27 and decreased infant HIV infection.28 The study 
findings support the need for a more in-depth understanding of the barriers to male partner 
involvement and interventions targeted at increasing male partner involvement in PMTCT 
programs.   
 
Limitations  
 It is important to address the various limitations of this study. First, this study did not 
include information about the HIV-infected pregnant women who were enrolled in care during 
the antenatal period but who did not return for a second visit before delivery or who were lost to 
follow-up after this initial ANC visit. For the purposes of program retention, it would have been 
useful to analyze and compare the baseline characteristics of these women to those included in 
the study to gain an improved understanding of the factors that affect early program retention 
during pregnancy. Similarly, baseline clinical and demographic information for women who did 




Next, utilization of pill counts as the measure of medication adherence was prone to 
measurement errors and resulted in incomplete adherence data at six weeks postpartum. The six 
week postpartum visit is crucial in the PMTCT care and treatment cascade since this is when 
infant testing most commonly occurs, and an understanding of adherence in the early postpartum 
period is crucial for improving the current understanding of when adherence is most challenging 
and when the risk for nonadherence and/or vertical HIV transmission is highest under the Option 
B+ approach. Similarly, pill counts could not be performed for women who did not bring back 
their pill boxes, and it is possible that these women were less likely to be adherent than women 
who successfully brought back the pill boxes at each visit, thus biasing the adherence results of 
the study. Nevertheless, pill counts are commonly relied upon in resource-limited settings are 
considered to be more objective and more closely associated with viral load measures than patient 
self-report techniques.  
  Another limitation of this study is that the effects of time-varying exposures on adherence 
and program retention could not be captured utilizing the data regularly collected and entered into 
the PMTCT database. For example, it is possible for factors such as disclosure and male partner 
involvement to change over time, potentially impact changes in adherence and program retention 
in the postpartum period. This limitation was brought up to PMTCT clinic staff at Mulago and 
has led to preliminary discussions about updating the PMTCT visit forms to include questions 
about changes to disclosure and male partner involvement over time. 
 Next, this study was not explicitly powered to detect the effects of the various factors of 
interest on adherence and clinic visit attendance since the study population came from the 
existing PMTCT program in 2014. For instance, only 18% of HIV-infected women included in 
this study had ever attended a psychosocial support group meeting between ART initiation in 
pregnancy and six months postpartum and only 20% had a partner who was counseled and test for 
HIV in ANC, so the effects of these factors on adherence and clinic visit attendance may be 
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uncertain. However, the low rate of psychosocial support group meeting attendance as well as the 
low level of male partner involvement in ANC are important findings that merit additional 
research to better understand how rates of psychosocial support group utilization and male partner 
involvement may be improved in the future.  
 A final limitation of this study is that pill count adherence measures greater than 100% 
were counted as adherent in this study. This was only the case for approximately 3% of adherence 
measures in ANC and 5% of adherence measures at six months postpartum. Further exploration 
of the pill count practices of PMTCT counselors, potentially through qualitative research, may be 
helpful to understand the significance of a pill count measure greater than 100%.  
 
CONCLUSION 
The goal of this study was to improve the current understanding of changes to Option B+ 
medication adherence and clinic visit attendance over time from pregnancy through six months 
postpartum for a cohort of HIV-infected women at Mulago National Referral Hospital who were 
first-time initiators of Option B+ for PMTCT in 2014. This study found that Option B+ adherence 
was relatively low and decreased over time while clinic visit attendance at six weeks postpartum 
and six months postpartum remained consistent at just over 70%. Since the large majority of 
women enrolled into the PMTCT program at Mulago are done so during pregnancy and few 
additional HIV-infected women present for care in the postpartum period, it is crucial to continue 
efforts to improve adherence during pregnancy in this setting and to tailor adherence and program 
retention interventions for the antenatal period. It is also equally important to continue efforts for 
further understanding the barriers and facilitators to postpartum HIV care and treatment in the 
early and late postpartum periods, especially as Option B+ implementation continues throughout 
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PART THREE:  
“It is the only way to stay healthy, live longer and have a child who is HIV negative”: 
Understanding the programmatic and adherence experiences of HIV-infected women 
receiving Option B+ for preventing mother-to-child transmission of HIV from ART 





Option B+ is the current strategy for eliminating vertical HIV transmission in resource-
limited settings. Long-term adherence and program retention are two important outcomes to 
measure when considering the success of Option B+ program implementation. A number of 
studies have reported Option B+ adherence and program retention rates at different time points 
and in various settings, yet limited research exists aimed at gaining an in-depth understanding of 
the factors affecting Option B+ ART adherence and program retention over time. This study 
utilized a series of longitudinal in-depth interviews with 16 HIV-infected women in the first 
month of ART initiation during pregnancy and again at six weeks postpartum to examine the 
changes in Option B+ adherence and clinic visit experiences for women seeking care for PMTCT 
at the Mulago National Referral Hospital in Kampala, Uganda.  Adherence and clinic visit 
attendance for all participants remained consistently high throughout pregnancy and the early 
postpartum period, and a number of themes emerged: 1) effective messaging and counseling at 
the time of HIV testing and treatment initiation; 2) reliance on health workers for support 
between clinic visits; 3) disclosure to an HIV-infected person; 4) variability of male partner 
involvement; 5) modified behaviors to prioritize health and ART adherence; 6) concern with 
unwanted HIV status exposure and 7) a desire for a healthy baby and a healthy life. Interviews at 
six weeks postpartum uncovered a number of factors that continued to affect the ART adherence 
and Option B+ program experiences of the participants: 1) consistent support from health 
workers; 2) limitations of the health facility; 3) ongoing support after disclosure; 4) variability of 
male partner involvement; 5) normalization of daily ART and 6) a continued desire for a healthy 
baby and a healthy life. As Option B+ program implementation continues, emphasis should be 
placed on continued training of health workers, the importance of counseling and support services 
at the facility level, ensuring satisfactory health service delivery, promoting HIV status disclosure 




 Option B+ is the current World Health Organization (WHO) strategy for eliminating 
vertical HIV transmission. Considered a universal strategy for the treatment of HIV-infected 
pregnant women and prevention of mother-to-child transmission (PMTCT), it includes the 
provision of triple antiretroviral therapy (ART) for HIV-infected pregnant women at the antenatal 
clinic (ANC) regardless of clinical stage or CD4 cell count, to be continued for life.1 Under this 
recommendation, HIV-exposed infants are expected to receive nevirapine (NVP) or zidovudine 
(AZT) syrup from birth through six weeks postpartum. The first HIV test for HIV-exposed 
infants is also generally administered at the six-week postpartum clinic visit. Based on 
preliminary PMTCT data from Malawi2, it was originally believed that the Option B+ approach 
could help overcome operational and programmatic complexities that countries had been 
experiencing with PMTCT program implementation and that had been obstacles for meeting the 
2015 deadline for eliminating maternal-to-child transmission (MTCT) set by the Global Plan.3 
The Uganda Ministry of Health (MoH) began implementing Option B+ for PMTCT as the 
national approach for HIV treatment and prophylaxis of pregnant women and mothers in October 
2012. While Option B+ has been scaled nationally and across sub-Saharan Africa, adherence to 
life-long ART initiated during pregnancy and continued in the postpartum period continues to be 
a challenge in many settings throughout the country and in the region, and rates of program 
retention may vary. For example, in its first year of implementation the Option B+ program in 
Malawi reported a large proportion of women lost to follow-up six months after ART initiation, 
with most losses occurring in the first three months of therapy and many women recorded as 
initiating treatment, accepting their first month of ART and then never returning for care.4  
Similarly, data from the Mulago National Referral Hospital in Kampala showed that while a 
majority of pregnant women were presenting for ANC, only 70% of HIV-infected pregnant 
women who were initiated on Option B+ returned for at least one visit in six weeks.5 
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As Option B+ implementation progresses across sub-Saharan Africa, data continue to be 
collected about long-term medication adherence and program retention in various settings, 
including Uganda. However, quantitative research studying ART adherence and Option B+ 
program retention should be coupled with qualitative studies exploring the changing experiences 
of HIV-infected pregnant women and mothers with the Option B+ program over time. One 
qualitative report addressing HIV-infected women on Option B+ in Malawi and Uganda found 
that community engagement, income-generating activities and male partner involvement may be 
key factors affecting the success of Option B+ program implementation.6 Similarly, the PURE 
Malawi Consortium found through in-depth interviews with women enrolled in Option B+ and 
focus group discussions with health care workers that lack of male involvement, concerns with 
the test-and-treat approach and fears surrounding lack of privacy and confidentiality at the health 
centers may be contributing to the rates of loss to follow-up observed in some areas of Malawi.7 
A different qualitative study in western Kenya looking specifically at health facility challenges 
surrounding Option B+ implementation found that same-day initiation of treatment, insufficient 
health worker training, lack of health worker confidence in the Option B+ program, facility 
resource constraints and a lack of client-friendly services were challenges to success of the 
Option B+ program.8 
The existing qualitative Option B+ research highlights some important factors that may 
be affecting medication adherence and program retention at specific time points, usually at ART 
initiation. However, little is known about the experiences of HIV-infected women enrolled in 
Option B+ in the postpartum period and how their experiences with the program have changed 
since pregnancy. This study aims to qualitatively explore the changing experiences of HIV-
infected women enrolled in the Option B+ program from pregnancy through six-weeks 
postpartum at Mulago National Referral Hospital in Kampala, Uganda and to further understand 
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how these changing experiences may affect Option B+ medication adherence and program 
retention over time.  
 
METHODS 
In-depth interviews were conducted with 16 HIV-infected pregnant women who were at 
least 18 years old and in the last trimester of pregnancy at the time of their first ANC visit. All 
participants were first-time initiators of Option B+ for PMTCT at Mulago National Referral 
Hospital and part of the “Friends for Life Circles” study, a randomized controlled trial aimed at 
assessing the effects of a community peer support group intervention on long-term clinic visit 
attendance, ARV drug adherence and viral suppression for HIV-infected pregnant women and 
mothers. For this qualitative study, the first 16 HIV-infected pregnant women in their last 
trimester of pregnancy who provided informed consent were purposively sampled from the 
control arm of the “Friends for Life Circles”. Participants in the control arm received the MoH 
standard of care for PMTCT. A sample size of 20-30 individuals has been recommended to reach 
saturation of themes for in-depth interviews, 9 but a smaller sample size can be justified when the 
same participants are being interviewed at multiple time points.10 
For each participant, basic demographic and clinical information was collected from the 
PMTCT database at Mulago National Referral Hospital. Adherence information for each 
participant at each study visit was also recorded. As per the “Friends for Life Circles” study 
protocol, a visual analog scale (VAS) was used for participants to indicate their adherence in the 
last 30 days. As part of routine data collection at Mulago, clinic counselors measure and record 
pill count adherence in every patient chart. This routinely recorded adherence measure was 
entered into the PMTCT database starting in 2015 and this information was also utilized to assess 
adherence of each participant. Participants were interviewed first during pregnancy, one month 
after their first ANC visit, and again at six-weeks postpartum. Interviews lasted between 30 
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minutes to one hour and took place upon completion of all other study activities. Interviews 
conducted during pregnancy focused on experiences with HIV testing and ART initiation, clinic 
visits and health workers, male partner involvement, HIV status disclosure, stigma and social 
networks and understanding how these experiences might relate to ART adherence and program 
retention. Interviews conducted  six-weeks postpartum focused on experiences with infant HIV 
testing and initiation of infant prophylaxis, clinic visits and health workers, male partner 
involvement, HIV status disclosure, stigma and social networks and understanding how changes 
in experiences between pregnancy and six-weeks postpartum might relate to ART adherence and 
program retention. All interviews were conducted with the aid of semi-structured field guides. 
Transcript summaries were also provided to the interview team prior to conducting the six-week 
postpartum interviews so that appropriate, participant-specific probes and follow-up questions 
could be asked at the time of each follow-up interview.  
All interviews were conducted by one of the local co-investigators or one of two study 
counselors who had received training on proper interview techniques, use of the semi-structured 
field guides and the goals of the study prior to study initiation. The semi-structured field guides 
can be found in Appendix F. All interviews were conducted in Luganda and digitally recorded 
after obtaining approval from each participant. Interviews were then directly transcribed and 
translated into English for analysis by a trained qualitative analysis consulting team with 
experience in previous NIH or PEPFAR-supported qualitative research studies. The in-depth 
interview team consisting of the study coordinator and the three interviewers met weekly with the 
first author prior to and during the initial data collection period and then monthly as data 
collection progressed, to practice interviewing techniques, discuss arising themes and refine the 
interview guides for a more iterative research process.  
Thematic analysis was used to analyze the transcripts.11 Transcripts were reviewed and 
read over multiple times as they were received, and analytic memos were written to reflect on 
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developing patterns, categories, themes and concepts in the data.  The analytic memos were then 
coded and categorized according to their content. The coding and categorization process was 
based both on emergent themes from the data and a priori themes based on the interview guides. 
All transcripts were coded using the scheme developed from the analytic memos, with additional 
codes added as they appeared, if considered relevant to addressing the study goal. Transcripts 
from interviews at pregnancy and six-weeks postpartum were coded and analyzed separately, and 
another series of analytic memos and codes were developed to reflect the changes in experiences 
of participants over time from pregnancy to six-weeks postpartum. Coding was performed 
manually and tracked through the use of multiple Excel spreadsheets.  
Ethical approval to conduct this research was obtained from the institutional review 
boards of the Johns Hopkins University School of Medicine, the University of California San 




Demographics, adherence and clinic visit attendance  
 At the time this manuscript was written, a total of 16 ANC interviews and eight six-week 
postpartum interviews were completed, transcribed and translated for analysis. Table 1 below 
summarizes the demographic characteristics and pill count adherence of each participant. The age 
of the participants ranged from 18 to 33 and the median participant age was 24. All participants 
resided in either the Kampala District or the Wakiso District of the Central Region of Uganda. 12 
of the 16 participants reported being married, three reported being single and marital status for 
one participant was missing. The majority of the participants reported a secondary education and 
were either housewives or self-employed. This was the first pregnancy for only four participants. 
The median CD4 count at ART initiation was 367.5 cells/mm3. 
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Table 1: Socio-demographic characteristics of participants 
























































































According to the VAS adherence measure, all participants reported 100% medication 
adherence at the ANC visit one month post-ART initiation and at six weeks postpartum. Using 
the pill count approach, all participants for whom adherence was able to be measured displayed 
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an adherence rate of 95% or better at both study visits, but adherence could not be calculated for 
five participants in ANC and 4 visits at six weeks postpartum.  
Based on information uncovered in the interviews, six of the 16 participants reported 
having missed one dose at the time of the study visit. Only two participants had ever missed a 
scheduled clinic visit. For the eight participants for whom the six-week postpartum in-depth 
interview transcripts could be reviewed, three out of eight participants reported having missed 
one dose at the time of the study visit, and in all three cases it was on the day of labor and 
delivery. One participant reported missing one scheduled clinic visit since her baby was born.  
 
Option B+ in the antenatal period 
 Some factors were found to notably influence the experiences of HIV-infected women 
with Option B+ during pregnancy. These factors could be grouped into seven key themes: 1) 
effective messaging and counseling at the time of HIV testing and treatment initiation; 2) reliance 
on health workers for support between clinic visits; 3) disclosure to an HIV-infected person; 4) 
variability of male partner involvement; 5) modified behaviors to prioritize health and ART 
adherence; 6) concern with inadvertent HIV status disclosure and 7) a desire for a healthy baby 
and a healthy life. The Option B+ program logistics was also a factor affecting the PMTCT 
experience during pregnancy. 
 
Effective messaging and counseling at the time of HIV testing and treatment initiation 
 15 of the 16 participants interviewed during pregnancy stated that the positive HIV test 
result was unexpected, and most expressed fear, shock or sadness upon receiving their results. As 
one participant describes: 
Health worker, I never expected it because in December on the 15th I went to Nsambya 
Hospital and I was tested and found HIV negative and didn’t have HIV…When I was told 
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[that I am HIV positive], I got shocked and broke down and cried… (27-year old HIV-
infected pregnant woman with 100% pill count adherence at study visit, IDI-09) 
 
In addition to results being unexpected, a number of participants also described confusion about 
the implications of a positive HIV test and difficulties with ART initiation due to the size of the 
tablet. As one participant explained: 
“When I was pregnant, I came here and I was tested and was told that I am HIV positive, 
but I first denied the results and I requested the health worker to re-do the test. She tested 
me again and confirmed to me that I was HIV positive…I was told to start medication but 
I first felt that the tablets were too big and I never started on that day…I would keep 
asking myself, “Who has infected me? How come that I am HIV positive yet I do not have 
support!” (22-year old HIV-infected pregnant woman with 100% pill count adherence at 
study visit, IDI-06) 
 
Despite these feelings of fear and uncertainty, the counseling services provided on this day and 
the messaging surrounding being HIV positive and initiating ART provided encouragement to the 
participants. With respect to overcoming the distress associated with being found HIV positive, 
participants consistently reported that hearing from health workers about others who were also 
infected with HIV and doing well helped them to overcome their initial fear about their own HIV 
status. For example, one participant talks about how speaking with health workers who were 
themselves infected with HIV helped her to gain confidence:  
They counseled me in a special way and I went home confident…What I mean is that they 
explained to me that they were also going through the same, that I will live a good life, I 
will be able to give birth to an HIV-negative baby, “That’s how I am too.” And I got 
encouraged. I got to know I am not alone. Even health workers get infected…something I 
didn’t know. (24-year old HIV-infected pregnant woman with 100% pill count adherence 
at study visit IDI-08) 
 
Another participant described a similar experience in which health workers encouraged her after 
she received her HIV test result by talking to her about others who are also infected:  
They told me that I should calm down and start taking drugs. I first got some fear and 
asked myself, “Up to when will I be taking this medicine?” A health worker told me, 
“You are not the only infected person; you are so many; others are coming.”…I calmed 
down and the health worker counseled me and gave me drugs. (30-year old HIV-infected 




The same participant went on to describe the effective way in which health workers were able to 
implement the test-and-treat approach associated with the Option B+ program requiring HIV-
infected pregnant women to initiate treatment on the day they were found to be HIV positive, as 
well as additional messaging that was often used to motivate the HIV-infected pregnant women to 
initiate treatment:  
The health workers helped me so much…so much…because I had refused and the 
counselor had already put on my file that I am not ready to start, but she kept on asking, 
“Are you sure?” I said, “Yes…” and she repeated it three times, “Aren’t you going to 
take medicine?” And I said, “No…” They later got another health worker who took me 
aside and started counselling me, “You have to take your medication because you will 
give birth to an HIV positive baby. Yet now it’s easy for you to take medication without 
anyone noticing. If you give birth to an HIV positive baby we shall give you medication 
for your baby and everyone will be able to tell that you are infected, yet if you had started 
taking, it would have saved the baby.” I then was able to start taking my medicine...At 
first I felt bad because it was as though they were forcing me, “Take the medication.” But 
later I realised that it was going to help me and my baby. I calmed down and accepted 
that they should give me the medicine and I started taking. I first felt bad and I wasn’t 
listening to anything they were saying. I later felt good because they were helping me and 
my baby. They were not benefiting anything; they do not know me, they do not know 
where I come from, they just wanted to save my life and the life of the child inside. (30-
year old HIV-infected pregnant woman with missing pill count adherence at study visit 
IDI-07) 
 
The excerpt above highlights the persistence of the health workers with respect to initiating 
treatment for HIV-infected pregnant women but also hints at the challenge that may arise if  HIV-
infected pregnant women feel forced into making a decision to initiate ART. In this case and in 
the case of many participants, the persistence exhibited by the health workers was viewed as a 
positive characteristic of the overall HIV test-and-treat experience that promoted ART initiation. 
The passage above also illustrates additional messaging put forth by the health workers attending 
to the HIV-infected pregnant women that participants described as convincing with respect to 
ART initiation. Most of the participants stated the desire to give birth to an HIV-negative baby as 
a strong motivator for initiating ART and throughout the ANC interviews, a number of 
participants expressed a desire to keep their HIV status hidden from others, feelings that were 
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taken into account by health workers when counseling their clients about the benefits of initiating 
ART for PMTCT right away.  
In contrast, another participant described a different counseling approach used by the 
health workers to ensure ART treatment initiation. Although the approach was different, it was 
clear that the goal of the counseling and the general message of ART adherence for the purpose 
of preventing vertical transmission remained the same. 
I was first given some time to cool down…later I was sent to another room where I also 
received counselling. But all those counselling sessions were pointing at one aim; having 
to take ARVs in case I want to give birth to an HIV negative baby. I was told that I have 
to take ARVs to help me stay healthy and protect my baby, and I accepted. (33-year old 
HIV-infected pregnant woman with missing pill count adherence at study visit, IDI-015) 
 
In the same interview, the participant talked about the positive effect counseling had on her clinic 
experience the day she tested positive for HIV. In this interview as in others, receiving immediate 
counseling and support from health workers was described as an effective strategy for initiating 
HIV-infected pregnant women on treatment and promoting ART adherence.  
I felt good and when I went back home I told them that I had met health workers who are 
so nice that I had never met before. If it were not for them I would have either refused to 
take medicine or did abortion. They counseled me that I can be able to give birth to an 
HIV negative baby if I take my ARVs well. It gave me courage to start taking ARVs and 
do what I had been told, which I accept and started doing it. (33-year old HIV-infected 
pregnant woman with missing pill count adherence at study visit, IDI-015) 
 
Reliance on health workers for support between clinic visits 
The large majority of participants described having good relationships with the health 
workers at the PMTCT and ANC clinics during their pregnancies and many identified the health 
workers as their primary source of support for their pregnancies or HIV status. The health 
workers often called participants between clinic visits and participants also felt comfortable to 
call the health workers. As one participant explained when asked about seeking support outside of 
the hospital:  
Apart from going back to the health workers, I do not go anywhere else. I usually call 
health workers and explain the problem I have and they advise me on what to do. At 
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whatever time you call them, because they gave me their telephone number. You can call 
and explain how you feel and she tells you what to do, asks you to go to the clinic if the 
situation does not change (30-year HIV-infected pregnant woman with missing pill count 
adherence at study visit, IDI-07).  
 
Maintaining contact by phone between clinic visits helped participants to feel close to the health 
workers and allowed them to view the health workers as more than health care providers. Many 
participants described forming meaningful relationships with the health workers that served as 
motivation for staying adherent to ART.  
They [the health workers] do call me…one thing that has made it easy is that some of the 
health workers became my friends. I felt that since a health worker has taken her time to 
call and counsel me, I should be strong and take my medication. (24-year old HIV-
infected pregnant woman with 100% pill count adherence at study visit, IDI-013) 
 
In one instance, a participant described how her husband worked together with the health worker 
between clinic visits to ensure the participant was adhering to ART. The health worker would 
maintain phone contact with the participant through her husband and work with him to support 
her with HIV treatment:  
Participant: And a nurse from this side who would also call my husband and remind him 
about the time we chose for ARVs. 
Interviewer: Your husband and the nurse?How did they do it? 
Respondent: The nurse would keep calling my husband on the time we agreed to be 
taking ARVs. She would remind him and then he also reminds me. 
Interviewer: And tell him what? 
Respondent: “It is time.” 
Interviewer: Even when it is at night? 
Respondent: Yes.  (18-year old with 96% pill count adherence, IDI-01) 
 
The relationships formed with the health workers also served as a great motivator for the 
participants in this study to return for their scheduled clinic visits. Most of the participants 
explained that they were motivated to return to the clinic on time to receive helpful health updates 
from the health workers and because they are treated very well by them during their clinic visits:  
I feel good when I am with them because they know my status and I also know my own 
status. When I am with them they do encourage me and they do not make me lose energy. 





Disclosure to an HIV-infected person  
 In this study, every participant had disclosed her HIV status to at least one person during 
pregnancy. Approximately half of the participants had disclosed to their male partners and half 
had disclosed to a friend or family member. While the nature of the relationship between each 
participant and the person to whom she disclosed her status varied by participant, the more 
productive disclosure experiences appeared to take place when the person to whom HIV status 
was being disclosed was also known by the participant to be infected with HIV or to have had 
first-hand experience with HIV. In one example, a participant who had not disclosed to her 
husband described her disclosure experience with a friend:  
How she got to know, one time I left home early, I had left my husband and yet he had the 
key and I asked her to help keep for me the drugs. That is when she got to know. I had 
nowhere to keep the medicine yet my husband was around and he had the key. I told her, 
“These drugs have been given to me in the hospital. Keep them for me until my husband 
opens.” That is how she came to know. I already knew that she was also infected and that 
is why I kept with her my medicine. If she wasn’t infected, I wouldn’t have kept it with 
her, but I knew that she was too infected. She got astonished and asked, “Are you also 
infected?” I told her, “I have been tested and found HIV positive.” And she told me, “Be 
strong and take your medication.” She used to comfort me and whenever medicine would 
treat me badly I would go to her and she said, “Be strong, all that will stop. Just be 
strong and take your medication.” 30-year old HIV-infected pregnant woman with 
missing pill count adherence at study visit, IDI-07) 
In another instance, a participant disclosed to her mother because she believed her mother would be 
able to assist with obtaining ART refills. HIV-infected pregnant women receiving the standard of 
care at Mulago National Referral Hospital were asked to bring a “treatment buddy,” usually a friend 
or partner, to support them with adherence to clinic visits and ART treatment. Like other participants, 
she felt the burden of keeping her HIV status a secret and chose to disclose to someone who 
understood what she was going through:  
I decided to tell my mother because I can fall sick or have no time to line up for medicine 
and my mother can help. I went there because it is not easy to know such a secret alone, 
and in case you don’t say it out to someone, then it can all the time be in your heart…she 
encouraged me to take medicine because my mother…my dad died of the same disease 
and my mother is also on the same treatment. (24-year old HIV-infected pregnant woman 




The participant said that her mother supported her ART adherence by calling every two days and 
asking, “How are you feeling? Do you take your medicine?” She also explained that even though 
she has many friends, the participant seeks support from her mother because, “She is the only 
person I can tell everything on my heart without leaving out anything.” In a different clinic 
experience, one participant described being paired with a fellow HIV-infected pregnant woman at 
the clinic on the day of her HIV test. While this was a unique situation described by only one 
participant, it emphasized the benefits of disclosing to a peer who is also infected with HIV and 
demonstrated the difficulties associated with trying to talk about being HIV positive with others 
who are not infected with HIV:  
It was clear that both of us were infected and there was nothing to hide…and it helped 
me because she was given her ARVs and I was given mine as well. We sat outside and 
discussed [our status]. And she told me, “I will come and pay you a visit” and I also told 
her that I would also want to see where she stays…I had been told to bring someone I 
knew but I feared telling any of my people. The only person who is like me that I would 
have told is not around, she is my sister and she is in the village. And yet we had been 
told that we have to choose someone who is nearby so that in case you are sick she can 
help to pick up your medicine if you are unable. If you failed to pick up the medicine she 
can pick it for you. Yes…even last week on Wednesday, we were both here. She stays in 
Mpererwe. I stay in Ndejje. She came from Mperewe and paid a visit. She is a great 
person!  
 
By the way to decide and tell someone [about your HIV status] is not easy. There are 
those who can frighten you and you lose focus. You can be having a conversation with 
people and if one says, “If you get infected with that HIV that would be the end of you.” 
And you try to cover it up and say, “Medication is available…” But they say, “No…you 
are at the point of death any time.” And you lose hope. You might have been at the point 
of disclosing but you decide not to (32-year old HIV-infected pregnant woman with 
96.4% pill count adherence at study visit, IDI-04) 
 
Variability of male partner involvement 
 The extent of male partner involvement in the health and HIV treatment of the 
participants varied from none to extensive and seemed linked to whether or not participants were 
aware of the HIV status of their partners, felt able to disclose their own status or were living 
together with their partners. Only six of the 16 participants were aware of their partners’ status 
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and the rest either did not know if their partners had been tested or had partners who refused HIV 
testing. Most of the participants who had not disclosed their HIV status to their partners were 
living separately and male partner involvement was non-existent or limited to providing money 
for food, transportation or general expenses. In the interview excerpt below, one participant 
described the lack of support she received from her husband in the first month since testing 
positive for HIV and initiating treatment and the circumstances surrounding this lack of 
involvement: 
When he is around and has not gone up country, I stay with him…my husband works but 
when you ask him to go to the clinic he becomes rude just like other men, so I decide to 
let that go. My father-in-law refused me to show him [not to disclose to him] and told me 
that in case he gets to know it he will completely refuse to go for testing, yet if we hide it 
from him he [father-in-law] can convince him to go for testing…he has never accepted to 
do so. My father-in-law told him, “Why don’t you want to go for testing?” But he 
completely refused…I do not tell him that I am coming for ARVs; I tell him I am going for 
antenatal services and he thinks I have come to give birth…I kept telling my husband to 
come with me to the hospital but he refused. He kept on saying. “You can go, it is not me 
who is going to push the baby…” Such things...“It is you who is carrying a baby.” I then 
asked him, “What should I do?” And he said, “You can go on your own and tell them I 
am not around.” (27-year old with 100% pill count adherence at study visit, IDI-09) 
 
The same participant also explained that she thought about separating from her husband but then 
decided to stay together because, “He is never around. When he goes for work he only comes 
back once a week or even not appearing at all and just sends money for home use.”  
In a different interview, a participant described how her husband provides no support or 
communication during the current pregnancy:  
I last saw my husband when this pregnancy was just a month. He left from where we used 
to stay and he told me that he was going to the village, but when I checked in the village 
he wasn’t there and his phone is also off. I do not know where he is and where he is staying. 
At this moment I am on my own, I am not with any man. I stay with my sister and that is 
where I come from to go for my medicine… I do not know where he is. We were together 
but then I do not know what happened, I hear rumors that he got another wife and even 
has a child with her. I do not know whether that was part of the reasons he decided to 
disappear. (33-year old HIV-infected pregnant woman with missing pill count adherence 
at study visit, IDI-015) 
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In contrast, HIV-infected pregnant women who did disclose to their male partners often found 
that their partners expressed a desire to help and exhibited more extensive involvement, even if 
the couple was found to be discordant:  
So I told him, “Eeehhh it didn’t go well today at the clinic. So they tested our blood but 
mine didn’t come out well…here is the result…”I gave him the result and then he was, 
“Eeehhh…this is an accident, something which already happened has happened…me I 
cannot refuse you…I cannot divorce you…this is my blood, I cannot refuse my child…so I 
will help you for the rest of my life.” He started giving me advice and counseling me but 
he also told me that next time we shall go together. Yes…that is when today we came 
together…we tested together and it was negative. (28-year old with 100% pill count 
adherence at study visit, IDI-05) 
 
The same participant also spoke about how her husband reminds her to take ART, despite testing 
negative for HIV:  
It was only one day when my husband asked, “Have you swallowed your medicine?” 
Then I also ask him, “What is the time?” And then he said, “It’s remaining four minutes 
to time…” Then I told him, “It is okay I am going to swallow.” From then up until now I 
don’t forget. (28-year old with 100% pill count adherence at study visit, IDI-05) 
 
In addition to receiving ART adherence support, HIV-infected pregnant women who disclosed to 
their partners were also able to find financial and emotional support from their male partners. As 
on participant described:  
He has helped me because when it reaches time for taking drugs, he reminds me, “Have 
you taken your medicine?” He keeps asking me…whenever it clocks time he says, “Go 
and take your drugs.” The second thing, he has encouraged me a lot. He tells me about 
real life situations like, “People have diabetes or cancers, but for our scenario, we have 
medicine to reduce it. So we can be sick but be able to stay alive for quite some 
time.”…He looks after me. He works and I do not work. He goes for work and provides 
everything at home. (27-year old with 100% pill count adherence at study visit, IDI-10)  
 
Modified behaviors to prioritize health and ART adherence  
 Often in the study, participants reported having to make adjustments to their behaviors 
and lifestyle choices to prioritize their health and ART adherence. For some participants, this 
meant discontinuing alcohol consumption. For instance: 
I used to take alcohol before I had been tested. Whenever I would get annoyed I would 
leave home and go take a bottle. One day I got annoyed and went to have one. I used to 
take one and I would not get drunk, but this time I got drunk. I asked myself, “Why has 
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this happened yet ever since I have never experienced this!” I got on my phone and 
called a health worker and she told me, “That is so wrong and never do it again.” I then 
got to know that I am not supposed to do that again. (24-year old HIV-infected pregnant 
woman with 100% pill count adherence at study visit at study visit, IDI-08) 
 
For other participants, modifying social behaviors was an essential change to ensure they 
remained healthy and adherent to ART. In some cases, this included changing the social 
environment. As one participant described: 
Because before, I used to go clubbing…But I never do that these days. I stopped doing 
that because whenever I take my medicine I have to go and rest. I also realised that in 
case I took it [ARVs] and go out to have fun it will still make me lose energy. But when I 
stay home and sleep I wake up without feeling any problem. I decided to stop doing that 
and I used to take alcohol but I eventually stopped. (24-year old HIV-infected pregnant 
woman with 100% pill count adherence at study visit, IDI-08) 
 
In other instances, participants described having to make sure to be home by a certain time to 
ensure being able to take ART. They also mentioned having to take into account balancing 
visitors in the home with taking ART and attending scheduled clinic visits.  As seen from the 
interview below:  
I automatically know that I have to take medicine…Unless I have left home and gone 
somewhere. But even so, I first get to know the time. I do not exceed 8pm before I set off 
for home because I do not move with ARVs…Or when you receive a visitor who is an 
adult and you can’t leave him/her around yet you have to return to the clinic.” (27-year 
old HIV-infected pregnant woman with 100% pill count adherence at study visit, IDI-
010) 
 
In every case of a participant reporting having missed a dose of ART, the circumstances 
surrounding the missed dose had to do with disruptions to the daily routine that had been 
established to prioritize ART adherence. In one example, a participant explained that she 
remembers to take her ART every day by setting an alarm on her cell phone. When the alarm did 
not go off, she forgot to take her ART. 
On Friday, I was sick and slept early…the children had played with my phone…and the 
alarm set off…only to wake up at 3am. And I forgot to take it. I woke up in a shock 
because I had never done it before. I was in fear but I had nothing to do. I resumed the 
following day. (28-year old HIV-infected pregnant woman with 95% pill count adherence 




On a different occasion, one participant described missing an ART dose because she had decided 
to spend the night outside the home with her sister to be in closer proximity to the clinic.  
I had spent a night somewhere else and I had forgotten the medicine at home. The 
following day I was supposed to come back to the clinic but the tablets I had carried were 
missing that tablet and I told the health worker…Anyway I feared and I really wanted to 
swallow it but time had passed, I had nothing to do. And when I came today I asked the 
health worker and she said…Actually she asked, “Why is it that this tablet remained?” 
And I explained it to her. She said, “Okay that is fine but the reasons why women take 
medicine is because of this and that…”  She told me all the reasons and I told her, “I 
encourage myself [to take the medicine] but it only happened once by mistake.” I thought 
I had packed it but when I reached where I had gone I realised I had left behind one 
tablet. (27-year old HIV-infected pregnant woman with 100% pill count adherence at 
study visit, IDI-09) 
 
For many participants, being HIV infected during pregnancy had a significant effect on 
their work. Of the nine participants who worked to generate income, four described having to 
stop working during this pregnancy and those who continued to work described challenges 
integrating their work schedules with their ART schedules. As one participant described, fatigue 
was the most common reason for stopping work:  
Health worker, I do not have much work to do…What might have been much work is that 
I used to walk to work but now I do not work. I do not walk to work these days. I closed 
the business because I do not have energy to walk to work and then walk home…When it 
reached a time and I couldn’t do it anymore I decided to rest until I give birth and then 
resume work…it has affected me because yesterday I saw the landlord yet I haven’t 
worked this month. (27-year old HIV-infected pregnant woman, 100% pill count 
adherence at study visit, IDI-09) 
 
However, in some cases the emotional impact an HIV-positive diagnosis also caused participants 
to stop working. One participant explained why after receiving her diagnosis, she initially stopped 
working: 
Everyone I would come across, I would think that probably he/she knows my status. I 
would feel ashamed and spent days without working. But later I got used to it and went 
back to my work…I spent like four days without working…I would stay home thinking 
that maybe everyone knows about me. But then I had to go back to work and start again. 





The same participant also described difficulties incorporating her ART schedule into her routine 
once deciding to go back to work. This experience was mostly due to the rigidity of the ART 
schedule and the participant wishing to follow instructions about taking ART at the same time 
every night. In the example below, the participant prepared and sold tea from a taxi park. She 
described needing to re-evaluate when she takes her ART every night because of excessive traffic 
on the way home from work.  
Sometimes I find a lot of jam along the way back home and find myself that it clocks 9:55 
PM and I have yet to cross a road, yet cars are at high speed…I leave work at exactly 
9PM. I travel for one hour but sometimes I meet a lot of jam. If there is no jam it can take 
me about 25 to 30 minutes. I move with it [drugs] but sometimes I fear swallowing it from 
the taxi where people are seeing me. Sometimes I use a lot of money to use a boda boda 
to be able to make it on time at home without taking a taxi because of the jam…But ever 
since health workers emphasized that when I chose 10 PM it has to be that, and in case I 
take it an hour later I give it [HIV] an opportunity of multiplying, I try my best and I feel 
I should change that time. I can take it at 8PM because I can excuse myself and run to my 
small office, take it and come back to continue with my work. It will help to reduce the 
tension whether jam is there or not. (24-year old HIV-infected pregnant woman with 
100% pill count adherence at study visit, IDI-08) 
 
Concern with inadvertent HIV status disclosure 
While practically every participant reported that being told they are just one of many 
infected with HIV or knowing others who are HIV-positive but otherwise healthy as motivating 
factors for ART adherence and clinic visit attendance, they also consistently brought up concerns 
surrounding having their HIV status exposed to others. This concern revealed itself in a number 
of situations. For example, one participant talked about traveling the long distance from her home 
in Entebbe to Mulago National Referral Hospital because she did not want to encounter anyone 
she knows at her community clinic. 
Participant: The area is bad. You might go and find someone who knows you very well 
and she informs everyone. But this side [clinic], when you come, sometimes you do not 
find anyone who knows you. You just get your medicine and go home…It would be of 
importance to collect ARVs from a place where you are not known. It is like say in 
Lweza, whoever goes there you hear people saying, “Here she comes, she is already HIV 
infected, she is also entering…she has come, she is HIV infected…”  
Interviewer: So, you advising that HIV infected people should go to… 
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Participant: To general clinics where you are not known [offer holistic care] as opposed 
to HIV-specific clinics.  
Interviewer: Like the way you are doing it whereby you stay in Entebbe and then come to 
Mulago… 
Participant: Hhhmm [Yes] because they don’t know who I am. But if I receive ARVs from 
my area they will say, “Eeehhh…Even XXXXX [name withheld] was found going to 
TASO. She goes to TASO to pick ARVs.” (32-year old HIV infected pregnant woman with 
96.4%  pill count adherence at clinic visit, IDI-04) 
 
A different participant talked about a similar concern regarding having to involuntarily disclose 
her HIV status at the clinic. She was worried that when she returned to the clinic after giving 
birth, she would be asked to reveal that she is HIV positive to strangers before receiving care.  
But the problem we have encountered, if you are not pregnant you might face many 
challenges because at the entrance you can’t keep telling everyone, “I have come for 
ARVs.” Those who are pregnant just move straight inside but when you are not pregnant, 
what will we do! They request some documents to look at before you enter, they need to 
know why you have come…Do they want us to disclose our status that we have come for 
ARVs? I do not know what we shall do for that. That is what they do at the Kampala City 
Council Authority [KCCA] clinics. (27 year old HIV-infected pregnant woman with 
100%  pill count adherence at study visit, IDI-010) 
 
In addition to having implications for where and when participants seek health care and 
treatment, fearing HIV status exposure also affected the relationships of participants with their 
friends and family. As one participant explained, she isolated herself from friends and family so 
that she could take her ART without having her HIV status discovered:   
I have a big challenge about that because my people do not know that I am HIV positive 
and I do not visit them. Even back home; I do not go there because I fear to be seen. My 
dad and mum are old now but I have never seen any drug [ARVs] at home, not even my 
brothers or sisters…I do not even want visitors at home; I want to be free at my home 
swallowing my medicine without worries. (24 year old, HIV-infected participant with 
100%  pill count adherence at study visit, IDI-08) 
 
A desire for a healthy baby and a healthy life 
 
 The predominant motivation for initiating ART and adhering to the Option B+ treatment 
program was ensuring the health and HIV-negative status of the unborn child. Every participant 
expressed this desire above all else. In addition to delivering a healthy baby, the majority of 
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participants were also driven to adhere to ART and attend their scheduled clinic visits to continue 
living a healthy life. As one participant responded:  
What encourages me? Trying to protect my baby inside the womb. And to keep my life 
moving on [well]. To have a longer life…To have a longer joyous life without having any 
worries. (20-year old HIV-infected pregnant woman with 95% pill count adherence at 
study visit, IDI-03) 
 
Even when the participants felt fear or stress about initiating treatment and adhering for life, a 
desire to stay healthy and to protect the baby overcame these feelings. For example, when one 
participant reflected on initiating ART, she explained:  
I thought it was going to be harmful to me but…When they give me advice…what what…I 
just feel, “I am okay…” and I am getting the ARV…I am swallowing the ARVs to protect 
me and my baby…Yes…I want my baby to come out when…the baby is negative. (25-year 
old HIV-infected pregnant woman with 100% pill count adherence at study visit, IDI-05) 
 
In a different interview, one participant also explained that she is motivated to continue taking 
ART so her unborn child will not have to go through the same process of always taking medicine 
and going to the hospital:  
So what encouraged me was because I want to have an HIV negative baby. I wasn’t 
ready to keep going to hospitals because of my child and since I didn’t like medicine I 
also didn’t wish it for my baby. That in a way encouraged me to sacrifice and take 
medicine to give birth to an HIV negative baby. (27-year old HIV-infected pregnant 
woman with 100% adherence at study visit, IDI-010)  
 
Other factors affecting Option B+ experiences during pregnancy  
 Additional factors identified by only a few participants as influencing their PMTCT 
experiences were specific to the Option B+ program logistics and treatment schedule. For 
example, one participant who had attended health talks prior to Option B+ expressed a desire for 
this previous PMTCT program when ART was not necessarily initiated immediately upon testing 
positive during pregnancy and was not required to be taken for life. It is unclear from the 
interview if this participant was referring specifically to the old WHO recommendation calling 
only for single-dose nevirapine to be administered at the onset of labor, or if she is speaking about 
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some other approach. Nevertheless, it is clear that that the concept of initiating ART immediately 
during pregnancy and continuing therapy for life was not the option of choice for this participant.  
I was told that I have to take that medicine [ARVs] for the rest of my life when I start it, 
without missing any day, and it should be at the same time…Some time back they taught 
us that you are given a tablet which you will swallow at the onset of labour before 24 
hours elapse. I wish it was maintained like that…during health talks, they used to tell us 
that if you are found to be HIV positive, you are given a tablet and you keep it and then 
take it at labour. If 24 hours elapse before giving birth, you are then given another tablet. 
However, you do not start right away from the day you are found to be HIV positive. (20-
year old HIV-infected pregnant woman with 100% pill count adherence at study visit, 
IDI-012) 
 
A different participant also expressed surprise about the Option B+ treatment schedule being for 
life. In this case the participant expected to be following the Option A approach previously 
implemented in Uganda that differentiated HIV-infected pregnant by CD4 count to decide if they 
qualified to receive treatment for their own health or prophylaxis for PMTCT.  
The other thing we were told was that I am going to be on treatment forever, yet I thought 
in case I gain some energy I stop for a while…You know some time back we used to hear 
rumours that when one gains energy she is asked to rest medications for some time and 
then resume when the CD4 count falls down. However, we were told that we shall stay on 
medication forever, which is something that is different from what I expected…(27-year 
old HIV-infected pregnant woman with 100% pill count adherence at study visit, IDI-
010) 
 
The same participant was uneasy about taking ART every day for the rest of her life due to the 
risk of unknown long-term side effects that may develop over time.  The participant explained 
that she would prefer a different treatment schedule that only required taking a pill once a week 
or once a month.  
What I wish to change is that issue of taking medicine every day...If they can come up 
with another type which you can take once in a month…Yes…where you take it once in a 
week or a month…Because taking every day…and within me I feel medicine is a chemical 
substance…As time goes on, the chemical is not good in your blood. I feel it has some 
effect apart from curing…you know everything has a side effect…Apart from eliminating 
viruses I feel it must be having side effects…Maybe within the liver, within me and maybe 
reach a time and it causes abnormality…I sometimes think about it…Those long term 
effects…That when you take ARVs for a long time what do you get…Do you stay 
normal…You know…I don’t know those long term effects. (27-year old HIV-infected 




Option B+ at six weeks postpartum 
Clinic visit attendance, maternal ART adherence and adherence to infant prophylaxis 
remained high from the time of labor and delivery through six week postpartum and all HIV-
exposed infants in the study received an HIV test at this study visit. Nevertheless, a variety of 
factors had an impact on the Option B+ program experience of the participants. These factors 
could be grouped into six themes: 1) consistent ongoing support from health workers; 2) health 
facility constraints; 3) continued support after disclosure; 4) variability of male partner 
involvement; 5) normalization of daily ART and 6) a continued desire for a healthy baby and a 
healthy life. During the course of the study, the location of some health services, including 
obstetrics and gynecology, were transferred from Mulago National Referral Hospital to Kawempe 
General Referral Hospital to allow for renovations at the Mulago site. This change in location 
also factored into the experiences of participants as described in the first two sections below. 
 
Consistent support from health workers 
 Each of the eight participants interviewed at six weeks postpartum described reliable 
health worker involvement in PMTCT from the time of labor and delivery. One participant 
described her satisfaction with the health workers during labor and delivery: 
Participant: They treated me well since I was unconscious, but they made sure my baby 
does not get infected with HIV…they cleaned me so fast so that the blood does not mix 
with the baby. I got so happy and I learned a lesson 
Interviewer: What lesson did you learn? 
Participant: Helping others.   
 
The health worker support from labor and delivery through six weeks postpartum was also found 
to be consistent with respect to ART adherence, clinic visit attendance and infant prophylaxis. In 
the same interview, the participant talked about the support provided to her by the health workers 
in the last six weeks since her baby was born and the way it made her feel: 
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The relationship I have with health workers; they have handled me like a person. A 
person, not like a child. Which has made me not go to that level of saying, “Why did I get 
infected to this virus?”… They have helped me not get worried and taking my medication 
at the right time.  
 
She also mentioned that when health workers visited her at home, “they encourage me which 
gives me more energy that they care about me and my life” (28-year old HIV-infected 
breastfeeding mother with missing pill count adherence at the six-week postpartum study visit, 
IDI-02).  In addition to providing support at the clinic, health workers continued to maintain 
regular phone contact with participants after labor and delivery. The phone calls included 
reminders of upcoming clinic appointments to pick up drugs as well as advice and answers to 
questions. It was also clear that in addition to making phone calls, health workers were receptive 
to receiving calls from HIV-infected mothers between clinic visits. As one participant described:  
Health workers do remind me the days for my clinic visit and it makes me feel so good 
because you never know, I might forget. It encourages me when they remind me to come 
and pick it and also take it at the right time…I call health workers and explain to them 
what I am going through and what my child is experiencing and they tell me what to do 
or take her here and there…health workers help me that whenever I call them they 
handle me well. Sometimes they actually call and inquire about my health. That also 
encourages me and I do not feel like an infected person. (24-year old HIV-infected 
breastfeeding mother with missing pill count adherence at the six-week postpartum study 
visit, IDI-08) 
 
In one instance, a participant arrived at the Mulago clinic site and found it closed. The participant 
explained how the health workers continued to be helpful, even in this unique case. She also 
echoed the feelings of the other interviewees with respect to the role of the health worker and the 
relationship between health workers and HIV-infected women in the early postpartum period.  
When I reached where we used to have antenatal clinic the place was all closed and some 
roads are closed. Health workers picked me and came with me to the right place. It made 
me feel great knowing that health workers are helping me and think about me… 
 
…They help me by providing medicine to me and deciding to counsel me to take my 
medication so that I will live longer. They make it easy whenever I come here to get hope 
that I will live longer and see my baby grow. The relationship is not bad at all, it is not 
bad. They care so much and they even call reminding us to come for medication. They 
give you a call and even go to the extent of picking you in case you are lost. They make 
me feel happy and that my life in future will go on. (32-year old HIV-infected 
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breastfeeding woman with missing pill count adherence at the six-week postpartum study 
visit, IDI-04) 
 
Health facility constraints  
 Although participants exhibited good adherence to ART and infant prophylaxis and 
regular clinic visit attendance in the early postpartum period, a majority of the interviews at the 
six-week postpartum study visit noted some unanticipated barriers to a satisfactory clinic 
experience at this time point. First, practically every participant expected to receive the infant 
HIV test results on the same day as the test was administered. As one participant explained: 
What I expected, I thought you get the results there and then but that never happened, 
they just took off the sample. So, I am waiting for the results so I don’t know whether my 
baby is infected or not. (27-year old HIV-infected breastfeeding woman with 100% pill 
count adherence at the six-week postpartum study visit, IDI-09) 
 
While this participant was able to remain patient for the results, in some instances participants 
described stress and anxiety associated with having to wait to receive the infant test results.  
I felt bad health worker, because when they were getting off blood from him yesterday 
they went on to tell me that results are not received immediately. I thought I was going to 
go back with the results…not receiving the test results on the same day…it keeps you 
worried every day. (28-year old HIV-infected breastfeeding woman with missing pill 
count adherence at the six-week postpartum study visit, IDI-02) 
 
Next, many of the HIV-infected mothers interviewed found long waiting times and overcrowding 
at the six-week postpartum visit. As one participant described:  
Participant: We are always many patients. You have to first wait [be patient] for the one 
who came first to be served first. Because the working space is small yet the patients are 
many.  
Interviewer: Which working space are you talking about?  
Participant: The side where we shifted…Where Mulago shifted…In Kawempe [Mulago 
Women Hospital for Obstetrics and Gynecology in Kawempe]. 
Interviewer: The working space is small? How do you find it? When you say that it is 
small, what do you mean? 
Participant: We have to first wait for those inside…we move step by step. You first see 
the doctor for the baby and then move to another place for medicine…Yes we spend a lot 
of time…It depends on the number of patients you have found there. They have to first 
counsel everyone. It can take about one hour or about 40 minutes. (22-year old HIV-
infected breastfeeding woman with 100% pill count adherence at the six-week 




In addition to feeling crowded, participants also believed that it took longer to get to Kawempe 
and were concerned about the quality of care they received due to unfamiliarity with the clinic 
staff at this site.  
There is a lot of jam in Kawempe, the journey is far, and you might get there and find 
other health workers who you don’t know and you do not get the help you thought you 
would get. (32-year old HIV-infected breastfeeding woman with missing pill count 
adherence at the six-week postpartum study visit, IDI-04) 
 
In one example, a participant described feeling uncomfortable sharing a health concern with a 
new doctor who was unfamiliar. In this case, the participant was not able to see her regular doctor 
because the PMTCT team she was expecting were all in a meeting on the day of her clinic visit.  
For the skin rash, I went to Kawempe Hospital and told a health worker because here, 
like I told you, it was a new doctor and I wasn’t open to tell her a lot about it. I just 
talked about it just a little and she also didn’t give me a solution. She just said, “It will 
clear…”(27-year old HIV-infected breastfeeding woman with 100% pill count adherence 
at the six-week postpartum study visit, IDI-09) 
 
Although the circumstance was unique to this participant, it emphasized the impact that a lack of 
trust can have on the relationship between the patient and the health worker, as well as the 
importance placed on establishing long-lasting relationships with health workers by the HIV-
infected mothers receiving care. 
 
Ongoing support after disclosure  
 All participants interviewed at six weeks postpartum described receiving continued 
support from the people to whom they had disclosed their HIV status during pregnancy. The most 
common forms of support received included encouragement of ART and infant prophylaxis 
adherence, having someone to talk to about being HIV positive and gaining courage from the 
experiences of others. In one interview, the participant had disclosed to a close female friend who 
had an HIV-infected mother and was therefore familiar with the infection and the importance of 
adhering to treatment. The friend had been disclosed to while the participant was still pregnant, 
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and provided adherence support as well as encouragement from pregnancy through six weeks 
postpartum. In the follow passage, the participant talked about this disclosure experience:  
She calls me over the phone and sometimes she comes home and we talk about it, she 
advises me and tells me that I have to take it, and gives me examples of different people 
and I a way I get contented [relieved]…I think she checked my stuff because she sent me 
a message saying, “I want you to tell me the truth…feel free with me, do not hide 
anything away from me…” And I told her, “That is fine, I will come and tell you the 
truth.” I then later told her and we sat and discussed about it and she told me, “You 
always have to take your ARVs on time and you have to go to the clinic as 
requested.”…She gave me advice and gave me some examples of people…Like her 
mother who is also infected. She is still alive and she looks so well to the extent that you 
can’t tell what she is…Yes it gave me confidence. (22-year old HIV-infected 
breastfeeding woman with 100% pill count adherence at the 6-week postpartum study 
visit, IDI-06) 
 
This experience also tied into earlier themes affecting the Option B+ program experience during 
pregnancy. In pregnancy, significant support was received from disclosing to someone who was 
also HIV-infected and participants gained strength from learning about others who were HIV-
infected but appeared healthy. In this case, significant support was received from an HIV-
negative friend who had first-hand experience with the infection through her mother. Similarly, 
learning about someone who was HIV-infected but able to remain healthy by adhering to ART 
treatment continued to serve as a source of inspiration for the participant in this case. A different 
participant who had also disclosed to a close female friend during pregnancy described a similar 
experience with receiving continued support in the early postpartum period:  
She is a very good friend of mine, I told her about the results that had come out of the 
testing. Sometimes she sends me a message to remind me about the time of taking 
medicine. She is the only person who knows [about my status]…She felt so bad and she 
kept on encouraging me, she has done a lot to encourage me. (24-year old HIV-infected 
breastfeeding woman with missing pill count adherence at six-week postpartum study 
visit, IDI-08) 
 
The majority of participants revealed that at six weeks postpartum they had not disclosed 
to any new individuals since choosing to disclose during pregnancy. The reasoning behind this 
warrants further exploration but may be due to participants feeling they did not need to take the 
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unnecessary risk of disclosing to someone who may react poorly when ample support was being 
consistently received by participants from the individuals to whom they had disclosed their HIV 
status during pregnancy. As one participant who had disclosed to her husband and sister during 
pregnancy responded when asked why she had not disclosed to anyone new since giving birth, 
“Now I cannot go telling all people that I am positive.” (28-year old HIV-infected breastfeeding 
mother with 98% pill count adherence at six-week postpartum study visit, IDI-05)  
 In the time between interviews, one participant did newly disclose to her husband, 
however the disclosure still happened during pregnancy and not in the postpartum period. In this 
case as in many of the others in this study, the husband continued to provide financial and 
emotional support throughout the pregnancy and the early postpartum period, even when his HIV 
test results came back negative. Despite the participant thinking the couple should separate 
because of their HIV discordance, her husband would not leave and continued to provide 
encouragement.  
He gave me support…he never left me alone…on that day, he came on the day we were 
discharged and he was also tested but he was negative. I told him “Let us separate” and 
he said “It’s not possible XXXX, The time we have spent with you we cannot separate. 
We shall ask health workers to direct us on what to do but we cannot separate after this 
long.” (32-year old HIV-infected breastfeeding woman with missing pill count adherence 
at six-week postpartum study visit, IDI-04) 
 
Variability in male partner involvement  
 The variability in male partner involvement with the health of the participants and their 
new infants continued through six weeks postpartum. On one side of the spectrum, one male 
partner provided extensive adherence support and attended clinic visits with the participant. In 
this case, the couple was married and the husband had been tested for HIV in the antenatal period 
and was found to be uninfected. 
I don’t see any problem with him [husband], he still cares the way he used to…sometimes 
he comes back home to see if I have taken my medication. Sometimes he reminds me to 
give the baby…hhhmmm…he can remind you, “Have you taken your medicine? Have you 
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given the baby syrup? He comes back and reminds me…even when he is driving [taxi 
driver] he will park the car and come to remind me and see if you took your 
medication…It felt good because he accepted to escort me to have the baby tested so that 
we come to know the truth whether he is sick or not, as opposed to having a baby whom 
we are not sure whether is infected or not. (18-year old, HIV-infected breastfeeding 
woman with missing pill count adherence at six-week postpartum study visit, IDI-01) 
    
On the other side of the spectrum, one participant reported receiving no financial or emotional 
support from her male partner at the time of the six-week postpartum study visit. In this case, the 
participant had not disclosed her HIV status to her partner and they were not living together. The 
participant chose not to disclose to her husband because she was worried he would think she had 
infected him, despite not knowing whether or not he was currently infected with HIV. 
He sends money though right now we have some misunderstandings…there are some 
people who I do not know who went and told him that the baby I have is not his. He got 
angry and does not come home anymore…of course he is not sending any help but before 
that, he would send money. (20 year-old HIV-infected breastfeeding woman with 100% 
pill count adherence at six-week postpartum study visit, IDI-03).  
A different participant described mixed levels of support with respect to the involvement of her 
male partner with her HIV care and the health of their baby. In this situation, the husband 
provided financial and adherence support to both the participant and the baby but continued to 
refuse initiating ART for his own HIV infection. In the excerpt below, the participant described 
her struggle with her husband’s disregard for his own health:  
Actually what is making me get so worried is that he knows I am HIV positive and he is 
HIV positive as well but he does not want to come and start taking drugs…I am not sure 
whether he is taking hiding…I do not know…Though I feel he is not taking because I 
would tell. But however much I tell him, he doesn’t allow…Yes, he looks after me and in 
most cases he provides everything I request for, be it food or anything…It is my husband 
who helps me...One day he saw that I was not giving the baby syrup and he asked me and 
I told him that it had got finished and that is why he told me that, “You were told to go 
back on the 13th...” I feel good but at the same time feel bad because inside that bag, 
there are documents and medicine; he is aware that I take them and they are for HIV but 
still he refused to take medication…so I feel bad about that…I actually told him today 
that remember I asked you last time that when I am taking back the baby to the hospital 
we must go together, but he pretended that someone had called him which proved to me 
that he is just dodging. I thought about it but left it at that...I told him that, “Are you 
waiting to be bedridden to start taking ARVs? Sometimes it might even fail to work.” He 
appeared as though he had understood and he said, “The day you go back to the hospital 
we shall go together.” But whenever it gets to that day he refuses. (28-year old HIV-
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infected breastfeeding woman with missing pill count adherence at six-week postpartum 
study visit, IDI-02) 
 
Participants with male partners who were supportive and exhibited involvement in 
PMTCT care and treatment during pregnancy continued to show high levels of support and 
involvement in the early postpartum period. Interestingly, an improvement in male partner 
support after labor and delivery was noted by most of the participants who described their 
partners to be uninvolved during pregnancy. In the example below, the participant was single and 
had yet to disclose her HIV status to her male partner. During her pregnancy the participant 
described receiving no support from the father of her baby. In contrast, since the baby was born 
the participant received financial support for herself and the baby:  
He now gives me support for the baby. He never used to care when I was still pregnant, 
but after giving birth he started caring about me…He gives me money for food and rent. 
He also provides money for treatment in case the baby is sick. (22-year old HIV-infected 
breastfeeding woman with 100% pill count adherence at six-week postpartum study visit, 
IDI-06) 
 
In a different interview, one participant talked about how her husband who was unaware of her 
HIV status and refused HIV testing for himself had been making an effort to control his alcohol 
consumption since the baby was born. When the participant was still pregnant, her husband 
would spend all his money on alcohol while they were apart. Now that they have a first born child 
together, his behavior has improved:  
When I am not around he does not save anything. In case I am not around he earns 
200,000, he will go in a bar and drink it all. When you call him about his baby or that 
just says, “I do not have money.”…Ever since I gave birth he has a lot of love for me 
[laughs]. He also loves his child very much, his thoughts are all taken up by her. That is 
our first born. Yes…So, the baby has taken most of his thoughts. From work he comes 
straight home and he stopped taking alcohol…So from work he bathes and spends most 
of his time with the baby. So when he comes home he first refreshes himself to carry the 
baby. So, in case you want something you can go through the baby. (27-year old HIV-
infected breastfeeding woman with 100% pill count adherence at six-week postpartum 
study visit, IDI-09) 
 
Normalization of daily ART 
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 It was seen in the ANC interviews that feelings of shock and fear often accompanied 
receipt of positive HIV test results and the immediate initiation of ART for PMTCT under the 
Option B+ program. Similarly, many changes were made to daily routines and behaviors to 
accommodate ART adherence during pregnancy. Nevertheless, over time the daily ART routine 
became normalized and less concerted effort was need to remember to take ART and attend clinic 
visits. As one participant described:  
At first I was just fearing, “Eeehhh will I really continue with this life, with this medicine 
for life?”…I was just expecting whether I would continue with it but now I am used to it 
and I know I will finish. I will continue. That thing is just normal now in my brain 
because I have to swallow it every day…it is within my mind. (28-year old HIV-infected 
breastfeeding woman with 98% pill count adherence at six-week postpartum study visit, 
IDI-05).  
 
Similarly, a different participant talked about being able to easily remember her ART every night 
and having less reliance on health workers for clinic visit reminders.  
Even when I am doing something, I first put it aside and take my medication; I know the 
date but health workers also try their best to call and remind you to come for help. (18-
year old HIV-infected breastfeeding woman with missing pill count adherence at six-
week postpartum study visit, IDI-01) 
 
This normalization could have been due in part to subsiding ART side effects over time. During 
pregnancy, the majority of participants described experiencing some degree of dizziness, nausea, 
exhaustion or hallucinations in the first month on ART. All but one participant interviewed at six 
weeks postpartum noted that these side effects had significantly subsided or completely stopped 
over time, and many described themselves as feeling as healthy as they had felt before becoming 
infected with HIV.  
I feel so so so good…I actually feel as though I am not infected with HIV. But still I take 
my ARVs. Whenever it clocks the time, I take it…But I feel the same way I was before I 
got infected with it. I do not have any problems with it. (24-year old HIV-infected 
breastfeeding woman with missing pill count adherence at six-week postpartum study 
visit, IDI-08) 
 
Continued desire for a healthy baby and a healthy life 
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 In spite of discrepancies in clinic visit experiences and male partner involvement, the 
desire for a healthy baby and a healthy life continued to be a driving force behind clinic visit 
attendance, maternal ART adherence and infant prophylaxis adherence throughout the early 
postpartum period for all participants. As one participant described, keeping clinic visit 
appointments was the only way to receive the ART and infant prophylaxis necessary to stay alive 
and keep the baby healthy:  
I come to get medicine and medicine for my baby as well as immunization. To help him 
feel better…That he might not go through what I am going through. (18-year old HIV-
infected breastfeeding woman with missing pill count adherence at six-week postpartum 
study visit, IDI-01) 
 
The same participant also explained that she is motivated to take her ART to stay alive for as long 
as it takes to find a cure for HIV. She also felt that her baby was actually healthier than other HIV 
unexposed infants:  
Participant: I hope that if I continue taking it, I might live to see the cure, but in case you 
do not take it you might not be around when a cure is discovered… 
Interviewer: And ever since you gave birth to your baby, what motivates you to take your 
medicine? 
Participant: Seeing my baby not falling sick so often yet babies for those who are not 
infected keep falling sick. (18-year old HIV-infected breastfeeding woman with missing 
pill count adherence at six-week postpartum study visit, IDI-01) 
 
A different participant also described the sentiments that came through in every interview with 
respect to ART adherence in the first six weeks postpartum:  
I feel so good and I have no problem. I take it at the right time to be able to get 
encouraging results the next time they take off blood from me…And my child is not in bad 
shape, she looks so healthy. Those made me choose to take my ARVs so that I do not 
infect her. (24-year old HIV-infected breastfeeding woman with missing pill count 




 This study aimed to explore the factors affecting the PMTCT adherence and program 
experiences of HIV-infected women under the Option B+ recommendation and how these factors 
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and experiences may change from pregnancy to six weeks postpartum through longitudinal in-
depth interviews with HIV-infected pregnant women receiving the standard of care at Mulago 
National Referral Hospital. ART adherence and clinic visit attendance were consistently high 
throughout the study for all participants. In the antenatal period, seven key themes related to the 
Option B+ experiences of HIV-infected pregnant women were identified: 1) effective messaging 
and counseling at the time of HIV testing and treatment initiation; 2) reliance on health workers 
for support between clinic visits; 3) disclosure to an HIV-infected person; 4) variability of male 
partner involvement; 5) modified behaviors to prioritize health and ART adherence; 6) concern 
with inadvertent HIV status disclosure and 7) a desire for a healthy baby and a healthy life. At six 
weeks postpartum, six additional themes representing the changes and consistencies experienced 
by HIV-infected mothers from pregnancy through the early postpartum period were also 
identified: 1) consistent support from health workers; 2) health facility challenges; 3) ongoing 
support after disclosure; 4) variability of male partner involvement; 5) normalization of daily 
ART and 6) a continued desire for a healthy baby and a healthy life.   
 The reliable health worker support received by HIV-infected women from HIV testing 
and ART initiation through labor, delivery and the early postpartum period definitively impacted 
the PMTCT experiences of all participants and positively affected ART initiation,  adherence and 
clinic visit attendance. In addition to providing support during clinic visits, the health workers 
also often served as a primary source of support between clinic visits in this study. This finding is 
in line with previous qualitative research that identified same-day initiation of treatment, health 
care providers being unconvinced of the benefits of Option B+ and insufficient health care 
provider training as barriers to the provision of Option B+.8 The findings of this study illustrate 
the value of well-trained and passionate PMTCT health workers and the need for continued 
training and support of health workers to effectively implement the Option B+ program.  
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 Some barriers to successful Option B+ program implementation at the facility level in the 
early postpartum period were identified by participants in this study. These barriers were 
primarily due to the shift in services from the Mulago National Referral Hospital location to  
Kawempe General Referral Hospital in the middle of the study, and included longer waiting times 
to receive treatment and services, overcrowding and unfamiliar clinic staff. A systematic 
literature review assessing the barriers and facilitators to uptake of ART for PMTCT in sub-
Saharan Africa also identified high patient volume and long wait times resulting from a shortage 
of trained clinic staff as a health systems barrier to the acceptance of ART.12 Although this study 
finding was due mostly to a specific disruptive event, it still demonstrates the potential impact of 
health systems barriers on long-term Option B+ adherence and program retention. At the six-
week postpartum study visit, many of the participants expected to receive the infant HIV test 
results on the same day and were surprised to learn that it would take weeks to obtain results. 
Indeed, a recent report outlining the impact of Option B+ on the infant PMTCT cascade in 
Malawi found that in comparison to the PMTCT program prior to Option B+ implementation, no 
change was found with respect to the median time for delivery of infant HIV test results to 
caregivers.13 This study indicates that communication at the health facility about the time it takes 
to receive infant HIV test results could be improved to ensure that expectations about the 
turnaround time for infant HIV test results are made clear to mothers prior to the date of testing. 
 HIV status was successfully disclosed to at least one person during the antenatal period 
by the majority of participants in the study. Often times the person to whom HIV status was 
disclosed was also known to be HIV-infected or known to have experience supporting other HIV-
infected people and provided the participant with adherence and emotional support. Moreover, 
very few new disclosure events occurred for participants in the early postpartum period. These 
findings may serve to justify the utilization of either clinic-based peer support models such as 
Mothers2Mothers in South Africa14 or community-based peer support models such as one in 
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Malawi training “expert mothers” experienced in PMTCT to provide education and psychosocial 
support to other HIV-infected pregnant women and mothers in the community.15 On the other 
hand, most of the participants in this study were able to disclose to someone in their natural social 
network such as a husband, friend or family member, indicating that a targeted approach should 
be utilized for peer-based support models to ensure that the HIV-infected pregnant women and 
mothers receiving the intervention are truly those with an unmet need for HIV status disclosure 
and support.  
 In this study, the degree of male partner involvement in the HIV care and treatment of the 
participants varied greatly by participant. In some cases male partners were willing to be tested 
for HIV and provided continuous support to the mother and child through the early postpartum 
period, independent of their own serostatus. In other cases, participants received little to no 
support from their male partners throughout pregnancy and through six weeks postpartum. In a 
few cases, male partner involvement improved over time with the birth of the child, but support 
was purely financial in nature. In this study, lack of male partner involvement seemed to have 
little effect on the ability of participants to maintain good ART adherence, administer infant 
prophylaxis and attend clinic visits due mostly to support received from other individuals such as 
friends, family members or health workers. While some studies, such as a systematic review of 
interventions to improve PMTCT outcomes, have found that male partner involvement is 
associated with reductions in infant HIV transmission,16 the degree to which male partners affect 
PMTCT outcomes warrants further qualitative and quantitative exploration.  
 Although most of the participants described having to modify their routine behaviors to 
accommodate ART adherence during pregnancy, many reported a normalization of this process 
over time, resulting in favorable adherence and clinic visit attendance experiences that were 
maintained through the early postpartum period. This is an interesting finding since existing 
literature suggests PMTCT ART adherence and program retention decrease over time. For 
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example, a meta-analysis of adherence to ART during and after pregnancy in low-income, 
middle-income and high-income settings found that while 73.5% of pregnant women exhibited 
good adherence, only 53% exhibited good adherence in the postpartum period.17 It is possible that 
the participants in this study were uniquely good adherers due to strong support networks 
provided by the health facility and created by the participants themselves. Alternatively, it may be 
the case that adherence in the late postpartum period may decrease as predicted by previous 
research. 
 The health of the baby and a desire to live a healthy life consistently motivated the 
participants of the study to maintain good ART adherence, provide infants with HIV prophylaxis 
and attend scheduled clinic visits throughout pregnancy and in the early postpartum period. 
Participants were specifically interested in updates about their own CD4 count and viral load 
results and expected that sustaining good ART adherence would result in an HIV-negative baby 
and allow for a healthy, normal life.  This finding indicates the positive impact that effective HIV 
counseling and education can have on long-term Option B+ adherence and program retention.  
  One limitation to this study is that only eight of the 16 six-week postpartum interviews 
were fully translated and transcribed for analysis at the time of manuscript preparation, 
suggesting that saturation at six weeks postpartum has yet to be reached. Nevertheless, a 
repetition of codes was becoming apparent within these first eight interviews, allowing for some 
conclusions to be made about the changes in experiences with the Option B+ program and ART 
adherence over time from pregnancy through the early postpartum period. The interview, 
translation and transcription process of the final eight interviews is ongoing and results will be 
added to the analysis as they become available. Similarly, this study is limited to the early 
postpartum period and does not explore the longitudinal changes in Option B+ adherence and 
program experiences in the later postpartum period. To address this limitation, a third set of 
interviews at six months postpartum with all sixteen study participants is currently under way.  
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The interviews completed at this third time point will allow for further exploration of the barriers 
and facilitators to successful ART adherence and program retention under Option B+ in the 
postpartum period and will illustrate the effects of infant HIV test results on adherence and 
program retention.  
 An additional limitation of this study is that adherence was high for all participants in the 
study so comparisons cannot be made between the experiences of adherent and non-adherent 
HIV-infected pregnant women and mothers with the Option B+ program. Similarly, pill count 
adherence measures were missing for many interview participants. If pill counts cannot be 
conducted by the PMTCT counselors, it is usually because patients have not returned with the pill 
box or the number of pills last dispensed cannot be determined by the counselor based on 
information in the medical chart. It is feasible that the adherence of participants for whom pill 
counts could not be conducted was lower than indicated using the VAS. As a result, the 
experiences of non-adherent HIV-infected pregnant women and mothers or the experiences of 
HIV-infected pregnant women and mothers who are lost to follow-up along the PMTCT cascade 
are not reflected in this study. 
Another limitation of this study is that it does not sufficiently explore the effects of 
stigma on Option B+ ART adherence and program retention. Throughout the study, participants 
noted that learning about other individuals who were also HIV-infected but successfully 
managing the virus through good ART adherence was a source of motivation and encouragement. 
At the same time, many of the same participants also expressed concern with their own HIV 
status exposure. More probing on this topic area during the course of the interview process would 
have been helpful to better understand the sources and the role of stigma in the lives of the 
participants. As interviews continue in the postpartum period, updates to the field guides and 
suggest probes will be made to address this issue.  
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  Finally, this study was also limited by interviewing only HIV-infected women who were 
currently enrolled in the Option B+ program and were participating in the control arm of the 
“Friends for Life Circles” randomized controlled trial. The adherence and Option B+ program 
experiences of the participants included in the study may therefore be different from those of 
HIV-infected pregnant women who are not regularly engaged in health facility-level care or from 
women receiving Option B+ for PMTCT at Mulago National Referral Hospital but not enrolled in 
the “Friends for Life” study. For example, the desire to maintain good ART adherence and 
receive PMTCT care and treatment services may be lower among HIV-infected pregnant women 
who declined to participate in the randomized controlled trial. Nonetheless, the experiences of the 
study participants do reflect the standard of care received at facilities such as Mulago National 
Referral Hospital and contribute to the limited body of research exploring the changes in PMTCT 
experiences under Option B+ that take place from pregnancy through the early postpartum 
period. As Option B+ program implementation continues, emphasis should be placed on 
continued training of health workers, the importance of counseling and support services at the 
facility level, ensuring satisfactory health service delivery, promoting HIV status disclosure and 
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DISCUSSION AND PUBLIC HEALTH IMPLICATIONS  
Summary of study findings 
 Substantial progress has been made over the last two and a half decades in reducing the 
rates of vertical HIV transmission. Nevertheless, program implementation challenges persist, 
especially in resource-limited settings. Under the Option B+ approach, long-term medication 
adherence and program retention are key outcomes that deserve attention. The goal of this project 
was to provide findings that could be useful for improving the current understanding of Option 
B+ adherence and program retention in pregnancy and the postpartum period. 
 
Systematic review of maternal ART adherence and program retention under Option B+ 
 The aim of this systematic review was to provide a summary of the maternal medication 
adherence and program retention literature since the beginning of the Option B+ era.  The 19 
studies included in this review were conducted in seven countries in sub-Saharan Africa. 15 of 
them evaluated retention in care, with loss to follow-up as the most common primary outcome, 
and 10 studies assessed medication adherence, with patient-self report and pill counts as the most 
commonly used measures of adherence. Rates of loss to follow-up ranged from 11.2% to 48.5% 
and that the proportion of adherent women ranged from 51.3% to 97.8%. Studies comparing 
program retention or adherence under the previous Option A recommendation to the current 
Option B+ approach found an increased risk of loss to follow-up and poorer adherence under 
Option B+. Women initiating antiretroviral therapy (ART) on the same day as HIV diagnosis 
were also more likely than women who initiated treatment at least one day after HIV diagnosis to 
be lost to follow-up. The majority of the included studies evaluated program retention or 
adherence at either pregnancy or in the postpartum period, but changes to program retention or 





Changes to Option B+ adherence and program retention at Mulago National Referral Hospital 
 The aim of this longitudinal cohort study was to assess changes in rates of Option B+ 
medication adherence and clinic visit attendance from pregnancy through six months postpartum, 
as well as factors that might be associated with these outcomes, for a cohort of HIV-infected 
women presenting for care at Mulago National Referral Hospital in 2014. This study found that 
utilizing a 95% cutoff, only 52.1% of HIV-infected pregnant women were adherent at the first 
antenatal care (ANC) visit post-ART initiation and only 44.8% were adherent at six months 
postpartum. 64.4% and 56.8% were adherent at the first ANC visit post-ART initiation and at six 
months postpartum, respectively, when an 80% adherence cutoff was used. Disclosure, having 
been previously diagnosed with HIV and higher education level were predictive of good 
adherence in ANC while higher baseline CD4 cell count, employment and previous prevention of 
mother-to-child transmission (PMTCT) experience were predictive of poor adherence in ANC. 
Good adherence at the first ANC visit post-ART initiation was the strongest predictor of good 
adherence at six months postpartum, while disclosure was the strongest predictor of maintaining 
good adherence at both time points.  
 71.9% of women included in this study attended the clinic at six weeks postpartum and 
73.8% attended the clinic at six months postpartum. Good adherence in ANC and having been 
diagnosed with HIV prior to the current pregnancy were both strong predictors of clinic visit 
attendance at six weeks postpartum. Older mothers were also more likely than younger mothers 
to attend the clinic at six weeks postpartum, while women who had previous PMTCT program 
experience were less likely than women who were new to the PMTCT program to attend the 
clinic at six weeks postpartum. Having attended at least one psychosocial support group meeting 
between ART initiation and six months postpartum, being married, initiating ART more than 30 
days before delivery and attendance at six weeks postpartum were all strong positive predictors of 
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clinic attendance at six months postpartum. Being employed outside of the home was a strong 
negative predictor of attendance at six months postpartum. Having a partner who had been 
counseled and tested for HIV in ANC and having spent more than 30 days on ART before 
delivery were positively predictive of consistently attending the clinic at both six weeks and six 
months postpartum. Previous PMTCT program experience was associated with a decreased odds 
of attendance at both postpartum clinic visits.  
 
Understanding experiences with the Option B+ program at Mulago National Referral Hospital  
 The aim of this qualitative work was to explore the changing experiences of HIV-infected 
women enrolled in the Option B+ program from pregnancy through six weeks postpartum at 
Mulago National Referral Hospital and how these experiences may affect adherence and program 
retention in pregnancy and the postpartum period. Longitudinal in-depth interviews in ANC and 
at six weeks postpartum were conducted with a subsample of women enrolled in the “Friends for 
Life Circles” randomized controlled trial (RCT) who had been assigned to receive the standard of 
care. The 16 women included in this study were found to have good adherence at the first 
monthly ANC visit post-ART initiation and at six weeks postpartum. In the antenatal period, 
seven key themes were identified: 1) effective messaging and counseling at the time of HIV 
testing and treatment initiation; 2) reliance on health workers for support between clinic visits; 3) 
disclosure to an HIV-infected person; 4) variability of male partner involvement; 5) modified 
behaviors to prioritize health and ART adherence; 6) concern with inadvertent status disclosure 
and 7) a desire for a healthy baby and a healthy life. At six weeks postpartum, six additional 
themes representing experiences of HIV-infected mothers in the early postpartum period were 
also identified: 1) consistent support from health workers; 2) limitations of the health facility; 3) 
ongoing support after disclosure; 4) variability in male partner involvement; 5) normalization of 
daily ART and 6) a continued desire for a healthy baby and a healthy life. The study results 
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emphasized the importance of having well-trained health workers providing continued counseling 
and support services throughout the ANC and early postpartum period for sustaining good 
medication adherence and program retention among HIV-infected pregnant women and mothers 
enrolled in the Option B+ program. This study also demonstrated that early HIV status disclosure, 
specifically to individuals who were also infected with HIV or who had a good understanding of 
HIV care and treatment, could be a key facilitator of sustained adherence from pregnancy through 
six weeks postpartum.  
 
Study strengths and limitations 
 The studies included in this dissertation have a number of limitations. First, time and 
financial constraints prevented double data abstraction from being performed in the systematic 
review. Although double data abstraction is not a requirement for a methodologically sound 
systematic review, it might have improved the consistency and accuracy of the study screening 
process. Next, the longitudinal data analysis of adherence was meant to include three time points: 
pregnancy, six weeks postpartum and six months postpartum. However, limitations in the way 
data were collected and recorded in labor and delivery prevented adherence calculations from 
being conducted at six weeks postpartum for more than half of the study population. As a result, 
adherence at the first ANC visit post-ART initiation and at six months postpartum were the only 
time points included in the analysis. Similarly, adherence could not be calculated for women who 
did not return to clinic with their pill boxes, thus highlighting a limitation of the pill count method 
for measuring adherence. In addition, because the study utilized program data from 2014, 
challenges surrounding missing or incomplete adherence measures were difficult to resolve two 
years later. In the qualitative study, one limitation was that all of the study participants reported 
good adherence in ANC and at six weeks postpartum so comparisons between experiences of 
adherers and non-adherers could not be compared in the study. In addition, delays in study start-
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up and enrollment for the “Friends for Life Circles” RCT meant that in-depth interviews for all 
participants at all three time points could not be included in this dissertation. Finally, although 
conducted at a single site, the quantitative and qualitative studies in this dissertation utilized 
different study populations so the findings from the in-depth interviews with new initiators of 
Option B+ enrolled in the control arm of a randomized trial in 2016 may not be completely 
generalizable to the new initiators of Option B+ enrolled in the Mulago PMTCT program in 2014 
who were included in the longitudinal cohort study.  
 Despite the limitations described above, the studies included in this project provide a 
unique perspective on the issue of medication adherence and program retention in the Option B+ 
era. At the time this dissertation was written, no other systematic reviews focusing specifically on 
adherence and program retention under the Option B+ approach existed in the literature. This 
systematic review provides a good first look at rates of adherence and loss to follow-up and the 
disparities that exist across different PMTCT care and treatment settings with respect to these 
outcomes. This review could also serve as a reference point for future PMTCT adherence and 
program retention research to assess whether or not adherence and program retention are 
improving over time with Option B+ or with future PMTCT recommendations.  Similarly, 
relatively little is currently known about longitudinal changes in medication adherence and 
program retention from pregnancy through the postpartum period. The longitudinal data analysis 
of adherence and clinic visit attendance was able to utilize the rich PMTCT database that exists at 
Mulago National Referral Hospital to look at changes in adherence and clinic visit attendance 
over time, as well as a number of different important factors that may be affecting these outcomes 
in pregnancy and the postpartum period. This information could be particularly useful to the 
PMTCT clinic at Mulago as they evaluate the program strengths and limitations but may also be 
useful for the broader PMTCT research and program implementation communities as they 
consider appropriate interventions to improve medication adherence and program retention under 
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the Option B+ approach.  The longitudinal in-depth interviews also provided a novel approach to 
understanding the experiences of HIV-infected pregnant women and mothers enrolled in Option 
B+ for PMTCT from pregnancy and through the postpartum period. By interviewing the same 
cohort of women in ANC and at six weeks and six months postpartum, this study will be able to 
look comprehensively at 16 individual experiences and provide 16 different stories while drawing 
conclusions about the collective challenges associated with successfully completing the PMTCT 
care and treatment cascade under Option B+ as well as potential strategies to address these 
challenges and improve health outcomes.  
 
Public health implications  
The results of this dissertation may be useful as PMTCT clinical care and research teams 
continue to strive toward the goals of eliminating vertical HIV transmission and meeting the 90-
90-90 targets put forth by the Joint United Nations Program on HIV/AIDS (UNAIDS) that 
consist of 90% of people living with HIV diagnosed, 90% of diagnosed people on ART and 90% 
of people on ART achieving full viral suppression by the year 2020.1   First, this project 
underscores the need for continued monitoring and evaluation of maternal medication adherence 
and program retention as well as interventions aimed at improving these outcomes.  For example, 
the longitudinal data analysis of PMTCT program data included in this dissertation found that 
while a number of factors such as disclosure, having been previously diagnosed with HIV, 
employment and previous PMTCT experience affected adherence in ANC, having good 
adherence during pregnancy was the strongest predictor for having good adherence later in the 
postpartum period. In addition, the longitudinal in-depth interviews supported these findings 
since fear surrounding immediate initiation of ART after HIV diagnosis, balancing work with 
prioritizing ART adherence and reconciling past PMTCT recommendations with the revised 
Option B+ recommendation were challenges for many of the women interviewed, while status 
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disclosure to individuals who were also infected with HIV or who had a good understanding of 
HIV care and treatment seemed to provide a great deal of support to the participants. It could be 
concluded from these findings that interventions aimed at improving adherence during pregnancy 
may be the most effective for improving and sustaining good adherence in the postpartum period. 
More specifically, interventions aimed at increasing effective status disclosure, supporting health 
workers to provide appropriate guidance during HIV testing and ART initiation as well as 
throughout pregnancy and addressing the specific needs of HIV-infected pregnant women who 
work outside the home or desire to work outside the home may be appropriate for improving 
adherence and program retention in pregnancy and the postpartum period.  
The studies included in this dissertation also emphasize the limitations associated with 
pill count adherence measures. Patient self-report and pill count are the common methods for 
determining adherence in resource-limited settings, but these methods have often been associated 
with lower reliability and overestimation of adherence in comparison to other options such as 
measuring plasma drug levels or viral load.2  As seen in this dissertation, self-report and pill count 
adherence measures varied greatly between studies included in the systematic review and pill 
count adherence could not be assessed in the longitudinal data analysis for women who did not 
return to clinic with their pill boxes. Similarly, while all women participating in the in-depth 
interviews were thought to have good adherence based on self-report or pill count measures, pill 
count measures could not be established for all participants and in some cases, the interviews 
revealed that adherence may not be as good as implied from these adherence measurements. A 
gold standard for measuring adherence, especially in developing countries, has yet to be 
established, and while one study looking at a composite score of pill count, self-report and 
medication event monitoring systems (MEMS) adherence found good correlation with treatment 
response,3  the feasibility of a MEMS approach in resource-limited settings remains uncertain. 
The ability to accurately measure treatment adherence is critical for understanding the problems 
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associated with adherence and for measuring the effects of interventions aimed at improving 
adherence. Recently, the limitations of pill count measures have been taken into account at 
Mulago National Referral Hospital and viral load measurements are now routinely collected. This 
change in practice may provide a more accurate depiction of medication adherence.  
One of the perceived advantages of the Option B+ approach is that it does not require 
CD4 testing as a prerequisite for treatment initiation for PMTCT. Nevertheless, this study showed 
that HIV-infected pregnant women with CD4 cell counts higher than 350 cells/mm3 were less 
likely to have good adherence in ANC than women with lower CD4 cell counts at baseline. This 
finding is important because it illustrates the potential importance of including a CD4 cell count 
assessment at baseline so that women with higher CD4 cell counts who may feel there is no need 
for ART are specifically targeted for additional counseling about the importance of good ART 
adherence. Similarly, although it has been found that transitioning to Option B+ has improved 
rates of ART initiation4, the systematic review found that program retention and adherence were 
higher under Option A vs. Option B+ while the quantitative and qualitative studies included in 
this project found that having previous PMTCT program experience was a barrier for good 
adherence and clinic visit attendance under the Option B+ approach. These findings indicate that 
as guidelines and recommendations continue to be updated and changed, adequate resources must 
be set aside for education, training  and support in the transition periods between 
recommendations for health workers as well as patients. It could also be helpful to utilize 
qualitative methods for formative research looking at best practices for the rollout of new 
guidelines prior to large-scale program implementation in the future.   
 
Next steps and future research  
 A number of next steps may prove relevant with respect to the work completed for this 
dissertation. First, it may be useful to add a meta-analysis component to the systematic review so 
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the results of each included study can be combined in a statistical analysis. In addition, the 
systematic review focuses specifically on medication adherence and program retention but does 
not include outcomes measuring ART initiation, receipt of infant prophylaxis, breastfeeding 
practices, or infant testing and diagnosis under Option B+.  As countries progress with Option B+ 
implementation, additional systematic reviews focusing specifically on each of these steps in the 
PMTCT care and treatment cascade could be useful for a more complete picture of the 
effectiveness of the Option B+ program at reducing vertical HIV transmission.  
 Next, there are a few directions in which the longitudinal data analysis of PMTCT 
medication adherence and clinic visit attendance could be taken to build upon the results of the 
study included in this dissertation. One relevant approach could be to compare the findings from 
2014 to adherence and clinic visit attendance outcomes in 2015 and 2016. This could provide 
information about progress being made with Option B+ program implementation or reveal areas 
where additional interventions or support may be necessary. A prospective longitudinal cohort 
study focusing specifically on obtaining adherence outcomes at six weeks postpartum could also 
be helpful to improve the understanding of how adherence changes from the early postpartum 
period to the later postpartum period. Since viral load measures are now being regularly collected 
at Mulago, it could also be productive to compare pill count adherence measures to viral load 
measurements to assess agreeability between measures. Furthermore, since the Option B+ 
program eliminates the starting and stopping of ART between pregnancies but therefore requires 
good adherence to be maintained at all times, a longitudinal cohort study looking at rates of 
adherence and program retention between pregnancies may also be beneficial to understanding 
the feasibility of sustained levels of good adherence under the Option B+ approach. Finally, 
adding infant outcomes such as HIV testing, receipt of results, receipt of prophylaxis and infant 




The longitudinal in-depth interviews at six weeks and six months postpartum are 
currently under way and be completed in the coming months. The addition of these two time 
points to the interviews conducted in ANC will provide a more complete picture of the Option B+ 
program and adherence experiences at Mulago National Referral Hospital and will be useful for 
thinking about effective interventions aimed at improving adherence and program retention over 
time. Theoretically and with appropriate funding and human resources, additional in-depth 
interviews with the same cohort of women could be continued through two years postpartum 
since the “Friends for Life Circles” study follows participants up until this time point. In addition, 
further qualitative work aimed at understanding the experiences of PMTCT counselors with HIV-
infected pregnant women and mothers as well as promoting and measuring adherence may 
provide insight into the challenges they face as well as what they have found to work well with 
regards to providing PMTCT care, treatment and adherence support.  
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APPENDIX A: PREVIOUS WHO GUIDELINESS FOR PMTCT 
 
Table 1: Recommendations for ART for women in resource-limited settings (2004)131 
Clinical situation             Recommendation 
A. HIV-infected women with indications 
for initiating ARV treatment who may 
become pregnant 
First line regimens: ZDV+3TC+NVP or 
d4T+3TC+NVP 
EFV should be avoided in women of childbearing age, 
unless effective contraception can be ensured.  Exclude 
pregnancy before starting treatment with EFV. 
B. HIV-infected women receiving ARV 
treatment who become pregnant 
Women: Continue with current regimen unless 
containing EFV, in which case substitute with NVP or 
PI if woman is in first trimester. Continue with ARV 
regimen during intrapartum period and after delivery. 
Infants: If born to women receiving first- or second- 
line ARV treatment regimens: ZDV for one week or 
sdNVP or sdNVP+ZDV for one week. 
C. HIV-infected pregnant women with 
indications for ARV treatment 
Women: Follow treatment guidelines as for non-
pregnant adults except that EFV should not be given in 
first trimester.  First line regimens: ZDV+3TC+NVP or 
d4T+3TC+NVP.  
Infants: ZDV for one week or sdNVP or sdNVP+ZDV 
for one week. 
D. HIV-infected pregnant women without 
indications for ARV treatment 
Women: ZDV starting at 28 weeks or as soon as 
feasible thereafter; continue during labor, plus sdNVP 
at onset of labor 
Infants: sdNVP+ZDV for one week 
Alternative regimens also provided in no specific order 
of preference. 
E. HIV-infected pregnant women who 
have indications for starting ARV 
treatment when treatment is not yet 
available. 
Follow recommendations in clinical situation D but use 
regimen that is most efficacious and available/feasible 
for use.  
F. HIV-infected pregnant women with 
active tuberculosis 
If ARV treatment is initiated, consider: 
ZDV+3TC+SQV/r or d4T+3TC+SQV/r 
If treatment initiated in third trimester,  
ZDV+3TC+EFV or d4T+3TC+EFV can be considered. 
If ARV treatment not initiated, follow recommendations 
in clinical situation D. 
G. Pregnant women of unknown HIV 
status at time of labor or women in 
labor known to be HIV-infected who 
have not received ARV drugs before 
labor 
Offer HIV testing/counseling if there is time and initiate 
intrapartum ARV prophylaxis if positive. If insufficient 
time for testing/counseling during labor offer as soon as 
possible postpartum and follow recommendations in 
clinical situation H.  
Women: sdNVP; if imminent delivery expected do not 
give dose but follow clinical situation H.  
Infants:  sdNVP 
OR 
Women: ZDV+3TC in labor and ZDV+3TC for one 
week postpartum 
Infants: ZDV+3TC for one week 
H. Infants born to HIV-infected women 
not receiving any ARV drugs 






Table 2a: Recommendations for initiating ARV treatment in pregnant women based on 
clinical stage and availability of immunological markers (2006)132 
WHO Clinical stage CD4 testing available CD4 testing not available 
1 Do not treat  Treat if CD4 cell count < 200 
cells/mm³ 2 Do not treat  
3 Treat Treat if CD4 cell count <350 
cells/mm³  
4 Treat Treat irrespective of CD4 cell 
count  
 
Table 2b: Recommended first-line ARV regimens for treating pregnant women and 





AZT+ 3TC+NVP twice daily  
AZT+ 3TC+NVP twice daily 
AZT+ 3TC+NVP twice daily 
Infant 
 AZT x 7 days; if mother receives less than four 
weeks of ART during pregnancy then four weeks 
instead of one week of infant AZT is recommended. 
 
Table 2c: Recommended prophylactic ARV regimens for pregnant women who are not yet 






AZT  starting at 28 weeks of pregnancy or as soon as 
feasible thereafter.  
sdNVP+AZT/3TC 
AZT/3TC x 7 days 
Infant 
 sdNVP+AZT x 7 days; if mother receives less than 
four weeks of ART during pregnancy then four weeks 
instead of one week of infant AZT is recommended. 
 
 
Table 3a: Eligibility criteria for initiating antiretroviral treatment or prophylaxis in HIV 
infected pregnant women (2010)38 
WHO Clinical stage CD4 cell count not 
available 
CD4 cell count available 
CD4≤ 350 cells/mm3 CD4 >350 cells/mm3 
1 ARV prophylaxis ART ARV prophylaxis 
2 ARV prophylaxis ART ARV prophylaxis 
3 ART ART ART 












Table 3b: Antiretroviral treatment options recommended for HIV-infected pregnant 
women who are eligible for treatment (2010)38 
Maternal ART Infant ARV prophylaxis 
Maternal antepartum daily ART starting as soon 
as possible irrespective of gestational age and 
continued during pregnancy, delivery and 
thereafter. Recommended regimens include: 
AZT+3TC+NVP or                                             
AZT+3TC+EFV* or                                                        
TDF+3TC (or FTC) +NVP or                                         
TDF+3TC (or FTC) + EFV* 
*Avoid use of EFV in the first trimester and use 
NVP instead. 
Daily NVP or twice-daily AZT from birth until 4 to 
6 weeks of age (irrespective of the mode of infant 
feeding) 
 
Table 3c: ARV prophylaxis options recommended for HIV-infected pregnant women not 
eligible for treatment for their own health (2010)38 
Maternal AZT + infant ARV prophylaxis (Option 
A) 
Maternal triple ARV prophylaxis (Option B) 
Mother 
Antepartum twice-daily AZT starting from as early as 
14 weeks gestation and continued during pregnancy. 
At onset of labor, sdNVP and initiation of twice-daily 
AZT+3TC for 7 days postpartum. 
(If maternal AZT was provided for more than 4 weeks 
antenatally, omission of sdNVP and AZT+3TC tail can 
be considered. In this case, continue maternal AZT 
during labor and stop at delivery.) 
Mother 
Triple ARV prophylaxis starting from as early as 14 
weeks gestation and continued until delivery, or if 
breastfeeding, continued until 1 week after all 
infant exposure to breast milk has ended. 
Recommended regimens include: 
AZT+3TC+LPV/r or                                                      
AZT+3TC+ABC or                                                 
AZT+3TC+EFV or                                                         
TDV+3TC (or FTC) + EFV 
Infant 
For breastfeeding infants                                                        
Daily NVP from birth for at least 4-6 weeks, and until 
1 week after all exposure to breast milk has ended.  
For replacement feeding infants                                                
Daily NVP or sdNVP+twice-daily AZT from birth to 
4-6 weeks of age. 
Infant 
Irrespective of infant feeding mode                                   
Daily NVP or twice-daily AZT from birth until 4-6 





APPENDIX B: PubMed search strategy  
Option B+ countries concept: 
Botswana[tiab] OR Burundi[tiab] OR Urundi[tiab] OR Cameroon[tiab] OR Cameroons[tiab] OR 
Cameron[tiab] OR Cameroun[tiab] OR Congo[tiab] OR Cote d'Ivoire[tiab] OR Ivory Coast[tiab] 
OR Eritrea[tiab] OR Ethiopia[tiab] OR Ghana[tiab] OR India[tiab] OR Kenya[tiab] OR 
Lesotho[tiab] OR Malawi[tiab] OR Mozambique[tiab] OR Namibia[tiab] OR Nigeria[tiab] OR 
Swaziland[tiab] OR Tanzania[tiab] OR “United Republic of Tanzania”[tiab] OR Uganda[tiab] 
OR Zambia[tiab] OR Zimbabwe[tiab] OR “Developing Countries”[Mesh] OR 
Africa[Mesh:NoExp] OR Africa, Northern[Mesh:NoExp] OR Africa South of the 
Sahara[Mesh:NoExp] OR Africa, Central[Mesh:NoExp] OR Africa, Eastern[Mesh:NoExp] OR 
Africa, Southern[Mesh:NoExp] OR Africa, Western[Mesh:NoExp] OR Asia[Mesh:NoExp] OR 
Asia, Central[Mesh:NoExp] OR Asia, Southeastern[Mesh:NoExp] OR “Southeast Asia”[Mesh] 
OR [Botswana[Mesh] OR Burundi[Mesh] OR Cameroon[Mesh] OR Congo[Mesh] OR “Cote 
d'Ivoire”[Mesh] OR "Democratic Republic of the Congo"[Mesh] OR Eritrea[Mesh] OR 
Ethiopia[Mesh] OR Ghana[Mesh] OR India[Mesh] OR Kenya[Mesh] OR Lesotho[Mesh] OR 
Malawi[Mesh] OR Mozambique[Mesh] OR Namibia[Mesh] OR Nigeria[Mesh] OR South 
Africa[Mesh] OR Swaziland[Mesh] OR Tanzania[Mesh] OR Uganda[Mesh] OR Zambia[Mesh] 
OR Zimbabwe[Mesh] OR “Southern African Development Community”[all fields] OR “East 
African Community"[all fields] OR “West African Health Organisation"[all fields] OR “Sub 
Saharan Africa "[all fields] OR “SubSaharan Africa "[all fields]) 
HIV concept: 
 
("HIV"[mesh] OR “HIV”[all fields] OR AIDS[all] OR “HIV-1”[mesh] OR “HIV-2”[mesh] OR 
“Human immunodeficiency viruses”[all] OR “HTLV-III”[all] OR “Human Immunodeficiency 
Virus”[all fields] OR "Acquired Immune Deficiency"[all fields] OR “Acquired Immuno-
Deficiency Syndrome”[all fields] OR “Acquired Immunodeficiency Syndrome”[Mesh] OR 
“Acquired Immunodeficiency”[all fields] OR "HIV Infections"[Mesh]) 
Mother-child concept: 
Search "Mother-Child Relations"[Mesh] OR “Mother Child Relations”[tw] OR “Mother-Child 
Relation”[tw] OR “mother-to-child”[tw] OR “Mother baby”[tw] OR “Mother fetal”[tw] OR 
“Mother infant”[tw] OR ((“Mother”[tw] OR “Mothers’[mesh] OR “Mothers”[tw] or 
“maternal’[tw]) AND (“Infant"[mesh] OR "infant"[tw] OR "infants"[tw] OR "neonate"[tw] OR 
"neonates"[tw] OR “Neo natal”[tw] OR "neonatal"[tw] OR "newborn"[tw] OR "newborns"[tw] 
OR "new-born"[tw] OR "new-borns"[tw] OR "Infant"[Mesh] OR "Infant, Newborn"[mesh] OR 
"baby"[tw] OR "babies"[tw] OR “child”[mesh] OR “child”[tw] OR “children”[tw])) OR 
"pregnancy"[mesh] OR "pregnancy"[tw] OR “pregnant”[tw] OR “antenatal”[tw] OR “ante 
natal”[tw] OR “prepartum”[tw] OR “pre partum”[tw] OR "Labor, Obstetric"[Mesh] OR 
"Obstetric Labor"[tw] OR "Parturition"[Mesh] OR "Parturition"[tw] OR Birth[tw] OR Births[tw] 
OR childbirth[tw] OR childbirths[tw] OR "Pregnant"[tw] OR "postpartum period"[mesh] OR 
"Puerperium"[tw] OR "Postpartum"[tw] OR" Post partum"[tw] OR "postnatal"[tw] OR "post 
natal"[tw] OR "intra-partum"[tw] OR "intrapartum"[tw]) OR “parent-to-child transmission”[tw] 






Prophylaxis concept:  
(“B+”[tw] OR “B plus”[tw] OR “Option B+”[tw] OR “Option B plus”[tw] OR “Option B”[tw] 
OR “PMTCT”[tw] OR “Prevention of mother-to-child-transmission”[tw] OR “mother-to-child 
transmission”[tw] OR “vertical transmission”[tw]) 




APPENDIX C: Study characteristics and outcomes  
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Table 2: Retention in care/loss to follow-up of HIV-infected pregnant women and mothers 

























Chan et al.  6 months 
since ART 
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Kim et al.   6 months 
since ART 
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 11.2%  LTFU PMTCT 
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81%  Not assessed 
Tenthani 
et al. 
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 17% LTFU  Age 
(30-39 vs. 
<30) 












































































































Auld et al. 6 months 
since ART 
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Ford et al.  6 months 
and 1 year 
since ART 
initiation 
 13.7% LTFU at 
6 months 
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66% 24% LTFU 
10% 
Transferred out 
Not assessed   
*LTFU: Loss to follow-up; OR=odds ratio; aOR= adjusted odds ratio; aRR= adjusted relative 
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Table 4: Maternal ART adherence among HIV-infected pregnant women and mothers  








Effect size  
(95% CI)         
p-value 
Factors investigated but 
not associated with 
outcome or association 
not assessed 
Malawi 





































1 year since 
ART 
initiation 
95.8%   PMTCT regimen: 98% 
adherent for HIV+ 
pregnant women 
receiving Option A 
Landes et al.  Not specified 97.8%   Pregnancy status at 
initiation: pregnant vs. 
breastfeeding 






88% Not assessed 
Ethiopia 
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on side 
effects  




(yes vs. no) 







WHO clinical stage, CD4 
cell count, male partner 
involvement, knowledge 
on Option B+, attitude 
toward Option B+, place 
of residence 

























Age, marital status, 
education level, 







(yes vs. no) 








Effect size  
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p-value 
Factors investigated but 
not associated with 
outcome or association 
not assessed 
South Africa 










































Schwartz et al.  12 months 
after delivery   
90% Not assessed 
Rwanda 
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Uganda 
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APPENDIX D: Quality assessment 
 

















Auld et al.  
2016 
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Chan et al. 
2016 
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Ford et al. 
2016 




Moderate Moderate Strong Moderate Strong N/A Moderate 
Kamuyan
go et al. 
2014 
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Kim et al. 
2015 
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Koss et al. 
2016 
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Chan et al. 
2016 
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Ebuy et al. 
2014 
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Gill et al. 
2016 
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Kamuyan
go et al. 
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Moderate Moderate Strong Moderate Moderate Moderate Moderate 
Phillips et 
al. 2016 
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Price et al. 
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APPENDIX E: Logistic regression results  
Table 1a: Univariate and multivariate logistic regression results for 95% adherence in ANC 
(nonadherence defined as medication adherence <95%) 





Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 











16 (69.6)  
 
Reference group 
1.40 (0.90, 2.17) 







1.22 (0.69, 2.17) 
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Table 1b: Univariate and multivariate logistic regression results for 95% adherence in ANC 
(nonadherence defined as medication adherence <95% or did not return with pill box/did 
not return for clinic visit) 





Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.39 (0.95, 2.03) 







1.32 (0.81, 2.14) 
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Table 1c: Univariate and multivariate logistic regression results for 80% adherence in ANC 
(nonadherence defined as medication adherence <80%) 





Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.04 (0.61, 1.78) 







0.89 (0.43, 1.81) 
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Table 1d: Univariate and multivariate logistic regression results for 80% adherence in ANC 
(nonadherence defined as medication adherence <80% or did not return with pill box/did 
not return for clinic visit) 





Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.14 (0.77, 1.71) 







1.10 (0.66, 1.85) 
























































































































































































































Table 2a: Univariate and multivariate logistic regression results for 95% adherence at six 
months postpartum (nonadherence defined as medication adherence <95%) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.01 (0.59, 1.72) 







1.81 (0.79, 4.14) 
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Table 2b: Univariate and multivariate results for 95% adherence at six months postpartum 
(nonadherence defined as medication adherence <95% or did not return with pill box/did 
not return for clinic visit) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.16 (0.79, 1.71) 







1.11 (0.64, 1.91) 












































































































































































































































































































Table 2c: Univariate and multivariate logistic regression results for 80% adherence at six 
months postpartum (nonadherence defined as medication adherence <80%) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 






























































































































































































































































































































Table 2d: Univariate and multivariate logistic regression results for 80% adherence at six 
months postpartum (nonadherence defined as medication adherence <80% or did not 
return with pill box/did not return for clinic visit) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 






















1.06 (0.60, 1.88) 







































































































































































































































































































Table 3a: Univariate and multivariate logistic regression results for 95% adherence at ANC 
and six months postpartum (nonadherence defined as medication adherence <95%) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.19 (0.70, 2.01) 







1.65 (0.78, 3.41) 




























































































































































































































































Table 3b: Univariate and multivariate logistic regression results for 95% adherence at ANC 
and six months postpartum (nonadherence defined as medication adherence <95% or did 
not return with pill box/did not return for clinic visit) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.25 (0.81, 1.91) 







1.41 (0.82, 2.45) 




























































































































































































































































Table 3c: Univariate and multivariate logistic regression results for 80% adherence at ANC 
and six months postpartum (nonadherence defined as medication adherence <80%) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.14 (0.60, 2.16) 







1.44 (0.60, 3.44) 
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Table 3d: Univariate and multivariate logistic regression results for 80% adherence at ANC 
and six months postpartum (nonadherence defined as medication adherence <80% or did 
not return with pill box/did not return for clinic visit) 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.20 (0.81, 1.78) 







1.26 (0.76, 2.09) 
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Table 4: Univariate and multivariate logistic regression results for clinic visit attendance at 
six weeks postpartum 




Unadjusted OR  
(95% CI) 
p-value  Adjusted OR (95% 
CI) 
p-value 














1.48 (0.94, 2.33) 







1.41 (0.75, 2.65) 

































































































































































































































































































Table 5: Univariate and multivariate logistic regression results for clinic visit attendance at 
six months postpartum  
Factor  Did not 
attend (%) 





















1.60 (0.99, 2.58) 







1.33 (0.66, 2.69) 



























































































































































































































































































































Table 6: Univariate and multivariate logistic regression results for clinic visit attendance at 
six weeks and six months postpartum  
Factor  Did not 
attend (%) 




Adjusted OR (95% 
CI) 
p-value 














1.32 (0.87, 2.00) 







1.34 (0.76, 2.36) 
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205 (71.7)  
 
Reference group 














APPENDIX F: Semi-structured in-depth interview guides 
MAKERERE UNIVERSITY – JOHNS HOPKINS UNIVERSITY RESEARCH 
COLLABORATION 
FRIENDS FOR LIFE CIRCLES FOR OPTION B+ STUDY 
IN DEPTH INTERVIEW (IDI) GUIDE FOR VISIT 0 (FIRST MONTHLY ANC 
VISIT) FOR MATERNAL PARTICIPANT ONLY.                                                                                                                                                                
 
Barriers to Option B+ program adherence for PMTCT in Uganda: a mixed methods study 
Interview guide for Visit 0 (first monthly ANC visit): Exploring factors affecting the Option 
B+ adherence experiences of pregnant women living with HIV in the ANC period 
 
Introduction: Thank you for agreeing to talk with us today about your experiences as a pregnant 
woman living with HIV. During this interview I would like you to tell me in your own words 
about your experiences with HIV treatment and prevention services during your pregnancy. The 
interview will last about one hour and with your permission, will be recorded. I will ask you 
several questions about your experiences with HIV testing and HIV medications since you got to 
know that you are HIV positive. I will also ask you about the people and things that have made 
taking your HIV medicine and coming to the clinic for scheduled visits easy or difficult. 
Remember that you may decline to answer any question if you feel uncomfortable and we can 
stop the interview at any point. Do you have any questions at this time? 
 
Part 1:  Experiences with HIV status discovery 
i. To start with, can you tell me a little about how you came to know of your HIV 
status? 
a. Probe: When and where did you find out your HIV status? 
b. Probe: Who was involved and how did they affect your experience?   
Part 2: Experiences with ART and the HIV clinic  
i. Now, can you tell me about your first experiences in the antenatal clinic and what it 
has been like to start taking ART during this pregnancy?  
a. Probe: Who was involved in the process of helping you start ART and how 
did they help or hurt the starting process? 
b. Probe: Can you describe your interactions with care providers? Who were 
they and how did they make you feel? 
c. Probe: What were your expectations for starting ART during this pregnancy 
and were they fulfilled, or were things you would have liked to be different? 
 
ii. Can you tell me specifically about what happened at your last visit to the clinic? 
a. Probe: How did you get there/how was the travel experience? 
b. Probe: Who were the clinic staff involved in your visit, how were you 
treated and how did they make you feel? 
c. Probe: How did you feel about your overall experience? 
d. Probe: What were your expectations for the visit and were they fulfilled, or 
were there things you would have liked to be different? 
 
iii. Can you tell me about your experiences taking ART over the last week? 
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a. Probe: What were your experiences with beginning to take ART and were 
they fulfilled or were there things you would have liked to be different?  
b. Probe: Can you tell me about any side effects you have experienced and how 
this has affected your ability to take your ART? 
 
iv. How do you remember to take your ART and attend your scheduled clinic visits? 
a. Probe: Can you describe your daily routine if you have one? 
b. Probe: Can you describe a time when your routine changed and how this 
affected your ability to remember to take your ART or attend the clinic?  
 
v. Can you tell me about a time since you became pregnant when you missed taking 
your ART or missed a clinic visit? 
vi. During your pregnancy, what keeps you motivated to take your HIV medication 
and/or keep your clinic visit appointments? 
Part 3: Experiences with male partners and disclosure to other people. 
i. Does anyone in your family or outside your family know about your HIV status, and 
how did she/he/they come to find out about your status? 
a. Probe: What was the process of telling this person like for you? 
b. Probe: What was the reaction of the person you were telling?   
 
ii. What experiences have you had discussing HIV with your partner during this 
pregnancy? 
c. Probe: Can you describe the process of your partner being tested for HIV? 
d. Probe: Can you describe the involvement of your partner with helping you 
manage your HIV status, either at your ANC/ART clinic visits or outside of 
the clinic?  
 
iii. Can you describe a time during this pregnancy when those who knew your HIV status 
made it easier or more difficult to take your ART and/or keep your clinic visit 
appointments? 
Part 4: Experiences with stigma and social networks  
i. Thinking about your experiences with HIV during your pregnancy, who do you go to 
for support with your pregnancy and HIV? 
a. Probe: When are these people/is this person most helpful and how do they 
help?  
 
ii. Can you describe a time during this pregnancy when you felt rejected or were treated 
differently due to your HIV status and how this affected your ability to take your ART 
or attend your scheduled clinic visits? 
 
iii. Can you describe a time when you felt shame or embarrassment about your HIV status 
and how this affected your ability to take your ART or attend your scheduled clinic 
visits? 
 
iv. Can you describe a time during this pregnancy when someone made it more difficult 
for you to take your ART and/or keep your scheduled clinic visits? 
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a. Probe: What did they do and how did it make you feel? 
  
v. Can you describe a time during this pregnancy when someone helped you take your 
ART and/or keep your scheduled clinic visits? 
a. Probe: What did they do and how did it make you feel?  
Conclusion: This is the end of our interview today. Thank you very much for your time. Do you 
have any questions for me [answer any questions]? If you have additional thoughts or questions, 
please feel free to contact me or a member of our study team. 
 
MAKERERE UNIVERSITY – JOHNS HOPKINS UNIVERSITY RESEARCH 
COLLABORATION 
FRIENDS FOR LIFE CIRCLES FOR OPTION B+ STUDY 
IN DEPTH INTERVIEW (IDI) GUIDE FOR VISIT 1 (6 WEEKS POSTPARTUM) 
FOR MATERNAL PARTICIPANT ONLY.                                                                                                                                                                
 
Barriers to Option B+ program adherence for PMTCT in Uganda: a mixed methods study 
Interview guide for Visit 1 (6 weeks postpartum): Exploring factors affecting the Option B+ 
adherence experiences of women at the time of infant HIV testing and diagnosis 
 
Introduction: Welcome back and thank you for agreeing to talk with us today about your 
experiences living with HIV and a new infant. During this interview I would like you to tell me in 
your own words about your experiences with HIV treatment and services since giving birth to 
your child. This interview will last about one hour and with your permission, will be recorded. I 
will ask you several questions about your experiences with HIV in the time since your baby was 
born and how these experiences may have changed since you were pregnant. I will also ask you 
about the people and things that have made taking your HIV medicine, giving medicine to your 
baby and coming to clinic visits easy or difficult. Remember that you may decline to answer any 
question if you feel uncomfortable and we can stop the interview at any point. Do you have any 
questions at this time?  
Part 1: Experiences with HIV testing for the baby 
i. To start out, can you tell me about your experiences getting your new baby tested for 
HIV? 
a. Probe: When and where did your baby receive an HIV test? 
b. Probe: Who was involved and how did they affect your experience?  
c. Probe: What were your expectations for getting your new baby tested and were 
they fulfilled, or were there things you would have liked to be different?  
Part 2: Experiences with ART and the HIV clinic 
i. Now, can you tell me about your experiences in the clinic and what it has been like to 
receive ART for yourself since your baby was born?  




b. Probe: Can you describe your interactions with care providers since your baby 
was born? Who were they and how did they make you feel? 
c. Probe: What were your expectations for continuing ART after your baby was 
born and were they fulfilled, or were there things you would have liked to be 
different? 
 
ii. Can you tell me about your experiences in the clinic and what it has been like to receive 
HIV prevention medicine for your baby since your baby was born?  
a. Probe: Who has been involved in the process and how do they help or hurt the 
process? 
b. Probe: Can you describe your interactions with care providers with regards to 
getting HIV prevention medicine for your baby? Who were they and how did 
they make you feel? 
c. Probe: What were your expectations for getting HIV prevention medicine for 
your baby and were they fulfilled, or were there things you would have liked to 
be different? 
 
iii. Can you tell me specifically about what happened at your last visit to the clinic? 
a. Probe: How did you get there/how was the travel experience? 
b. Probe: Who were the clinic staff involved in your visit, how were you treated 
and how did they make you feel? 
c. Probe: How did you feel about your overall experience? 
d. Probe: What were your expectations for the visit and were they fulfilled, or 
were there things you would have liked to be different? 
e. Probe: Have your experiences at the clinic changed in any way since the time 
your baby was born, and if so, in what way(s)? 
 
iv. Can you tell me about your experiences taking ART over the last week? 
a. Probe: What were your expectations with beginning to take ART and were they 
fulfilled or were there things you would have liked to be different?  
b. Probe: Can you tell me about any side effects you have experienced and how 
this has affected your ability to take your ART? 
c. Probe: Have your experiences taking ART changed in any way since the time 
your baby was born, and if so, in what way(s)? 
 
v. How do you remember to take your ART and attend your scheduled clinic visits since 
your baby was born? 
a. Probe: Can you describe your daily routine since your baby was born, if you 
have one? 
b. Probe: Can you describe a time when your routine changed and how this 
affected your ability to remember to take your ART or attend the clinic?  
 
vi. Can you tell me about a time since your baby was born when you missed taking your 
ART, you missed giving your baby HIV prevention medicine or missed a clinic visit? 
 
vii. Since your baby was born, what keeps you motivated to take your HIV medication 
and/or keep your clinic visit appointments? 
a. Probe: Have your motivations changed in any way since the time your baby 
was born, and if so, in what way(s)? 
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Part 3: Experiences with male partners and disclosure to other people. 
i. Since the last time we spoke and especially in the time since your baby was born, do 
any new people in your family or outside  your family know about your HIV status, 
and how did she/he/they come to find out about your status? 
 
a. Probe: What was the process of telling this person like for you? 
b. Probe: What was the reaction of the person you were telling? 
 
ii. Since the last time we spoke and especially since the time since your baby was born, 
what experiences have you had discussing HIV with your partner? 
a. Probe: Can you describe your partner’s involvement with helping you manage 
your HIV status and how it may have changed since the last time we spoke? 
b. Probe: Can you describe your partner’s involvement with the health of your 
baby? 
 
iii. Can you describe a time since your baby was born when those who know your HIV 
status made it easier or more difficult to take your ART, give medicine to your baby 
and keep your clinic visit appointments? 
Part 4: Experiences with stigma and social networks  
i. Thinking about your experiences with HIV since your baby was born, who do you go 
to for support with keeping yourself and your baby healthy? 
a. Probe: When are these people/this person most helpful and how do they help? 
  
ii. Can you describe a time since your baby was born when you felt rejected or were 
treated differently due to your HIV status and how this affected your ability to take 
your ART, give your baby HIV prevention medicine or attend your scheduled clinic 
visits? 
 
iii. Can you describe a time since your baby was born when you felt shame or 
embarrassment about your HIV status and how has this affected your ability to take 
your ART, attend clinic visits or give your baby HIV prevention medicine? 
 
 
iv. Can you describe a time since your baby was born when someone made it more 
difficult for you to take your ART and/or keep your scheduled clinic visits? 
a. Probe: What did they do and how did it make you feel? 
  
v. Can you describe a time since your baby was born when someone helped you take 
your ART and/or keep your scheduled clinic visits? 
a. Probe: What did they do and how did it make you feel?  
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Conclusion: This is the end of our interview today. Thank you very much for your time. Do you 
have any questions for me [answer any questions]? If you have additional thoughts or questions, 
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publication of longitudinal in-depth interviews nested in a large 
NIH-funded randomized controlled trial to understand 
changing experiences of HIV+ pregnant women and mothers 
with Option B+ over time; Collaborated with data management 
and PMTCT team and supervised medical chart data 
abstraction efforts to create a longitudinal cohort study 
measuring rates of adherence and factors affecting adherence 




















































October 2007-August 2008 
Collected data from X-rays and ultrasounds to study novel 
techniques for diagnosis of pediatric tuberculosis; Assisted 
with data analysis and drafting of additional materials related 
to preventing vertical HIV transmission for publication and 
presentation. (Professor Philippa Musoke, Dr. Monica Nolan, 
Dr. Mary Glenn Fowler)  
 Conducted a systematic review of the Option B+ adherence 
and program retention literature to compare and contrast 
findings from the Mulago Hospital Option B+ program to 
those in different countries and health care settings. (Dr. 
Andrea Ruff) 
 
Research Assistant, International Injury Research Unit, Department of 
International Health, JHSPH, Baltimore, MD 
 Assisted country managers of the Road Safety-10 project with 
data analyses and manuscript preparations. (Dr. Abdulgafoor 
M. Bachani) 
 
Research Assistant, Department of International Health, JHSPH, 
Baltimore, MD 
 Contributed to a systematic review by screening abstracts and 
articles for inclusion, abstracting relevant data from the 
literature, contacting corresponding authors and assessing data 
quality to study the relationship between maternal folate status 
and neonatal health outcomes. (Dr. Anne Palaia) 
 
Research Assistant, Child Health Epidemiology Reference Group 
(CHERG), Department of International Health, JHSPH, Baltimore, MD  
 Collaborated on the systematic review, double data abstraction 
and manuscript preparation for a meta-analysis assessing 
effects of breastfeeding practices on diarrheal morbidity and 
mortality and measures of diarrhea incidence, prevalence, 
mortality and hospitalization with respect to breastfeeding 
practices. (Dr. Christa Fischer-Walker) 
 
Advanced Clinical Monitoring Intern, Johns Hopkins Technical 
Support for the Ethiopian HIV/AIDS Initiative (TSEHAI), Addis 
Ababa, Ethiopia  
 Prepared for study enrollment by assessing site readiness, 
completed literature reviews to determine categorical variables 
for analysis, analyzed programmatic data, randomized potential 
participants and assessed selection bias, created screening, 
informed consent and data collection forms, developed job 
aides to assist study staff with screening and enrollment and 
assisted with trainings for the Advanced Clinical Monitoring 
Project consisting of a large, multi-site, PEPFAR-funded study 
assessing longitudinal effectiveness of ART. (Dr. William 




Clinical Trials Associate, Global Development, Bristol-Myers Squibb 
Company, Princeton, NJ  
 Performed study management tasks for large, global, double-
blind placebo-controlled, randomized immunology trials 
studying the efficacy of different biologics and protein kinase 
inhibitors; Authored monthly newsletter to study sites; 
presented professional development seminars to improve team 



















Instructor, Department of  Public Health, Johns Hopkins University 
School of Arts and Sciences, Baltimore, MD  
Course title: Fundamentals of Epidemiology  
 Created new lab materials for confounding, effect modification 
and critical analysis of public health papers, updated lab 
materials to reflect current and relevant public health issues, 
led and prepared weekly lab sessions with 25-30 undergraduate 
students, held weekly office hours, proctored midterm and final 
exams, graded homework and examinations.  4 terms. (Dr. 
Darcy Phelan-Emrick and Dr. Ian Saldanha)  
 
Teaching Assistant, Department of International Health, JHSPH, 
Baltimore, MD 
Course title: Infectious Diseases and Child Survival  
 Scheduled guest lecturers, communicated with students, 
maintained course website and graded exams and assignments; 
2 terms. (Dr. Andrea Ruff and Dr. Ruth Karron)  
Course title: Global Disease Epidemiology and Control Seminar 
 Scheduled guest speakers and coordinated the creation of a 
skills-based lecture series and discussion panels on various 
public health topics, mentored first-year M.H.S. students and 















Instructor, Community Adolescent Sexuality Education (CASE), 
Johns Hopkins School of Medicine, Baltimore, MD  
 Educated a class of 25 8th grade males about sexual health and 
sexuality through an 8-week course intended to increase self-
esteem, improve relationships and decrease incidence of teen 
pregnancies and sexually transmitted infections.  
 
Director of Parent Engagement, Thread, Baltimore, MD  
 Designed, implemented and analyzed surveys to identify 
barriers to engagement of parents/families of Thread students 
with the organization, utilized data from surveys to plan and 
execute inaugural Thread Resource Fair, coordinated with 
Thread staff and community partners to provide resources and 
services at the fair, created a mechanism for future 
226 
 
communications and drafted a proposal for parent/family 
engagement to be implemented in the following academic year.  
 
Lead Mentor, Thread, Baltimore, MD 
 Provided ongoing intensive academic and social support for 3 
Baltimore City high school students at risk for failing out of 
high school in their freshmen years during and post-high 
school, managed teams of 3-6 volunteers and communicated 
with Thread Staff to address emergent or unmet needs of 
students.  
 
Director of Summer Programs, Thread, Baltimore, MD  
 Identified summer employment and successfully placed 72 at-
risk high school students at Johns Hopkins Schools, hospitals 
and affiliated centers as well as companies and organizations in 
Baltimore, facilitated partnerships between Thread, Johns 
Hopkins and new community partners, ensured compensation 
for students through coordination with Baltimore City 
YouthWorks Program, provided students with free lunch daily 
through work with Baltimore City Free Lunch Program, 
developed professional development curriculum for students, 
supervised 2 undergraduate interns assisting with day-to-day 
implementation of the 6-week summer program and planned 
and executed a summer symposium for students, employers 











2017 Tong Zhang Innovation Fellow 
2015 Thread Hall of Fame Award for “Endless Hope”  
2014-2015 Johns Hopkins Martin Luther King Jr. Award for 
Community Service  
2012 Student Outreach Resource Center (SOURCE) Community 
Service Award 
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